{"report_id":"685487ce-db2a-4b10-afa2-36805f1db69e","version":6,"status":"done","tags":[],"date":"2025-08-13T17:39:36Z","url":{"schema":"http","addr":"ir.serestherapeutics.com/news-releases/news-release-details/seres-therapeutics-reports-ser-155-phase-1b-placebo-controlled","fqdn":"ir.serestherapeutics.com","domain":"serestherapeutics.com","tld":"com"},"ip":{"addr":"23.36.77.170","port":0,"asn":20940,"as":"Akamai International B.V.","country":"Norway","country_code":"NO"},"final":{"url":{"schema":"https","addr":"ir.serestherapeutics.com/news-releases/news-release-details/seres-therapeutics-reports-ser-155-phase-1b-placebo-controlled","fqdn":"ir.serestherapeutics.com","domain":"serestherapeutics.com","tld":"com"},"title":"Seres Therapeutics Reports SER-155 Phase 1b Placebo-Controlled Cohort 2 Study Safety and Clinical Results in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant (allo-HSCT) | Seres Therapeutics"},"submit":{"url":{"schema":"http","addr":"ir.serestherapeutics.com/news-releases/news-release-details/seres-therapeutics-reports-ser-155-phase-1b-placebo-controlled","fqdn":"ir.serestherapeutics.com","domain":"serestherapeutics.com","tld":"com"},"ip":{"addr":"23.36.77.170","port":0,"asn":20940,"as":"Akamai International B.V.","country":"Norway","country_code":"NO"},"tags":null,"meta":null},"settings":{"access":"public","device_type":"desktop","expires_at":"2026-09-17T17:39:36Z","useragent":"Mozilla/5.0 (Windows NT 10.0; Win64; x64; rv:134.0) Gecko/20100101 Firefox/134.0","referer":"","cookies":null,"exit_node":"z0yflva4pidy47h"},"stats":{"alert_count":{"ids":3,"urlquery":0,"analyzer":0}},"detection":{"ids":[{"sensor_name":"suricata","title":"Suricata IDS","description":"Suricata /w Emerging Threats Pro","date":"2025-08-13T17:39:10Z","timestamp":1755106750,"ip_dst":{"addr":"192.169.69.26","port":80,"asn":27323,"as":"SERVERSTADIUM","country":"United States","country_code":"US"},"ip_src":{"addr":"172.18.0.17","port":48228,"asn":0,"as":"","country":"","country_code":"zz"},"severity":"medium","alert":"ET INFO DYNAMIC_DNS HTTP Request to a *.duckdns .org Domain","source":"{\"timestamp\":\"2025-08-13T17:39:10.081047+0000\",\"flow_id\":198602732439327,\"in_iface\":\"br-31613a7ed13b\",\"event_type\":\"alert\",\"src_ip\":\"172.18.0.17\",\"src_port\":48228,\"dest_ip\":\"192.169.69.26\",\"dest_port\":80,\"proto\":\"TCP\",\"tx_id\":0,\"alert\":{\"action\":\"allowed\",\"gid\":1,\"signature_id\":2042937,\"rev\":2,\"signature\":\"ET INFO DYNAMIC_DNS HTTP Request to a *.duckdns .org Domain\",\"category\":\"Potentially Bad Traffic\",\"severity\":2,\"metadata\":{\"attack_target\":[\"Client_and_Server\"],\"confidence\":[\"High\"],\"created_at\":[\"2022_12_15\"],\"deployment\":[\"Perimeter\"],\"mitre_tactic_id\":[\"TA0011\"],\"mitre_tactic_name\":[\"Command_And_Control\"],\"mitre_technique_id\":[\"T1568\"],\"mitre_technique_name\":[\"Dynamic_Resolution\"],\"performance_impact\":[\"Low\"],\"signature_severity\":[\"Informational\"],\"updated_at\":[\"2023_03_02\"]}},\"http\":{\"hostname\":\"ejhdaza.duckdns.org\",\"url\":\"/\",\"http_user_agent\":\"Mozilla/5.0 (Windows NT 10.0; Win64; x64; rv:134.0) Gecko/20100101 Firefox/134.0\",\"http_method\":\"GET\",\"protocol\":\"HTTP/1.1\",\"length\":0},\"app_proto\":\"http\",\"flow\":{\"pkts_toserver\":3,\"pkts_toclient\":2,\"bytes_toserver\":466,\"bytes_toclient\":116,\"start\":\"2025-08-13T17:37:21.952095+0000\"}}"},{"sensor_name":"suricata","title":"Suricata IDS","description":"Suricata /w Emerging Threats Pro","date":"2025-08-13T17:39:14Z","timestamp":1755106754,"ip_dst":{"addr":"192.169.69.26","port":80,"asn":27323,"as":"SERVERSTADIUM","country":"United States","country_code":"US"},"ip_src":{"addr":"172.18.0.17","port":48226,"asn":0,"as":"","country":"","country_code":"zz"},"severity":"medium","alert":"ET INFO DYNAMIC_DNS HTTP Request to a *.duckdns .org Domain","source":"{\"timestamp\":\"2025-08-13T17:39:14.145164+0000\",\"flow_id\":60008432776635,\"in_iface\":\"br-31613a7ed13b\",\"event_type\":\"alert\",\"src_ip\":\"172.18.0.17\",\"src_port\":48226,\"dest_ip\":\"192.169.69.26\",\"dest_port\":80,\"proto\":\"TCP\",\"tx_id\":0,\"alert\":{\"action\":\"allowed\",\"gid\":1,\"signature_id\":2042937,\"rev\":2,\"signature\":\"ET INFO DYNAMIC_DNS HTTP Request to a *.duckdns .org Domain\",\"category\":\"Potentially Bad Traffic\",\"severity\":2,\"metadata\":{\"attack_target\":[\"Client_and_Server\"],\"confidence\":[\"High\"],\"created_at\":[\"2022_12_15\"],\"deployment\":[\"Perimeter\"],\"mitre_tactic_id\":[\"TA0011\"],\"mitre_tactic_name\":[\"Command_And_Control\"],\"mitre_technique_id\":[\"T1568\"],\"mitre_technique_name\":[\"Dynamic_Resolution\"],\"performance_impact\":[\"Low\"],\"signature_severity\":[\"Informational\"],\"updated_at\":[\"2023_03_02\"]}},\"http\":{\"hostname\":\"ejhdaza.duckdns.org\",\"url\":\"/\",\"http_user_agent\":\"Mozilla/5.0 (Windows NT 10.0; Win64; x64; rv:134.0) Gecko/20100101 Firefox/134.0\",\"http_method\":\"GET\",\"protocol\":\"HTTP/1.1\",\"length\":0},\"app_proto\":\"http\",\"flow\":{\"pkts_toserver\":3,\"pkts_toclient\":2,\"bytes_toserver\":466,\"bytes_toclient\":116,\"start\":\"2025-08-13T17:37:21.701883+0000\"}}"},{"sensor_name":"suricata","title":"Suricata IDS","description":"Suricata /w Emerging Threats Pro","date":"2025-08-13T17:39:25Z","timestamp":1755106765,"ip_dst":{"addr":"192.169.69.26","port":80,"asn":27323,"as":"SERVERSTADIUM","country":"United States","country_code":"US"},"ip_src":{"addr":"172.18.0.17","port":48268,"asn":0,"as":"","country":"","country_code":"zz"},"severity":"medium","alert":"ET INFO DYNAMIC_DNS HTTP Request to a *.duckdns .org Domain","source":"{\"timestamp\":\"2025-08-13T17:39:25.525183+0000\",\"flow_id\":66493833498184,\"in_iface\":\"br-31613a7ed13b\",\"event_type\":\"alert\",\"src_ip\":\"172.18.0.17\",\"src_port\":48268,\"dest_ip\":\"192.169.69.26\",\"dest_port\":80,\"proto\":\"TCP\",\"tx_id\":0,\"alert\":{\"action\":\"allowed\",\"gid\":1,\"signature_id\":2042937,\"rev\":2,\"signature\":\"ET INFO DYNAMIC_DNS HTTP Request to a *.duckdns .org Domain\",\"category\":\"Potentially Bad Traffic\",\"severity\":2,\"metadata\":{\"attack_target\":[\"Client_and_Server\"],\"confidence\":[\"High\"],\"created_at\":[\"2022_12_15\"],\"deployment\":[\"Perimeter\"],\"mitre_tactic_id\":[\"TA0011\"],\"mitre_tactic_name\":[\"Command_And_Control\"],\"mitre_technique_id\":[\"T1568\"],\"mitre_technique_name\":[\"Dynamic_Resolution\"],\"performance_impact\":[\"Low\"],\"signature_severity\":[\"Informational\"],\"updated_at\":[\"2023_03_02\"]}},\"http\":{\"hostname\":\"ejhdaza.duckdns.org\",\"url\":\"/\",\"http_user_agent\":\"Mozilla/5.0 (Windows NT 10.0; Win64; x64; rv:134.0) Gecko/20100101 Firefox/134.0\",\"http_method\":\"GET\",\"protocol\":\"HTTP/1.1\",\"length\":0},\"app_proto\":\"http\",\"flow\":{\"pkts_toserver\":3,\"pkts_toclient\":2,\"bytes_toserver\":586,\"bytes_toclient\":116,\"start\":\"2025-08-13T17:37:23.151112+0000\"}}"}],"analyzer":null,"urlquery":null},"summary":[{"fqdn":"analytics.imirwin.com","ip":{"addr":"3.20.69.173","port":443,"asn":16509,"as":"AMAZON-02","country":"United States","country_code":"US"},"domain_registered":"2018-03-16","domain_rank":797842,"first_seen":"2022-10-28T02:31:35Z","last_seen":"2025-08-12T07:29:55.64639Z","alert_count":0,"request_count":2,"received_data":112853,"sent_data":1600,"comment":"","tags":null,"fingerprints":[{"name":"HSTS","description":"HTTP Strict Transport Security (HSTS) informs browsers that the site should only be accessed using HTTPS.","website":"https://www.rfc-editor.org/rfc/rfc6797#section-6.1","common_platform_enumeration":"","icon":"","categories":["Security"]},{"name":"Nginx:1.27.5","description":"Nginx is a web server that can also be used as a reverse proxy, load balancer, mail proxy and HTTP cache.","website":"https://nginx.org/en","common_platform_enumeration":"cpe:2.3:a:f5:nginx:*:*:*:*:*:*:*:*","icon":"Nginx.svg","categories":["Web servers","Reverse proxies"]},{"name":"PHP:8.3.19","description":"PHP is a general-purpose scripting language used for web development.","website":"https://php.net","common_platform_enumeration":"cpe:2.3:a:php:php:*:*:*:*:*:*:*:*","icon":"PHP.svg","categories":["Programming languages"]}]},{"fqdn":"ir.serestherapeutics.com","ip":{"addr":"23.36.77.170","port":443,"asn":20940,"as":"Akamai International B.V.","country":"Norway","country_code":"NO"},"domain_registered":"2011-06-03","domain_rank":0,"first_seen":"2015-06-29T09:38:48Z","last_seen":"2023-09-17T12:29:14Z","alert_count":0,"request_count":30,"received_data":3566480,"sent_data":74530,"comment":"","tags":null,"fingerprints":[{"name":"Akamai","description":"Akamai is global content delivery network (CDN) services provider for media and software delivery, and cloud security solutions.","website":"https://akamai.com","common_platform_enumeration":"","icon":"Akamai.svg","categories":["CDN"]},{"name":"Akamai Bot Manager","description":"Akamai Bot Manager detect bots using device fingerprinting bot signatures.","website":"https://www.akamai.com/us/en/products/security/bot-manager.jsp","common_platform_enumeration":"","icon":"Akamai.svg","categories":["Security"]},{"name":"Modernizr","description":"Modernizr is a JavaScript library that detects the features available in a user's browser.","website":"https://modernizr.com","common_platform_enumeration":"","icon":"Modernizr.svg","categories":["JavaScript libraries"]},{"name":"Drupal Multisite","description":"Drupal Multisite enables separate, independent sites to be served from a single codebase.","website":"https://www.drupal.org/docs/multisite-drupal","common_platform_enumeration":"","icon":"Drupal.svg","categories":["Hosting"]},{"name":"Drupal:10","description":"Drupal is a free and open-source web content management framework.","website":"https://www.drupal.org/","common_platform_enumeration":"cpe:2.3:a:drupal:drupal:*:*:*:*:*:*:*:*","icon":"Drupal.svg","categories":["CMS"]},{"name":"jQuery","description":"jQuery is a JavaScript library which is a free, open-source software designed to simplify HTML DOM tree traversal and manipulation, as well as event handling, CSS animation, and Ajax.","website":"https://jquery.com","common_platform_enumeration":"cpe:2.3:a:jquery:jquery:*:*:*:*:*:*:*:*","icon":"jQuery.svg","categories":["JavaScript libraries"]},{"name":"Typekit","description":"Typekit is an online service which offers a subscription library of fonts.","website":"https://typekit.com","common_platform_enumeration":"","icon":"Typekit.png","categories":["Font scripts"]},{"name":"DataTables","description":"DataTables is a plug-in for the jQuery Javascript library adding advanced features like pagination, instant search, themes, and more to any HTML table.","website":"https://datatables.net","common_platform_enumeration":"cpe:2.3:a:datatables:datatables.net:*:*:*:*:*:*:*:*","icon":"DataTables.png","categories":["JavaScript libraries"]},{"name":"PHP","description":"PHP is a general-purpose scripting language used for web development.","website":"https://php.net","common_platform_enumeration":"cpe:2.3:a:php:php:*:*:*:*:*:*:*:*","icon":"PHP.svg","categories":["Programming languages"]},{"name":"Acquia Cloud Site Factory","description":"Acquia Site Factory is a multisite platform for Drupal.","website":"https://www.acquia.com/products/drupal-cloud/site-factory","common_platform_enumeration":"","icon":"acquia-site-factory.png","categories":["Hosting"]},{"name":"HSTS","description":"HTTP Strict Transport Security (HSTS) informs browsers that the site should only be accessed using HTTPS.","website":"https://www.rfc-editor.org/rfc/rfc6797#section-6.1","common_platform_enumeration":"","icon":"","categories":["Security"]},{"name":"Adobe Fonts","description":"Adobe Fonts is a web-based service providing access to a vast library of high-quality fonts for web and print design.","website":"https://fonts.adobe.com","common_platform_enumeration":"","icon":"Adobe Fonts.svg","categories":["Font scripts"]},{"name":"Acquia Cloud Platform","description":"Acquia Cloud Platform is a Drupal-tuned application lifecycle management suite with an infrastructure to support Drupal deployment workflow processes.","website":"https://www.acquia.com/products/drupal-cloud/cloud-platform","common_platform_enumeration":"","icon":"acquia-cloud.png","categories":["PaaS"]}]},{"fqdn":"ml.globenewswire.com","ip":{"addr":"23.36.77.251","port":443,"asn":20940,"as":"Akamai International B.V.","country":"Norway","country_code":"NO"},"domain_registered":"2007-09-08","domain_rank":451564,"first_seen":"2019-03-10T19:25:09Z","last_seen":"2025-08-08T18:55:27.618631Z","alert_count":0,"request_count":1,"received_data":430,"sent_data":538,"comment":"","tags":null,"fingerprints":[{"name":"HSTS","description":"HTTP Strict Transport Security (HSTS) informs browsers that the site should only be accessed using HTTPS.","website":"https://www.rfc-editor.org/rfc/rfc6797#section-6.1","common_platform_enumeration":"","icon":"","categories":["Security"]}]},{"fqdn":"assets.adobedtm.com","ip":{"addr":"96.6.17.25","port":443,"asn":16625,"as":"AKAMAI-AS","country":"Norway","country_code":"NO"},"domain_registered":"2013-11-22","domain_rank":3051,"first_seen":"2014-01-28T04:51:35Z","last_seen":"2025-08-06T17:25:44.710315Z","alert_count":0,"request_count":2,"received_data":204716,"sent_data":1024,"comment":"","tags":null,"fingerprints":null},{"fqdn":"use.typekit.net","ip":{"addr":"23.36.77.81","port":443,"asn":20940,"as":"Akamai International B.V.","country":"Norway","country_code":"NO"},"domain_registered":"2010-08-02","domain_rank":4054,"first_seen":"2012-07-05T01:42:39Z","last_seen":"2025-08-06T21:01:47.389838Z","alert_count":0,"request_count":3,"received_data":67898,"sent_data":1672,"comment":"","tags":null,"fingerprints":[{"name":"Nginx","description":"Nginx is a web server that can also be used as a reverse proxy, load balancer, mail proxy and HTTP cache.","website":"https://nginx.org/en","common_platform_enumeration":"cpe:2.3:a:f5:nginx:*:*:*:*:*:*:*:*","icon":"Nginx.svg","categories":["Web servers","Reverse proxies"]},{"name":"HSTS","description":"HTTP Strict Transport Security (HSTS) informs browsers that the site should only be accessed using HTTPS.","website":"https://www.rfc-editor.org/rfc/rfc6797#section-6.1","common_platform_enumeration":"","icon":"","categories":["Security"]}]},{"fqdn":"www.globenewswire.com","ip":{"addr":"23.36.77.218","port":443,"asn":20940,"as":"Akamai International B.V.","country":"Norway","country_code":"NO"},"domain_registered":"2007-09-08","domain_rank":91503,"first_seen":"2012-09-26T01:35:47Z","last_seen":"2025-08-08T18:55:27.556575Z","alert_count":0,"request_count":1,"received_data":601,"sent_data":487,"comment":"","tags":null,"fingerprints":[{"name":"HSTS","description":"HTTP Strict Transport Security (HSTS) informs browsers that the site should only be accessed using HTTPS.","website":"https://www.rfc-editor.org/rfc/rfc6797#section-6.1","common_platform_enumeration":"","icon":"","categories":["Security"]},{"name":"Microsoft ASP.NET","description":"ASP.NET is an open-source, server-side web-application framework designed for web development to produce dynamic web pages.","website":"https://www.asp.net","common_platform_enumeration":"cpe:2.3:a:microsoft:asp.net:*:*:*:*:*:*:*:*","icon":"Microsoft ASP.NET.svg","categories":["Web frameworks"]}]},{"fqdn":"p.typekit.net","ip":{"addr":"23.36.77.57","port":443,"asn":20940,"as":"Akamai International B.V.","country":"Norway","country_code":"NO"},"domain_registered":"2010-08-02","domain_rank":4638,"first_seen":"2012-05-23T14:28:57Z","last_seen":"2025-08-06T17:49:37.839428Z","alert_count":0,"request_count":1,"received_data":340,"sent_data":591,"comment":"","tags":null,"fingerprints":[{"name":"Nginx","description":"Nginx is a web server that can also be used as a reverse proxy, load balancer, mail proxy and HTTP cache.","website":"https://nginx.org/en","common_platform_enumeration":"cpe:2.3:a:f5:nginx:*:*:*:*:*:*:*:*","icon":"Nginx.svg","categories":["Web servers","Reverse proxies"]}]}],"files":null,"artifacts":{"windows_shortcuts":null,"files":null,"telegram":null,"pdfs":null,"clipboard":null},"sensors":{"ids":[{"sensor_name":"suricata","description":"Suricata /w Emerging Threats Pro","alerts":[{"sensor_name":"suricata","title":"Suricata IDS","description":"Suricata /w Emerging Threats Pro","date":"2025-08-13T17:39:10Z","timestamp":1755106750,"ip_dst":{"addr":"192.169.69.26","port":80,"asn":27323,"as":"SERVERSTADIUM","country":"United States","country_code":"US"},"ip_src":{"addr":"172.18.0.17","port":48228,"asn":0,"as":"","country":"","country_code":"zz"},"severity":"medium","alert":"ET INFO DYNAMIC_DNS HTTP Request to a *.duckdns .org Domain","source":"{\"timestamp\":\"2025-08-13T17:39:10.081047+0000\",\"flow_id\":198602732439327,\"in_iface\":\"br-31613a7ed13b\",\"event_type\":\"alert\",\"src_ip\":\"172.18.0.17\",\"src_port\":48228,\"dest_ip\":\"192.169.69.26\",\"dest_port\":80,\"proto\":\"TCP\",\"tx_id\":0,\"alert\":{\"action\":\"allowed\",\"gid\":1,\"signature_id\":2042937,\"rev\":2,\"signature\":\"ET INFO DYNAMIC_DNS HTTP Request to a *.duckdns .org Domain\",\"category\":\"Potentially Bad Traffic\",\"severity\":2,\"metadata\":{\"attack_target\":[\"Client_and_Server\"],\"confidence\":[\"High\"],\"created_at\":[\"2022_12_15\"],\"deployment\":[\"Perimeter\"],\"mitre_tactic_id\":[\"TA0011\"],\"mitre_tactic_name\":[\"Command_And_Control\"],\"mitre_technique_id\":[\"T1568\"],\"mitre_technique_name\":[\"Dynamic_Resolution\"],\"performance_impact\":[\"Low\"],\"signature_severity\":[\"Informational\"],\"updated_at\":[\"2023_03_02\"]}},\"http\":{\"hostname\":\"ejhdaza.duckdns.org\",\"url\":\"/\",\"http_user_agent\":\"Mozilla/5.0 (Windows NT 10.0; Win64; x64; rv:134.0) Gecko/20100101 Firefox/134.0\",\"http_method\":\"GET\",\"protocol\":\"HTTP/1.1\",\"length\":0},\"app_proto\":\"http\",\"flow\":{\"pkts_toserver\":3,\"pkts_toclient\":2,\"bytes_toserver\":466,\"bytes_toclient\":116,\"start\":\"2025-08-13T17:37:21.952095+0000\"}}"},{"sensor_name":"suricata","title":"Suricata IDS","description":"Suricata /w Emerging Threats Pro","date":"2025-08-13T17:39:14Z","timestamp":1755106754,"ip_dst":{"addr":"192.169.69.26","port":80,"asn":27323,"as":"SERVERSTADIUM","country":"United States","country_code":"US"},"ip_src":{"addr":"172.18.0.17","port":48226,"asn":0,"as":"","country":"","country_code":"zz"},"severity":"medium","alert":"ET INFO DYNAMIC_DNS HTTP Request to a *.duckdns .org Domain","source":"{\"timestamp\":\"2025-08-13T17:39:14.145164+0000\",\"flow_id\":60008432776635,\"in_iface\":\"br-31613a7ed13b\",\"event_type\":\"alert\",\"src_ip\":\"172.18.0.17\",\"src_port\":48226,\"dest_ip\":\"192.169.69.26\",\"dest_port\":80,\"proto\":\"TCP\",\"tx_id\":0,\"alert\":{\"action\":\"allowed\",\"gid\":1,\"signature_id\":2042937,\"rev\":2,\"signature\":\"ET INFO DYNAMIC_DNS HTTP Request to a *.duckdns .org Domain\",\"category\":\"Potentially Bad Traffic\",\"severity\":2,\"metadata\":{\"attack_target\":[\"Client_and_Server\"],\"confidence\":[\"High\"],\"created_at\":[\"2022_12_15\"],\"deployment\":[\"Perimeter\"],\"mitre_tactic_id\":[\"TA0011\"],\"mitre_tactic_name\":[\"Command_And_Control\"],\"mitre_technique_id\":[\"T1568\"],\"mitre_technique_name\":[\"Dynamic_Resolution\"],\"performance_impact\":[\"Low\"],\"signature_severity\":[\"Informational\"],\"updated_at\":[\"2023_03_02\"]}},\"http\":{\"hostname\":\"ejhdaza.duckdns.org\",\"url\":\"/\",\"http_user_agent\":\"Mozilla/5.0 (Windows NT 10.0; Win64; x64; rv:134.0) Gecko/20100101 Firefox/134.0\",\"http_method\":\"GET\",\"protocol\":\"HTTP/1.1\",\"length\":0},\"app_proto\":\"http\",\"flow\":{\"pkts_toserver\":3,\"pkts_toclient\":2,\"bytes_toserver\":466,\"bytes_toclient\":116,\"start\":\"2025-08-13T17:37:21.701883+0000\"}}"},{"sensor_name":"suricata","title":"Suricata IDS","description":"Suricata /w Emerging Threats Pro","date":"2025-08-13T17:39:25Z","timestamp":1755106765,"ip_dst":{"addr":"192.169.69.26","port":80,"asn":27323,"as":"SERVERSTADIUM","country":"United States","country_code":"US"},"ip_src":{"addr":"172.18.0.17","port":48268,"asn":0,"as":"","country":"","country_code":"zz"},"severity":"medium","alert":"ET INFO DYNAMIC_DNS HTTP Request to a *.duckdns .org Domain","source":"{\"timestamp\":\"2025-08-13T17:39:25.525183+0000\",\"flow_id\":66493833498184,\"in_iface\":\"br-31613a7ed13b\",\"event_type\":\"alert\",\"src_ip\":\"172.18.0.17\",\"src_port\":48268,\"dest_ip\":\"192.169.69.26\",\"dest_port\":80,\"proto\":\"TCP\",\"tx_id\":0,\"alert\":{\"action\":\"allowed\",\"gid\":1,\"signature_id\":2042937,\"rev\":2,\"signature\":\"ET INFO DYNAMIC_DNS HTTP Request to a *.duckdns .org Domain\",\"category\":\"Potentially Bad Traffic\",\"severity\":2,\"metadata\":{\"attack_target\":[\"Client_and_Server\"],\"confidence\":[\"High\"],\"created_at\":[\"2022_12_15\"],\"deployment\":[\"Perimeter\"],\"mitre_tactic_id\":[\"TA0011\"],\"mitre_tactic_name\":[\"Command_And_Control\"],\"mitre_technique_id\":[\"T1568\"],\"mitre_technique_name\":[\"Dynamic_Resolution\"],\"performance_impact\":[\"Low\"],\"signature_severity\":[\"Informational\"],\"updated_at\":[\"2023_03_02\"]}},\"http\":{\"hostname\":\"ejhdaza.duckdns.org\",\"url\":\"/\",\"http_user_agent\":\"Mozilla/5.0 (Windows NT 10.0; Win64; x64; rv:134.0) Gecko/20100101 Firefox/134.0\",\"http_method\":\"GET\",\"protocol\":\"HTTP/1.1\",\"length\":0},\"app_proto\":\"http\",\"flow\":{\"pkts_toserver\":3,\"pkts_toclient\":2,\"bytes_toserver\":586,\"bytes_toclient\":116,\"start\":\"2025-08-13T17:37:23.151112+0000\"}}"}]}],"analyzer":null,"urlquery":null},"javascript":{"script":[{"url":{"schema":"https","addr":"ir.serestherapeutics.com/RNdDsxyv1HCi8/5bsN/eeYDOHqv5c/8X9XwQGY/cggyWQ/S2ZjfUY/dTWdCAQ?v=a9e8c51b-ea55-72b0-f92e-4d2e035b1724","fqdn":"ir.serestherapeutics.com","domain":"serestherapeutics.com","tld":"com"},"ip":{"addr":"23.36.77.170","port":443,"asn":20940,"as":"Akamai International B.V.","country":"Norway","country_code":"NO"},"introduction_type":"scriptElement","is_inline":false,"md5":"cda6065bdbfecc0ed6b518996f20f21b","sha1":"c130c276c2e24f12cd74a462b715790163849cc2","sha256":"2038e6c3871f16104567cd3184cb2ac3fe7fff304d4cfd5fb428edabd4dae05a","sha512":"c5abdf71e8cc3b893df3749daaa29a9d7c0ecb9946124cb46ed65d8036f13de1550219d1080cf3195f4ed967ff1db402d46fb945c6f3cb6bde368a121c99b515","ssdeep":"6144:9WjwUpQn/TtrobH0KHTUKzUe4ILRys3ApJyTm:9U8ob5osNm","tlshash":"3894f7f29193287a825795c5088e35172d0f5ce3b5fcd27ee901ce970c68b6866fda2c","size":408805,"data":"","first_seen":"2025-08-13T17:39:41.439959Z","last_seen":"2025-08-13T17:39:41.439959Z","times_seen":1,"alerts":{"ids":null,"analyzer":null,"urlquery":null}},{"url":{"schema":"https","addr":"analytics.imirwin.com/js/container_hNB1lXl3.js","fqdn":"analytics.imirwin.com","domain":"imirwin.com","tld":"com"},"ip":{"addr":"3.20.69.173","port":443,"asn":16509,"as":"AMAZON-02","country":"United States","country_code":"US"},"introduction_type":"scriptElement","is_inline":false,"md5":"764b45cea9e09417beaba5a207bb7e15","sha1":"7eb4390c79688a778e9a01f6824d11131671b076","sha256":"d11a1d5dd8c8fe5b0b6df036df581dc1df9906866ab33c675a284e099a4639f7","sha512":"2df2f086bc157455c66d165085ea775f2a0154a6e175f2e31cef326683a77c2f328f1cadfba3f3602533008738f3c15613a7df2c0666840d84e6d87009d4242b","ssdeep":"3072:ZFKT+Z2fu7dzsyWbbVdda8EbdAA0XvBvGlh/X:DKSUu7dzszRdd8dngpvGlh/X","tlshash":"d5b3e88a32c3753647de6074943f0246f27d9dab240cd064e56ad8ea393c91ea53bf78","size":112046,"data":"","first_seen":"2025-08-13T17:39:41.30633Z","last_seen":"2025-08-13T17:39:41.30633Z","times_seen":1,"alerts":{"ids":null,"analyzer":null,"urlquery":null}},{"url":{"schema":"https","addr":"www.google-analytics.com/analytics.js","fqdn":"www.google-analytics.com","domain":"google-analytics.com","tld":"com"},"ip":{"addr":"0.0.0.0","port":0,"asn":0,"as":"","country":"","country_code":"ZZ"},"introduction_type":"scriptElement","is_inline":false,"md5":"f24128d0c9cba7be2916c693427a3483","sha1":"1b6397d496ea896ebc2018b01b995cee4f166029","sha256":"58173de4697da1a218f04c3a783a733bab4e769ceabc37cd42da9dc3e036a7e8","sha512":"c4950733b44e258bbc817ce6396f002caec1e11a6413fd0038c9baef2d5f1d992b1fd0ec52515aba52faedb52c28b996a7fc063f28a0f45f3aab5e2f91bf5be5","ssdeep":"96:A1VdZYqhPnjpWx4/eTe8qSMbqaQd6VL2Jyt9LdJoyayCVPVD5wdBfQPfCHiUr3:AXdZYqNjpU4yPqSMbqaQGL2QfdDayCZC","tlshash":"a6a1dc9939fb50210233b1bd1bafa918b23895236208dd61b98c9364bf94437d7f1fc9","size":4691,"data":"","first_seen":"2023-04-11T21:07:53Z","last_seen":"2026-04-03T18:31:01.223924Z","times_seen":768645,"alerts":{"ids":null,"analyzer":null,"urlquery":null}},{"url":{"schema":"https","addr":"assets.adobedtm.com/898335afd880/c52ee8aa1e90/a9a9246fcf93/EX9f1ce69e4b404891b885911666e7b92a-libraryCode_source.min.js","fqdn":"assets.adobedtm.com","domain":"adobedtm.com","tld":"com"},"ip":{"addr":"96.6.17.25","port":443,"asn":16625,"as":"AKAMAI-AS","country":"Norway","country_code":"NO"},"introduction_type":"scriptElement","is_inline":false,"md5":"f89b497f4495320cabaa3adbb2c2a0d5","sha1":"69275e61906377fe8122fe44c5ef9e5292465271","sha256":"f2d45bebe310e6913fb1846dd661fc9fad22185c8b06e499feae67726fc5ab17","sha512":"d4794cfc74191f2c9b662dcba806b0eb1b2213d3c3e6a13a3b344307905c201364dd3b4fac1a1cf6d15b18c4ff0acce7e36fdd0d7d06cc8646100b9da266ebe5","ssdeep":"768:Qa6IY9mkYhhm7S/5I0XlTCrOoboxI5WdfD6DrVySyEmy/I6/k:Xh0bYhhYS/y+VCdsHWISPI6/k","tlshash":"bef22dc531eab47f165271f42c6f080ee139cf5a888994b4e081c9e16878ed651affb7","size":37000,"data":"","first_seen":"2023-03-13T20:39:53Z","last_seen":"2026-04-02T06:14:20.721378Z","times_seen":65,"alerts":{"ids":null,"analyzer":null,"urlquery":null}},{"url":{"schema":"https","addr":"ir.serestherapeutics.com/news-releases/news-release-details/seres-therapeutics-reports-ser-155-phase-1b-placebo-controlled","fqdn":"ir.serestherapeutics.com","domain":"serestherapeutics.com","tld":"com"},"ip":{"addr":"23.36.77.170","port":443,"asn":20940,"as":"Akamai International B.V.","country":"Norway","country_code":"NO"},"introduction_type":"scriptElement","is_inline":false,"md5":"813f7afe12806d2df1c685b53ab49c0e","sha1":"8ebc2ee97e18dd336b670b53dbccdfb8788a5825","sha256":"ab008176ac77145e392d8392787e81c90c2592a54b1590d8779c74f956c0e46a","sha512":"2cfd9473c2bc8c0c516c30d1b03838ae0e89dc97ce4c7e105c9ae7a33e507660d7b3ece76116ca79570d95bde32d0cbf86798b49983e3e9ffe29d3c2c505cc0a","ssdeep":"","tlshash":"ee80008a08b0082a0220a00cc8e3a838002080020a0a00a228802000ba808c308000c0","size":26,"data":"","first_seen":"2023-03-07T01:02:36Z","last_seen":"2026-04-03T17:37:32.323881Z","times_seen":96577,"alerts":{"ids":null,"analyzer":null,"urlquery":null}},{"url":{"schema":"https","addr":"ir.serestherapeutics.com/news-releases/news-release-details/seres-therapeutics-reports-ser-155-phase-1b-placebo-controlled","fqdn":"ir.serestherapeutics.com","domain":"serestherapeutics.com","tld":"com"},"ip":{"addr":"23.36.77.170","port":443,"asn":20940,"as":"Akamai International B.V.","country":"Norway","country_code":"NO"},"introduction_type":"scriptElement","is_inline":false,"md5":"8cf91652fc7787b535b26f390f9ed9af","sha1":"d39e49793059ab3b8a97b61bac69ad2a451c8ff2","sha256":"f876a7b1e6234843f5d8487af055addd42fe6018d4f4e2f29ab08c0f08a85d94","sha512":"1a1a87797e2e0a21486a88f87573cab0910b46f7be3f68d9c04cdca6f9645f1de8af87b12ebe9bcebd52a9bd54fc3232063ea1cfa8c1f10d4f3a129ecde7de94","ssdeep":"","tlshash":"fe80008a0ab8082a0220a000c8c3a83800a080020e0a00a228802000ba808c308000c0","size":26,"data":"","first_seen":"2023-03-07T01:02:35Z","last_seen":"2026-04-03T17:37:32.324613Z","times_seen":96366,"alerts":{"ids":null,"analyzer":null,"urlquery":null}},{"url":{"schema":"https","addr":"ir.serestherapeutics.com/news-releases/news-release-details/seres-therapeutics-reports-ser-155-phase-1b-placebo-controlled","fqdn":"ir.serestherapeutics.com","domain":"serestherapeutics.com","tld":"com"},"ip":{"addr":"23.36.77.170","port":443,"asn":20940,"as":"Akamai International B.V.","country":"Norway","country_code":"NO"},"introduction_type":"scriptElement","is_inline":false,"md5":"339aaaa033bd435bc3d3442976b21150","sha1":"309497f761b4649d113688cb611242810ed2a8bc","sha256":"47536a23eb95f0f1d8f00b6ef54ac4553cc05d06ddce49260dab7dc9f083296d","sha512":"65675d696c7315d55825bfd99ee02ed0d7f7a240f82d6f691e2df1d2fe4ebc6eeb4a409af3b0d0b74c7bff7700b6b141ae469071353dd9d391a5406f8c838c2f","ssdeep":"","tlshash":"3380008a08b0082a02a0a000c8c3a838002080020a0a00a228802000be808c388020c0","size":26,"data":"","first_seen":"2023-03-07T01:02:37Z","last_seen":"2026-04-03T17:37:32.315649Z","times_seen":96059,"alerts":{"ids":null,"analyzer":null,"urlquery":null}},{"url":{"schema":"https","addr":"ir.serestherapeutics.com/profiles/nasdaqir/modules/custom/nir_ckeditor_datatables/js/build/datatables.js?v=1.10.9","fqdn":"ir.serestherapeutics.com","domain":"serestherapeutics.com","tld":"com"},"ip":{"addr":"23.36.77.170","port":443,"asn":20940,"as":"Akamai International B.V.","country":"Norway","country_code":"NO"},"introduction_type":"scriptElement","is_inline":false,"md5":"e8f5ef34f9aec47f102221346f808ea5","sha1":"076fd225f030af6b40bf0f92737691236a89bd83","sha256":"8299e462bd401d41bb12d29c3daf388e40a7681f4bf609d733a0df91f043a5d8","sha512":"5e43f1267e83380017233a4fcfc6394af2fa290e555ad88d4e52b746309e014cabcfbe19d52959d4853894cc44dbc821f7a7b6ed0d991c1fe018737040cdc5f7","ssdeep":"3072:/GoUvqY0bAS0GetPWJzBCO+IOS2pqL/+GkUcrvTO:Eqpr","tlshash":"ba74a4ac9f2456fcd98e43d08cbe586c2b1fa2fd3a078535d26c57e05d2bd0dc986a42","size":361843,"data":"","first_seen":"2025-02-13T16:09:49.443604Z","last_seen":"2026-04-02T06:14:20.657521Z","times_seen":70,"alerts":{"ids":null,"analyzer":null,"urlquery":null}},{"url":{"schema":"https","addr":"ir.serestherapeutics.com/news-releases/news-release-details/sandbox%20eval%20code","fqdn":"ir.serestherapeutics.com","domain":"serestherapeutics.com","tld":"com"},"ip":{"addr":"0.0.0.0","port":0,"asn":0,"as":"","country":"","country_code":"ZZ"},"introduction_type":"","is_inline":false,"md5":"92b651082ce234f66bb544e678befda3","sha1":"14c21c55ddce43b6f677caadf51d4ab98c6a3df8","sha256":"25d57d1d97abeb84531d3d3e5754dd5cb19a2c115edfa7cfc7af8247084faded","sha512":"b4fcbc037e0a3d91db2a624921e96b878e9e18dd998ad5649d77d7d053faf28b09c8725a0542aef702310bf85f3037b70985c274db8acabd021efb171d41f361","ssdeep":"","tlshash":"34c08ca3e74026ae2a1166b2b810e003a2866b015aa78402b00a003b1441fe21aaa1a8","size":147,"data":"","first_seen":"2023-04-11T21:07:53Z","last_seen":"2026-04-03T18:31:01.216471Z","times_seen":770188,"alerts":{"ids":null,"analyzer":null,"urlquery":null}},{"url":{"schema":"https","addr":"assets.adobedtm.com/898335afd880/c52ee8aa1e90/launch-5ef258dce664.min.js","fqdn":"assets.adobedtm.com","domain":"adobedtm.com","tld":"com"},"ip":{"addr":"96.6.17.25","port":443,"asn":16625,"as":"AKAMAI-AS","country":"Norway","country_code":"NO"},"introduction_type":"scriptElement","is_inline":false,"md5":"48246fd3c5f42a4da830ac25312a135f","sha1":"54384065724227a5b5671752bf5f2da785a856d4","sha256":"3777c25911c0259e059287354a170a0046dabc074b075d6e5ff47045f7a51492","sha512":"42781f96080608dea9650077430417c377b762e049999c8819f224e0918155fa578651805cb4a5a0d11f491d0cc1dee72c2286b83e0e11afcf236f432d894281","ssdeep":"1536:dNOsnc0ZM5ZwzNXIuqJ04zscoS10xSvWF4cLOPeqqcNFHemJB83szK8FekuOOCfz:8T1C4cLOPScDHlkct3Upntj2ImkRBRI","tlshash":"8cf3398a72a4b4a61bd331b5903f210af37b6959285cc034f691d8e17c7968e5273f3d","size":166662,"data":"","first_seen":"2023-03-13T20:39:53Z","last_seen":"2026-04-02T06:14:20.709218Z","times_seen":75,"alerts":{"ids":null,"analyzer":null,"urlquery":null}},{"url":{"schema":"https","addr":"ir.serestherapeutics.com/news-releases/news-release-details/seres-therapeutics-reports-ser-155-phase-1b-placebo-controlled","fqdn":"ir.serestherapeutics.com","domain":"serestherapeutics.com","tld":"com"},"ip":{"addr":"23.36.77.170","port":443,"asn":20940,"as":"Akamai International B.V.","country":"Norway","country_code":"NO"},"introduction_type":"scriptElement","is_inline":false,"md5":"0096b3a75c132c10f6a90df56192e4d7","sha1":"07cfa420d654e1531d97a9dccd23f4bede5edde7","sha256":"7e519b79026424c478dc1b72f347eb1327c9d01dc2458973bafe2690ca7d016d","sha512":"e6a302829a2b112324b04d3a0eaa094d34e38cef1cfdc1d83dabcfd540c9b6d866e661d3e55f021202164709babdf9e88685ca38dfdd52ea8eb66773fc9519ce","ssdeep":"","tlshash":"6880008a0bb0082a8220a200c8c3a838002080020a0a00a228802080ba808c308000e0","size":26,"data":"","first_seen":"2023-03-07T01:02:36Z","last_seen":"2026-04-03T17:37:32.269074Z","times_seen":96775,"alerts":{"ids":null,"analyzer":null,"urlquery":null}},{"url":{"schema":"https","addr":"ir.serestherapeutics.com/news-releases/news-release-details/seres-therapeutics-reports-ser-155-phase-1b-placebo-controlled","fqdn":"ir.serestherapeutics.com","domain":"serestherapeutics.com","tld":"com"},"ip":{"addr":"23.36.77.170","port":443,"asn":20940,"as":"Akamai International B.V.","country":"Norway","country_code":"NO"},"introduction_type":"scriptElement","is_inline":false,"md5":"91e37f24be76111b93a0ff728b96cddb","sha1":"e1740ea479e156d424cb918060d779528ecc8fae","sha256":"49ef43da1c84ec34b398aaab43e8debad168559596297c7586e9c9e8239c79bf","sha512":"f6794302c65cd64c0d6fca102f0233c49b2cdcee3caaaa18f42d3a6e3a7c3f59fc72461a36069c6af967a2e8dabbca580096e87abdc36b1e1324a041e3aefe66","ssdeep":"","tlshash":"ce80008a08b0082a0220a000c8c3e8b8002080020a0a00a228802000be808c308200c0","size":26,"data":"","first_seen":"2023-03-07T01:02:35Z","last_seen":"2026-04-03T17:37:32.337129Z","times_seen":95994,"alerts":{"ids":null,"analyzer":null,"urlquery":null}},{"url":{"schema":"https","addr":"ir.serestherapeutics.com/sites/g/files/knoqqb52941/files/js/js_PtDMcSRiFptmwcSpb0SAL1rDxUyMsgq3E5pFfNxiZUQ.js?scope=footer\u0026delta=5\u0026language=en\u0026theme=nir_pid2065\u0026include=eJyFjtsOAjEIRH_IbI2J_g6hhSiKZUNZL3_v2jXx8mJ4YGY4mVDFASvqPaS0VD_dgGSZQXGq5bCqf8HRjTqWsXEnwkwzeg_LiUnCHAhjnqzc0lt25DxpyHnGMH3bfh1xv7Q-xYBHvAESQVFsDVDZY2kZhTbr3TbZhd2FuIdXzk2Codr8MC___2TDaz8ANtZsDQ","fqdn":"ir.serestherapeutics.com","domain":"serestherapeutics.com","tld":"com"},"ip":{"addr":"23.36.77.170","port":443,"asn":20940,"as":"Akamai International B.V.","country":"Norway","country_code":"NO"},"introduction_type":"scriptElement","is_inline":false,"md5":"ba7b5058dd4458874d391ccb4b9255b4","sha1":"88207a2ba1fe8e595da1e1804ff1cf6fe65060fd","sha256":"70172f18455d34079d19b9e22ccf94b90144ae38f78c8f6f86240df2235fc1b7","sha512":"93feba18748b82c85a8fe55d7fa2015b8b2e900722fc712f6a3c8c5aa07b950f6e7ae37e410c1bc2bd460868746eba71301e8877ea85acf0ba11152cf8498c89","ssdeep":"6144:ay9ic07hVOESsw1MyW3knUUBYMmsH5JgTZC:ay9ic0qESsiMyW3kpJgTZC","tlshash":"9e641848bb50313943efb0fba49f4709723a990a8449e468f538c9d81eb5c45b5abf7c","size":331879,"data":"","first_seen":"2025-08-13T17:39:41.404533Z","last_seen":"2025-08-13T17:39:41.404533Z","times_seen":1,"alerts":{"ids":null,"analyzer":null,"urlquery":null}},{"url":{"schema":"https","addr":"ir.serestherapeutics.com/akam/13/6167875b","fqdn":"ir.serestherapeutics.com","domain":"serestherapeutics.com","tld":"com"},"ip":{"addr":"23.36.77.170","port":443,"asn":20940,"as":"Akamai International B.V.","country":"Norway","country_code":"NO"},"introduction_type":"scriptElement","is_inline":false,"md5":"f31d2ec966807d3b27af05b9a2abdf7d","sha1":"70f73b2b646a38fbfd3e95e9c8df92c65495965f","sha256":"676296369c77b3a4ec69d376e1b8bc4f0a515b24cd9e634835a6dd715666110b","sha512":"77f96a89520a79d08d889c5ce112375fdf2168dbc83ef833264909cd5a10ab52e4afaa5c22a5ff4e578ecbb021261095101e629f922081a34640fce54957bb7d","ssdeep":"768:7m+7iP/4DUfVutdN0of4fDnbwkVq4SoNfLqlsO:7NiP/WUfVlof4bbwKPO","tlshash":"bdc297d872d7ed0b678f4a83fd945efe2172857790c53247c3aeb98d16e828bd208944","size":26708,"data":"","first_seen":"2024-10-29T08:43:30.204658Z","last_seen":"2026-04-02T09:24:50.916416Z","times_seen":58,"alerts":{"ids":null,"analyzer":null,"urlquery":null}},{"url":{"schema":"https","addr":"ir.serestherapeutics.com/news-releases/news-release-details/seres-therapeutics-reports-ser-155-phase-1b-placebo-controlled","fqdn":"ir.serestherapeutics.com","domain":"serestherapeutics.com","tld":"com"},"ip":{"addr":"23.36.77.170","port":443,"asn":20940,"as":"Akamai International B.V.","country":"Norway","country_code":"NO"},"introduction_type":"scriptElement","is_inline":true,"md5":"f4337880d03431e9b560620c1598c4a5","sha1":"74e02c7aa6a620bbf963db8f866b058a4f952579","sha256":"4c2e57f71b786b795a2c1262ffcf923ba4261639c8988085f51d3a04e8127ae8","sha512":"7d0f2f8fb1c366ea0a921f538b61f3bf9077624f1d5f6ab649efc6f4e0a97c116b35f3db4f5147bfaf07c56e42a63c20db5a922f1c37d53b6e67e98b247458e3","ssdeep":"","tlshash":"42e07d42388042a6b687017e13ba4e8af712569556d1c03bdc5ecde9fc587da8c2d0c8","size":331,"data":"","first_seen":"2025-08-13T17:39:41.466768Z","last_seen":"2025-08-13T17:39:41.466768Z","times_seen":1,"alerts":{"ids":null,"analyzer":null,"urlquery":null}},{"url":{"schema":"https","addr":"ir.serestherapeutics.com/core/assets/vendor/modernizr/modernizr.min.js?v=3.11.7","fqdn":"ir.serestherapeutics.com","domain":"serestherapeutics.com","tld":"com"},"ip":{"addr":"23.36.77.170","port":443,"asn":20940,"as":"Akamai International B.V.","country":"Norway","country_code":"NO"},"introduction_type":"scriptElement","is_inline":false,"md5":"f96d807bae17f9897b9e9ab70a7e2b03","sha1":"4b0217fe11c12eaed7e590cd292541e5b89b626e","sha256":"939fe220ac3999512e38ecd5397d7334210c1568e7aec55eb6c6f4d1316c8353","sha512":"9baf4cd76ee496c9748024599f55f66a4174ebb2164ffd50126f33d950024031759fc16692a3c4ba61d9486cab8164f288d712504f20889f91749cd437093322","ssdeep":"192:q2Tm7k6zcGypAoyeF/X0it9yP0HYEs5I/1T/2nH:lr6zcGypAlE/XTtYP0HPs5uT/2H","tlshash":"28e1c5997393b172839930b021bf480e687a5d186e45cc04f02de1b8ae7cae56377e3c","size":7234,"data":"","first_seen":"2023-03-07T01:17:58Z","last_seen":"2026-04-02T21:46:26.18734Z","times_seen":1007,"alerts":{"ids":null,"analyzer":null,"urlquery":null}}],"eval":null,"write":null},"http":[{"url":{"schema":"https","addr":"analytics.imirwin.com/js/container_hNB1lXl3.js","fqdn":"analytics.imirwin.com","domain":"imirwin.com","tld":"com"},"ip":{"addr":"3.20.69.173","port":443,"asn":16509,"as":"AMAZON-02","country":"United States","country_code":"US"},"is_navigation_request":false,"resource_type":"script","requested_by":"https://ir.serestherapeutics.com/news-releases/news-release-details/seres-therapeutics-reports-ser-155-phase-1b-placebo-controlled","date":"2025-08-13T17:39:13.022Z","timestamp":0,"http_version":"","security_state":"secure","security_info":{"cipher_suite":"TLS_ECDHE_RSA_WITH_AES_128_GCM_SHA256","key_group_name":"P256","signature_name":"RSA-PKCS1-SHA256","protocol":"TLSv1.2","cert":{"subject":{"commonName":"analytics.imirwin.com","organization":""},"issuer":{"commonName":"Amazon RSA 2048 M04","organization":"Amazon"},"validity":{"start":"Mon, 19 May 2025 00:00:00 GMT","end":"Wed, 17 Jun 2026 23:59:59 GMT"},"fingerprint":{"sha1":"16:AE:C9:5B:15:E9:8D:4C:8E:FE:FD:30:19:4F:64:13:35:0C:E2:96","sha256":"53:75:12:9A:25:BD:14:3D:DC:A6:7E:44:7E:4B:69:48:EB:D8:28:7D:99:33:B5:94:B9:6F:F6:31:60:7E:0B:2E"}}},"request":{"raw":"GET /js/container_hNB1lXl3.js HTTP/1.1\r\nHost: analytics.imirwin.com\r\nUser-Agent: Mozilla/5.0 (Windows NT 10.0; Win64; x64; rv:134.0) Gecko/20100101 Firefox/134.0\r\nAccept: */*\r\nAccept-Language: en-US,en;q=0.5\r\nAccept-Encoding: gzip, deflate, br\r\nDNT: 1\r\nConnection: keep-alive\r\nReferer: https://ir.serestherapeutics.com/\r\nSec-Fetch-Dest: script\r\nSec-Fetch-Mode: no-cors\r\nSec-Fetch-Site: cross-site\r\nPragma: no-cache\r\nCache-Control: no-cache\r\n\r\n","headers":null,"cookies":null,"method":"GET"},"response":{"raw":"HTTP/2 200 OK\r\ndate: Wed, 13 Aug 2025 17:39:13 GMT\r\ncontent-type: application/javascript\r\ncontent-length: 112046\r\nserver: nginx/1.27.5\r\nlast-modified: Tue, 12 Aug 2025 16:01:49 GMT\r\netag: \"689b656d-1b5ae\"\r\nexpires: Wed, 13 Aug 2025 18:39:13 GMT\r\nreferrer-policy: origin\r\nstrict-transport-security: max-age=31536000; includeSubDomains\r\nx-frame-options: deny\r\npragma: public\r\ncache-control: max-age=3600, public\r\naccept-ranges: bytes\r\nX-Firefox-Spdy: h2\r\n\r\n","headers":null,"cookies":null,"status_code":"200","status_text":"OK","fingerprints":[{"name":"HSTS","description":"HTTP Strict Transport Security (HSTS) informs browsers that the site should only be accessed using HTTPS.","website":"https://www.rfc-editor.org/rfc/rfc6797#section-6.1","common_platform_enumeration":"","icon":"","categories":["Security"]},{"name":"Nginx:1.27.5","description":"Nginx is a web server that can also be used as a reverse proxy, load balancer, mail proxy and HTTP cache.","website":"https://nginx.org/en","common_platform_enumeration":"cpe:2.3:a:f5:nginx:*:*:*:*:*:*:*:*","icon":"Nginx.svg","categories":["Web servers","Reverse proxies"]}],"data":{"size":112046,"size_decoded":0,"mime_type":"application/javascript","magic":"JavaScript source, ASCII text, with very long lines (2878)","md5":"764b45cea9e09417beaba5a207bb7e15","sha1":"7eb4390c79688a778e9a01f6824d11131671b076","sha256":"d11a1d5dd8c8fe5b0b6df036df581dc1df9906866ab33c675a284e099a4639f7","sha512":"2df2f086bc157455c66d165085ea775f2a0154a6e175f2e31cef326683a77c2f328f1cadfba3f3602533008738f3c15613a7df2c0666840d84e6d87009d4242b","ssdeep":"3072:ZFKT+Z2fu7dzsyWbbVdda8EbdAA0XvBvGlh/X:DKSUu7dzszRdd8dngpvGlh/X","tlshash":"d5b3e88a32c3753647de6074943f0246f27d9dab240cd064e56ad8ea393c91ea53bf78","first_seen":"2025-08-13T17:39:41.30633Z","last_seen":"2025-08-13T17:39:41.30633Z","times_seen":1,"resource_available":true,"data":null}},"time_used":1461,"timings":{"blocked":511,"dns":19,"connect":109,"send":0,"wait":220,"receive":219,"ssl":377},"alerts":{"ids":null,"analyzer":null,"urlquery":null}},{"url":{"schema":"https","addr":"ir.serestherapeutics.com/core/assets/vendor/modernizr/modernizr.min.js?v=3.11.7","fqdn":"ir.serestherapeutics.com","domain":"serestherapeutics.com","tld":"com"},"ip":{"addr":"23.36.77.170","port":443,"asn":20940,"as":"Akamai International B.V.","country":"Norway","country_code":"NO"},"is_navigation_request":false,"resource_type":"script","requested_by":"https://ir.serestherapeutics.com/news-releases/news-release-details/seres-therapeutics-reports-ser-155-phase-1b-placebo-controlled","date":"2025-08-13T17:39:12.421Z","timestamp":0,"http_version":"","security_state":"secure","security_info":{"cipher_suite":"TLS_AES_256_GCM_SHA384","key_group_name":"x25519","signature_name":"RSA-PSS-SHA256","protocol":"TLSv1.3","cert":{"subject":{"commonName":"leapfrog-ssl-30.gcs-web.com","organization":""},"issuer":{"commonName":"R10","organization":"Let's Encrypt"},"validity":{"start":"Fri, 13 Jun 2025 04:44:47 GMT","end":"Thu, 11 Sep 2025 04:44:46 GMT"},"fingerprint":{"sha1":"76:56:CB:1C:2A:EB:BC:6C:AD:AC:F9:46:52:00:98:68:6F:36:7E:4D","sha256":"2E:92:CD:78:D5:3F:E1:8C:2B:75:38:93:FD:B6:D7:66:20:2F:C1:D0:0B:A0:AE:7D:AE:10:26:7A:9B:48:60:40"}}},"request":{"raw":"GET /core/assets/vendor/modernizr/modernizr.min.js?v=3.11.7 HTTP/1.1\r\nHost: ir.serestherapeutics.com\r\nUser-Agent: Mozilla/5.0 (Windows NT 10.0; Win64; x64; rv:134.0) Gecko/20100101 Firefox/134.0\r\nAccept: */*\r\nAccept-Language: en-US,en;q=0.5\r\nAccept-Encoding: gzip, deflate, br\r\nReferer: https://ir.serestherapeutics.com/news-releases/news-release-details/seres-therapeutics-reports-ser-155-phase-1b-placebo-controlled\r\nDNT: 1\r\nConnection: keep-alive\r\nCookie: bm_ss=ab8e18ef4e; ak_bmsc=8B3E3F53D6F1D551950B130550D015A2~000000000000000000000000000000~YAAQ9U0kF2FfO52YAQAAsLaDpBzYHEeJiZORhrKmMvVJl6htT4U5E/6alOnsN1WLbK0JNN0FxV6QIk3CXK6SZzJXWuElqmWB1WWYdY8quqhpWza5ivcl5im9nJoX7vrrq3G0vDVDRbOFK+CpHpJKlNA7AFE8qUMYv2oy8l08ONFK9GC3Aonufb2qXf/9ZjIkKIaaJrJwo1KUNgFeJmFTmRFsbb4oS3Jv2xmpV6uIXbaBeN9UhBTyS0HA2CF3KtgNehkaNLOEZnMBc1mLg/Q+bEEutjMUDLWyhdWbq0cnrrkhtimNWHnJcupfFzlIfpxdU3sj4xzZZ/Md5pzLYIOYZrVV2/12xnbT2CkSBSpx2FJsR/0yDsO84EToiNJUl0y3pFgjA1wezQP5EqYWYF8qXo/BI+qA; bm_s=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; bm_so=076452BA7F785C26C0D039192D414EE322EFEBEE47C9D32A826B033A65229333~YAAQ9U0kF2RfO52YAQAAsLaDpARpo2xHJdjU4Jxa73zUq51KuxsW+QSmb5iP/ENmk7iqOGRhZyjdzqR50bYOPoK0krDYMKoypGPYm3hLRIvJAjzEPSWU9v0AmtzNP00zTXG2hPxPx54udTSSuGTM2KzBDJRiwCiOkJhUWlTdDefECbi1wnKokP5hnBjxGDCQMAE2aCXe4HqNbDgvHE7G5jmtqONfD1YgD6Cw25QL5pfAPYy0BKE94QkgYz+X0zy3rLB0HCSNr0ZOGQwVNzi2iZcJKo5SMvwmYjG5K9U0kZTVIUSy4tJGLP5ot1++FSPm+vy3pNdvnFN2MubC56GIGbx4fuz6N7DiabN7PeQYi+r8MvS04Dnfb7d5OjiIIOID16B38U5M8NVX3SXmdkNgusrIqEHOgLTigWBDKbEIIu1+fexPgsghoQRNJTdw9HEjOj0FOJyf/HSuHOBqCbNWdmrBXQvBXBkw\r\nSec-Fetch-Dest: script\r\nSec-Fetch-Mode: no-cors\r\nSec-Fetch-Site: same-origin\r\nPragma: no-cache\r\nCache-Control: no-cache\r\n\r\n","headers":null,"cookies":null,"method":"GET"},"response":{"raw":"HTTP/2 200 OK\r\naccept-ranges: bytes\r\ncontent-encoding: gzip\r\ncontent-type: application/javascript\r\nlast-modified: Mon, 14 Jul 2025 09:42:25 GMT\r\nx-age: 902237\r\nx-cache-hits: 631\r\nx-content-type-options: nosniff\r\nx-request-id: v-bbaf458a-6c39-11f0-b180-8fb56d511624\r\ncontent-length: 3090\r\nx-edgeconnect-midmile-rtt: 17, 17\r\nx-edgeconnect-origin-mex-latency: 81, 81\r\ncache-control: max-age=600\r\nexpires: Wed, 13 Aug 2025 17:49:12 GMT\r\ndate: Wed, 13 Aug 2025 17:39:12 GMT\r\nvary: Accept-Encoding\r\nX-Firefox-Spdy: h2\r\n\r\n","headers":null,"cookies":null,"status_code":"200","status_text":"OK","fingerprints":[{"name":"Akamai","description":"Akamai is global content delivery network (CDN) services provider for media and software delivery, and cloud security solutions.","website":"https://akamai.com","common_platform_enumeration":"","icon":"Akamai.svg","categories":["CDN"]}],"data":{"size":7234,"size_decoded":0,"mime_type":"application/javascript","magic":"JavaScript source, ASCII text, with very long lines (7080)","md5":"f96d807bae17f9897b9e9ab70a7e2b03","sha1":"4b0217fe11c12eaed7e590cd292541e5b89b626e","sha256":"939fe220ac3999512e38ecd5397d7334210c1568e7aec55eb6c6f4d1316c8353","sha512":"9baf4cd76ee496c9748024599f55f66a4174ebb2164ffd50126f33d950024031759fc16692a3c4ba61d9486cab8164f288d712504f20889f91749cd437093322","ssdeep":"192:q2Tm7k6zcGypAoyeF/X0it9yP0HYEs5I/1T/2nH:lr6zcGypAlE/XTtYP0HPs5uT/2H","tlshash":"28e1c5997393b172839930b021bf480e687a5d186e45cc04f02de1b8ae7cae56377e3c","first_seen":"2023-03-07T01:17:58Z","last_seen":"2026-04-02T21:46:26.18734Z","times_seen":1007,"resource_available":true,"data":null}},"time_used":237,"timings":{"blocked":-1,"dns":0,"connect":0,"send":0,"wait":237,"receive":0,"ssl":0},"alerts":{"ids":null,"analyzer":null,"urlquery":null}},{"url":{"schema":"https","addr":"ir.serestherapeutics.com/sites/g/files/knoqqb52941/files/js/js_TvvMneviumwnWzrsAEnkCIevzGc9cao2ikDugPgFZzc.js?scope=header\u0026delta=1\u0026language=en\u0026theme=nir_pid2065\u0026include=eJyFjtsOAjEIRH_IbI2J_g6hhSiKZUNZL3_v2jXx8mJ4YGY4mVDFASvqPaS0VD_dgGSZQXGq5bCqf8HRjTqWsXEnwkwzeg_LiUnCHAhjnqzc0lt25DxpyHnGMH3bfh1xv7Q-xYBHvAESQVFsDVDZY2kZhTbr3TbZhd2FuIdXzk2Codr8MC___2TDaz8ANtZsDQ","fqdn":"ir.serestherapeutics.com","domain":"serestherapeutics.com","tld":"com"},"ip":{"addr":"23.36.77.170","port":443,"asn":20940,"as":"Akamai International B.V.","country":"Norway","country_code":"NO"},"is_navigation_request":false,"resource_type":"script","requested_by":"https://ir.serestherapeutics.com/news-releases/news-release-details/seres-therapeutics-reports-ser-155-phase-1b-placebo-controlled","date":"2025-08-13T17:39:12.422Z","timestamp":0,"http_version":"","security_state":"secure","security_info":{"cipher_suite":"TLS_AES_256_GCM_SHA384","key_group_name":"x25519","signature_name":"RSA-PSS-SHA256","protocol":"TLSv1.3","cert":{"subject":{"commonName":"leapfrog-ssl-30.gcs-web.com","organization":""},"issuer":{"commonName":"R10","organization":"Let's Encrypt"},"validity":{"start":"Fri, 13 Jun 2025 04:44:47 GMT","end":"Thu, 11 Sep 2025 04:44:46 GMT"},"fingerprint":{"sha1":"76:56:CB:1C:2A:EB:BC:6C:AD:AC:F9:46:52:00:98:68:6F:36:7E:4D","sha256":"2E:92:CD:78:D5:3F:E1:8C:2B:75:38:93:FD:B6:D7:66:20:2F:C1:D0:0B:A0:AE:7D:AE:10:26:7A:9B:48:60:40"}}},"request":{"raw":"GET /sites/g/files/knoqqb52941/files/js/js_TvvMneviumwnWzrsAEnkCIevzGc9cao2ikDugPgFZzc.js?scope=header\u0026delta=1\u0026language=en\u0026theme=nir_pid2065\u0026include=eJyFjtsOAjEIRH_IbI2J_g6hhSiKZUNZL3_v2jXx8mJ4YGY4mVDFASvqPaS0VD_dgGSZQXGq5bCqf8HRjTqWsXEnwkwzeg_LiUnCHAhjnqzc0lt25DxpyHnGMH3bfh1xv7Q-xYBHvAESQVFsDVDZY2kZhTbr3TbZhd2FuIdXzk2Codr8MC___2TDaz8ANtZsDQ HTTP/1.1\r\nHost: ir.serestherapeutics.com\r\nUser-Agent: Mozilla/5.0 (Windows NT 10.0; Win64; x64; rv:134.0) Gecko/20100101 Firefox/134.0\r\nAccept: */*\r\nAccept-Language: en-US,en;q=0.5\r\nAccept-Encoding: gzip, deflate, br\r\nReferer: https://ir.serestherapeutics.com/news-releases/news-release-details/seres-therapeutics-reports-ser-155-phase-1b-placebo-controlled\r\nDNT: 1\r\nConnection: keep-alive\r\nCookie: bm_ss=ab8e18ef4e; ak_bmsc=8B3E3F53D6F1D551950B130550D015A2~000000000000000000000000000000~YAAQ9U0kF2FfO52YAQAAsLaDpBzYHEeJiZORhrKmMvVJl6htT4U5E/6alOnsN1WLbK0JNN0FxV6QIk3CXK6SZzJXWuElqmWB1WWYdY8quqhpWza5ivcl5im9nJoX7vrrq3G0vDVDRbOFK+CpHpJKlNA7AFE8qUMYv2oy8l08ONFK9GC3Aonufb2qXf/9ZjIkKIaaJrJwo1KUNgFeJmFTmRFsbb4oS3Jv2xmpV6uIXbaBeN9UhBTyS0HA2CF3KtgNehkaNLOEZnMBc1mLg/Q+bEEutjMUDLWyhdWbq0cnrrkhtimNWHnJcupfFzlIfpxdU3sj4xzZZ/Md5pzLYIOYZrVV2/12xnbT2CkSBSpx2FJsR/0yDsO84EToiNJUl0y3pFgjA1wezQP5EqYWYF8qXo/BI+qA; bm_s=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; bm_so=076452BA7F785C26C0D039192D414EE322EFEBEE47C9D32A826B033A65229333~YAAQ9U0kF2RfO52YAQAAsLaDpARpo2xHJdjU4Jxa73zUq51KuxsW+QSmb5iP/ENmk7iqOGRhZyjdzqR50bYOPoK0krDYMKoypGPYm3hLRIvJAjzEPSWU9v0AmtzNP00zTXG2hPxPx54udTSSuGTM2KzBDJRiwCiOkJhUWlTdDefECbi1wnKokP5hnBjxGDCQMAE2aCXe4HqNbDgvHE7G5jmtqONfD1YgD6Cw25QL5pfAPYy0BKE94QkgYz+X0zy3rLB0HCSNr0ZOGQwVNzi2iZcJKo5SMvwmYjG5K9U0kZTVIUSy4tJGLP5ot1++FSPm+vy3pNdvnFN2MubC56GIGbx4fuz6N7DiabN7PeQYi+r8MvS04Dnfb7d5OjiIIOID16B38U5M8NVX3SXmdkNgusrIqEHOgLTigWBDKbEIIu1+fexPgsghoQRNJTdw9HEjOj0FOJyf/HSuHOBqCbNWdmrBXQvBXBkw\r\nSec-Fetch-Dest: script\r\nSec-Fetch-Mode: no-cors\r\nSec-Fetch-Site: same-origin\r\nPragma: no-cache\r\nCache-Control: no-cache\r\n\r\n","headers":null,"cookies":null,"method":"GET"},"response":{"raw":"HTTP/2 200 OK\r\naccept-ranges: bytes\r\ncontent-encoding: gzip\r\ncontent-type: text/javascript\r\nlast-modified: Tue, 15 Jul 2025 04:13:19 GMT\r\nx-age: 23806\r\nx-cache-hits: 10\r\nx-content-type-options: nosniff\r\nx-request-id: v-52a29816-6140-11f0-90a6-8362d99db695\r\ncontent-length: 819\r\nx-edgeconnect-midmile-rtt: 3, 17, 17\r\nx-edgeconnect-origin-mex-latency: 81, 81, 331\r\ncache-control: max-age=600\r\nexpires: Wed, 13 Aug 2025 17:49:12 GMT\r\ndate: Wed, 13 Aug 2025 17:39:12 GMT\r\nvary: Accept-Encoding\r\nX-Firefox-Spdy: h2\r\n\r\n","headers":null,"cookies":null,"status_code":"200","status_text":"OK","fingerprints":[{"name":"Akamai","description":"Akamai is global content delivery network (CDN) services provider for media and software delivery, and cloud security solutions.","website":"https://akamai.com","common_platform_enumeration":"","icon":"Akamai.svg","categories":["CDN"]}],"data":{"size":1904,"size_decoded":0,"mime_type":"text/javascript","magic":"ASCII text, with very long lines (610)","md5":"f822de69de8feaeee4fe1059567f9408","sha1":"ae078e5c46379343b81bdced29455f18172ef5e4","sha256":"a4006f09aef8eab1c7a6f5d7b76487d20714faab9c3d9011761e142106bcd1dd","sha512":"56b52d937f4500eb2aeddffea642c906e064f40fb87b794118f32df17365860ae8d1545b43398a0caa1e2ea359d7960807e87d245c3d4252a8e898ac6037f868","ssdeep":"","tlshash":"83412171f0f0163e5897109ac5e451907b6f000b7701d0d87abc79f47bec9e40ba495e","first_seen":"2025-02-18T17:49:31.898565Z","last_seen":"2026-04-02T06:14:20.696803Z","times_seen":51,"resource_available":true,"data":null}},"time_used":506,"timings":{"blocked":-1,"dns":0,"connect":0,"send":0,"wait":506,"receive":0,"ssl":0},"alerts":{"ids":null,"analyzer":null,"urlquery":null}},{"url":{"schema":"https","addr":"ml.globenewswire.com/media/NTE2NzRiODEtMWUxNS00YWNlLTlhMTEtNzY5NjYxMGQ4Mzc3LTEwMjg5MzQ=/tiny/Seres-Therapeutics-Inc-.png","fqdn":"ml.globenewswire.com","domain":"globenewswire.com","tld":"com"},"ip":{"addr":"23.36.77.251","port":443,"asn":20940,"as":"Akamai International B.V.","country":"Norway","country_code":"NO"},"is_navigation_request":false,"resource_type":"img","requested_by":"https://ir.serestherapeutics.com/news-releases/news-release-details/seres-therapeutics-reports-ser-155-phase-1b-placebo-controlled","date":"2025-08-13T17:39:12.428Z","timestamp":0,"http_version":"","security_state":"secure","security_info":{"cipher_suite":"TLS_AES_256_GCM_SHA384","key_group_name":"x25519","signature_name":"ECDSA-P256-SHA256","protocol":"TLSv1.3","cert":{"subject":{"commonName":"ml.globenewswire.com","organization":""},"issuer":{"commonName":"E6","organization":"Let's Encrypt"},"validity":{"start":"Mon, 11 Aug 2025 10:27:32 GMT","end":"Sun, 09 Nov 2025 10:27:31 GMT"},"fingerprint":{"sha1":"89:7F:B2:BE:16:18:E9:79:3F:DE:A2:F6:7F:60:58:05:DA:68:58:B2","sha256":"63:C0:F6:BB:B5:03:8A:F4:B4:CF:2D:D9:D9:B7:E9:64:E9:2F:75:1A:AE:F0:E2:58:33:EB:FC:B2:F4:8E:87:49"}}},"request":{"raw":"GET /media/NTE2NzRiODEtMWUxNS00YWNlLTlhMTEtNzY5NjYxMGQ4Mzc3LTEwMjg5MzQ=/tiny/Seres-Therapeutics-Inc-.png HTTP/1.1\r\nHost: ml.globenewswire.com\r\nUser-Agent: Mozilla/5.0 (Windows NT 10.0; Win64; x64; rv:134.0) Gecko/20100101 Firefox/134.0\r\nAccept: image/avif,image/webp,*/*\r\nAccept-Language: en-US,en;q=0.5\r\nAccept-Encoding: gzip, deflate, br\r\nDNT: 1\r\nConnection: keep-alive\r\nReferer: https://ir.serestherapeutics.com/\r\nSec-Fetch-Dest: image\r\nSec-Fetch-Mode: no-cors\r\nSec-Fetch-Site: cross-site\r\nPragma: no-cache\r\nCache-Control: no-cache\r\n\r\n","headers":null,"cookies":null,"method":"GET"},"response":{"raw":"HTTP/2 200 OK\r\npragma: no-cache\r\ncontent-type: image/png\r\nx-content-type-options: nosniff\r\nx-frame-options: ALLOWALL\r\nx-xss-protection: 1; mode=block\r\nstrict-transport-security: max-age=31536000; includeSubDomains; preload\r\ncontent-length: 35\r\ncache-control: no-cache, no-store, must-revalidate\r\nexpires: Wed, 13 Aug 2025 17:39:12 GMT\r\ndate: Wed, 13 Aug 2025 17:39:12 GMT\r\nX-Firefox-Spdy: h2\r\n\r\n","headers":null,"cookies":null,"status_code":"200","status_text":"OK","fingerprints":[{"name":"HSTS","description":"HTTP Strict Transport Security (HSTS) informs browsers that the site should only be accessed using HTTPS.","website":"https://www.rfc-editor.org/rfc/rfc6797#section-6.1","common_platform_enumeration":"","icon":"","categories":["Security"]}],"data":{"size":35,"size_decoded":0,"mime_type":"image/gif","magic":"GIF image data, version 89a, 1 x 1","md5":"c2196de8ba412c60c22ab491af7b1409","sha1":"5fbd472222feb8a22cf5b8aa5dc5b8e13af88e2b","sha256":"6adc3d4c1056996e4e8b765a62604c78b1f867cceb3b15d0b9bedb7c4857f992","sha512":"84e24a70b78e9de9c9d0dfeb49f3f4247dbc1c715d8844471ee40669270682e199d48f5fbec62bd984c9c0270534b407c4d2561dd6c05adec3c83c1534f32d5c","ssdeep":"","tlshash":"d4800003e280c002c2a2c0300e0ccb802b88b0208a28030fb0ec2baeec3a2a00c02000","first_seen":"2023-04-05T07:36:27Z","last_seen":"2026-04-03T18:27:01.406188Z","times_seen":150639,"resource_available":true,"data":null}},"time_used":371,"timings":{"blocked":95,"dns":89,"connect":6,"send":0,"wait":165,"receive":0,"ssl":0},"alerts":{"ids":null,"analyzer":null,"urlquery":null}},{"url":{"schema":"https","addr":"ir.serestherapeutics.com/core/assets/vendor/ckeditor5/ckeditor5-dll/ckeditor5-dll.js?v=44.0.0","fqdn":"ir.serestherapeutics.com","domain":"serestherapeutics.com","tld":"com"},"ip":{"addr":"23.36.77.170","port":443,"asn":20940,"as":"Akamai International B.V.","country":"Norway","country_code":"NO"},"is_navigation_request":false,"resource_type":"script","requested_by":"https://ir.serestherapeutics.com/news-releases/news-release-details/seres-therapeutics-reports-ser-155-phase-1b-placebo-controlled","date":"2025-08-13T17:39:12.433Z","timestamp":0,"http_version":"","security_state":"secure","security_info":{"cipher_suite":"TLS_AES_256_GCM_SHA384","key_group_name":"x25519","signature_name":"RSA-PSS-SHA256","protocol":"TLSv1.3","cert":{"subject":{"commonName":"leapfrog-ssl-30.gcs-web.com","organization":""},"issuer":{"commonName":"R10","organization":"Let's Encrypt"},"validity":{"start":"Fri, 13 Jun 2025 04:44:47 GMT","end":"Thu, 11 Sep 2025 04:44:46 GMT"},"fingerprint":{"sha1":"76:56:CB:1C:2A:EB:BC:6C:AD:AC:F9:46:52:00:98:68:6F:36:7E:4D","sha256":"2E:92:CD:78:D5:3F:E1:8C:2B:75:38:93:FD:B6:D7:66:20:2F:C1:D0:0B:A0:AE:7D:AE:10:26:7A:9B:48:60:40"}}},"request":{"raw":"GET /core/assets/vendor/ckeditor5/ckeditor5-dll/ckeditor5-dll.js?v=44.0.0 HTTP/1.1\r\nHost: ir.serestherapeutics.com\r\nUser-Agent: Mozilla/5.0 (Windows NT 10.0; Win64; x64; rv:134.0) Gecko/20100101 Firefox/134.0\r\nAccept: */*\r\nAccept-Language: en-US,en;q=0.5\r\nAccept-Encoding: gzip, deflate, br\r\nReferer: https://ir.serestherapeutics.com/news-releases/news-release-details/seres-therapeutics-reports-ser-155-phase-1b-placebo-controlled\r\nDNT: 1\r\nConnection: keep-alive\r\nCookie: bm_ss=ab8e18ef4e; ak_bmsc=8B3E3F53D6F1D551950B130550D015A2~000000000000000000000000000000~YAAQ9U0kF2FfO52YAQAAsLaDpBzYHEeJiZORhrKmMvVJl6htT4U5E/6alOnsN1WLbK0JNN0FxV6QIk3CXK6SZzJXWuElqmWB1WWYdY8quqhpWza5ivcl5im9nJoX7vrrq3G0vDVDRbOFK+CpHpJKlNA7AFE8qUMYv2oy8l08ONFK9GC3Aonufb2qXf/9ZjIkKIaaJrJwo1KUNgFeJmFTmRFsbb4oS3Jv2xmpV6uIXbaBeN9UhBTyS0HA2CF3KtgNehkaNLOEZnMBc1mLg/Q+bEEutjMUDLWyhdWbq0cnrrkhtimNWHnJcupfFzlIfpxdU3sj4xzZZ/Md5pzLYIOYZrVV2/12xnbT2CkSBSpx2FJsR/0yDsO84EToiNJUl0y3pFgjA1wezQP5EqYWYF8qXo/BI+qA; bm_s=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; bm_so=076452BA7F785C26C0D039192D414EE322EFEBEE47C9D32A826B033A65229333~YAAQ9U0kF2RfO52YAQAAsLaDpARpo2xHJdjU4Jxa73zUq51KuxsW+QSmb5iP/ENmk7iqOGRhZyjdzqR50bYOPoK0krDYMKoypGPYm3hLRIvJAjzEPSWU9v0AmtzNP00zTXG2hPxPx54udTSSuGTM2KzBDJRiwCiOkJhUWlTdDefECbi1wnKokP5hnBjxGDCQMAE2aCXe4HqNbDgvHE7G5jmtqONfD1YgD6Cw25QL5pfAPYy0BKE94QkgYz+X0zy3rLB0HCSNr0ZOGQwVNzi2iZcJKo5SMvwmYjG5K9U0kZTVIUSy4tJGLP5ot1++FSPm+vy3pNdvnFN2MubC56GIGbx4fuz6N7DiabN7PeQYi+r8MvS04Dnfb7d5OjiIIOID16B38U5M8NVX3SXmdkNgusrIqEHOgLTigWBDKbEIIu1+fexPgsghoQRNJTdw9HEjOj0FOJyf/HSuHOBqCbNWdmrBXQvBXBkw\r\nSec-Fetch-Dest: script\r\nSec-Fetch-Mode: no-cors\r\nSec-Fetch-Site: same-origin\r\nPragma: no-cache\r\nCache-Control: no-cache\r\n\r\n","headers":null,"cookies":null,"method":"GET"},"response":{"raw":"HTTP/2 200 OK\r\naccept-ranges: bytes\r\ncontent-encoding: gzip\r\ncontent-type: application/javascript\r\nlast-modified: Mon, 14 Jul 2025 09:42:25 GMT\r\nx-age: 1140855\r\nx-cache-hits: 737\r\nx-content-type-options: nosniff\r\nx-request-id: v-40c8afac-6c3c-11f0-97ac-c70bd2acc842\r\ncontent-length: 222571\r\nx-edgeconnect-midmile-rtt: 19, 17\r\nx-edgeconnect-origin-mex-latency: 91, 89\r\ncache-control: max-age=600\r\nexpires: Wed, 13 Aug 2025 17:49:12 GMT\r\ndate: Wed, 13 Aug 2025 17:39:12 GMT\r\nvary: Accept-Encoding\r\nX-Firefox-Spdy: h2\r\n\r\n","headers":null,"cookies":null,"status_code":"200","status_text":"OK","fingerprints":[{"name":"Akamai","description":"Akamai is global content delivery network (CDN) services provider for media and software delivery, and cloud security solutions.","website":"https://akamai.com","common_platform_enumeration":"","icon":"Akamai.svg","categories":["CDN"]}],"data":{"size":906816,"size_decoded":0,"mime_type":"application/javascript","magic":"JavaScript source, ASCII text, with very long lines (59930)","md5":"0829cd485a97b172a20d9b4440177663","sha1":"754da1464b4ed1cbae25470694a833d115fa0db6","sha256":"949d7c22a15dc8849b42cafaf60d600dba1001e5aa873b89f49919611b4d224a","sha512":"b2febce2fc6282ac7a9483c1d4d5e384cff246957c99e28260098e8faf8bcf83a8d16dd8df16214f2a37e3a80a3f2dfe45540822ea96aca9e20700682ba275a9","ssdeep":"6144:S5p7ISED/w6g0E8CwJ7D8CwJ7P8CwJ7BYr5ej9V8kPRwQ+nHSehWLR9xfgnjuEqb:Sd0xdjVJ6WLR3D7Ere3v","tlshash":"a115279131a475b717da92bf60b50542f33d0c44b406816cbaacdcdf289f88a26b7b7d","first_seen":"2025-03-08T05:33:16.190483Z","last_seen":"2026-03-07T03:35:09.779249Z","times_seen":69,"resource_available":true,"data":null}},"time_used":317,"timings":{"blocked":-1,"dns":0,"connect":0,"send":0,"wait":309,"receive":8,"ssl":0},"alerts":{"ids":null,"analyzer":null,"urlquery":null}},{"url":{"schema":"https","addr":"ir.serestherapeutics.com/RNdDsxyv1HCi8/5bsN/eeYDOHqv5c/8X9XwQGY/cggyWQ/S2ZjfUY/dTWdCAQ","fqdn":"ir.serestherapeutics.com","domain":"serestherapeutics.com","tld":"com"},"ip":{"addr":"23.36.77.170","port":443,"asn":20940,"as":"Akamai International B.V.","country":"Norway","country_code":"NO"},"is_navigation_request":false,"resource_type":"xhr","requested_by":"https://ir.serestherapeutics.com/news-releases/news-release-details/seres-therapeutics-reports-ser-155-phase-1b-placebo-controlled","date":"2025-08-13T17:39:17.838Z","timestamp":0,"http_version":"","security_state":"secure","security_info":{"cipher_suite":"TLS_AES_256_GCM_SHA384","key_group_name":"x25519","signature_name":"RSA-PSS-SHA256","protocol":"TLSv1.3","cert":{"subject":{"commonName":"leapfrog-ssl-30.gcs-web.com","organization":""},"issuer":{"commonName":"R10","organization":"Let's Encrypt"},"validity":{"start":"Fri, 13 Jun 2025 04:44:47 GMT","end":"Thu, 11 Sep 2025 04:44:46 GMT"},"fingerprint":{"sha1":"76:56:CB:1C:2A:EB:BC:6C:AD:AC:F9:46:52:00:98:68:6F:36:7E:4D","sha256":"2E:92:CD:78:D5:3F:E1:8C:2B:75:38:93:FD:B6:D7:66:20:2F:C1:D0:0B:A0:AE:7D:AE:10:26:7A:9B:48:60:40"}}},"request":{"raw":"POST /RNdDsxyv1HCi8/5bsN/eeYDOHqv5c/8X9XwQGY/cggyWQ/S2ZjfUY/dTWdCAQ HTTP/1.1\r\nHost: ir.serestherapeutics.com\r\nUser-Agent: Mozilla/5.0 (Windows NT 10.0; Win64; x64; rv:134.0) Gecko/20100101 Firefox/134.0\r\nAccept: */*\r\nAccept-Language: en-US,en;q=0.5\r\nAccept-Encoding: gzip, deflate, br\r\nReferer: https://ir.serestherapeutics.com/news-releases/news-release-details/seres-therapeutics-reports-ser-155-phase-1b-placebo-controlled\r\nContent-Type: application/json\r\nContent-Length: 2672\r\nOrigin: https://ir.serestherapeutics.com\r\nDNT: 1\r\nConnection: keep-alive\r\nCookie: bm_ss=ab8e18ef4e; ak_bmsc=4E19C384354D9168EC037A0AE57F6E73~000000000000000000000000000000~YAAQ9U0kF35fO52YAQAAx7+DpBySZ/dfHdC4B5oUtNpuV2adhHIky7zORHESo+cA0boAKlpN0M1F0xemTlMj/fjitsk1gqPk8Rnv/JXOTVU1pJjkRHE4cvI1fxp7EOGzBft8N148JDVfar1U580eQu7mdWb4woUsrQ9CiwpG3Sh/GCoUOTSod4yVM6PXFf0x6S+wv0PQcfS8Adrxzqfl1Ma+/rkBJb9LxKTjiedjFZ2dIy3Hkd0qo9v67qkS0kSAzuHAgYjwXUROH/c6DnpyWQWD6GuvM4QWEhRa1q3HQdkE+HEd4nQrs6wKVajPvLFHGf+YkJRmLWLlPd5np30wqIS7bymQ/R6U7rSFiwI55664EdT1uWwylPUhd9tgyXc0G1RPEzRBF+HMs3Vj0hPTvjvNZYGjuGZN7oA2Uls4Z1LLzAPNLg4rFXi4vFoOl9OGIwqJ+w1ROra+oPpmbDznVyX1t53SC/Hh; bm_s=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; bm_so=076452BA7F785C26C0D039192D414EE322EFEBEE47C9D32A826B033A65229333~YAAQ9U0kF2RfO52YAQAAsLaDpARpo2xHJdjU4Jxa73zUq51KuxsW+QSmb5iP/ENmk7iqOGRhZyjdzqR50bYOPoK0krDYMKoypGPYm3hLRIvJAjzEPSWU9v0AmtzNP00zTXG2hPxPx54udTSSuGTM2KzBDJRiwCiOkJhUWlTdDefECbi1wnKokP5hnBjxGDCQMAE2aCXe4HqNbDgvHE7G5jmtqONfD1YgD6Cw25QL5pfAPYy0BKE94QkgYz+X0zy3rLB0HCSNr0ZOGQwVNzi2iZcJKo5SMvwmYjG5K9U0kZTVIUSy4tJGLP5ot1++FSPm+vy3pNdvnFN2MubC56GIGbx4fuz6N7DiabN7PeQYi+r8MvS04Dnfb7d5OjiIIOID16B38U5M8NVX3SXmdkNgusrIqEHOgLTigWBDKbEIIu1+fexPgsghoQRNJTdw9HEjOj0FOJyf/HSuHOBqCbNWdmrBXQvBXBkw; bm_lso=076452BA7F785C26C0D039192D414EE322EFEBEE47C9D32A826B033A65229333~YAAQ9U0kF2RfO52YAQAAsLaDpARpo2xHJdjU4Jxa73zUq51KuxsW+QSmb5iP/ENmk7iqOGRhZyjdzqR50bYOPoK0krDYMKoypGPYm3hLRIvJAjzEPSWU9v0AmtzNP00zTXG2hPxPx54udTSSuGTM2KzBDJRiwCiOkJhUWlTdDefECbi1wnKokP5hnBjxGDCQMAE2aCXe4HqNbDgvHE7G5jmtqONfD1YgD6Cw25QL5pfAPYy0BKE94QkgYz+X0zy3rLB0HCSNr0ZOGQwVNzi2iZcJKo5SMvwmYjG5K9U0kZTVIUSy4tJGLP5ot1++FSPm+vy3pNdvnFN2MubC56GIGbx4fuz6N7DiabN7PeQYi+r8MvS04Dnfb7d5OjiIIOID16B38U5M8NVX3SXmdkNgusrIqEHOgLTigWBDKbEIIu1+fexPgsghoQRNJTdw9HEjOj0FOJyf/HSuHOBqCbNWdmrBXQvBXBkw^1755106754250; _pk_id.310.7332=2c4a18add8648920.1755106754.; _pk_ses.310.7332=1; AMCV_98CF678254E93B1B0A4C98A5%40AdobeOrg=179643557%7CMCMID%7C50545728401776829424379634313304809965%7CMCOPTOUT-1755113954s%7CNONE%7CvVersion%7C5.5.0; AMCVS_98CF678254E93B1B0A4C98A5%40AdobeOrg=1; s_cc=true\r\nSec-Fetch-Dest: empty\r\nSec-Fetch-Mode: cors\r\nSec-Fetch-Site: same-origin\r\nPragma: no-cache\r\nCache-Control: no-cache\r\n\r\n","headers":null,"cookies":null,"method":"POST"},"response":{"raw":"HTTP/2 200 OK\r\ncontent-type: application/json\r\ncontent-encoding: gzip\r\nexpires: Wed, 13 Aug 2025 17:39:17 GMT\r\ncache-control: max-age=0, no-cache, no-store\r\npragma: no-cache\r\ncontent-length: 20\r\ndate: Wed, 13 Aug 2025 17:39:17 GMT\r\nvary: Accept-Encoding\r\nset-cookie: bm_s=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; Domain=.serestherapeutics.com; Path=/; Expires=Sat, 13 Sep 2025 17:39:17 GMT; Max-Age=2678400; Secure; HttpOnly\r\nX-Firefox-Spdy: h2\r\n\r\n","headers":null,"cookies":null,"status_code":"200","status_text":"OK","fingerprints":null,"data":{"size":0,"size_decoded":0,"mime_type":"application/json","magic":"","md5":"d41d8cd98f00b204e9800998ecf8427e","sha1":"da39a3ee5e6b4b0d3255bfef95601890afd80709","sha256":"e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855","sha512":"cf83e1357eefb8bdf1542850d66d8007d620e4050b5715dc83f4a921d36ce9ce47d0d13c5d85f2b0ff8318d2877eec2f63b931bd47417a81a538327af927da3e","ssdeep":"","tlshash":"","first_seen":"0001-01-01T00:00:00Z","last_seen":"2026-04-03T18:31:03.533086Z","times_seen":13299059,"resource_available":true,"data":null}},"time_used":31,"timings":{"blocked":1,"dns":0,"connect":0,"send":0,"wait":30,"receive":0,"ssl":0},"alerts":{"ids":null,"analyzer":null,"urlquery":null}},{"url":{"schema":"https","addr":"ir.serestherapeutics.com/sites/g/files/knoqqb52941/files/css/css_aO3gfVpreLC_ok0rmlGqfTNnOYGIjQgI1drc006UnII.css?delta=5\u0026language=en\u0026theme=nir_pid2065\u0026include=eJyNj9EKwjAMRX9orCLo74TbNsxim4w0Cvt7O_eiD4Jvl8NNcpLUOGR7rKhzLqi6TFKMIjqHPZSk0r-Rq9YIe8MGu7NThoNi1XQPENStOxm8yDKmjNIN5n_VOzli5R_dxhAyTtoay-BF5WP3iuXw28M8tJ3FqW-ShoQIH8JryefT9RL0yWYl89THdW5h_-4Fhv1pRA","fqdn":"ir.serestherapeutics.com","domain":"serestherapeutics.com","tld":"com"},"ip":{"addr":"23.36.77.170","port":443,"asn":20940,"as":"Akamai International B.V.","country":"Norway","country_code":"NO"},"is_navigation_request":false,"resource_type":"stylesheet","requested_by":"https://ir.serestherapeutics.com/news-releases/news-release-details/seres-therapeutics-reports-ser-155-phase-1b-placebo-controlled","date":"2025-08-13T17:39:12.419Z","timestamp":0,"http_version":"","security_state":"secure","security_info":{"cipher_suite":"TLS_AES_256_GCM_SHA384","key_group_name":"x25519","signature_name":"RSA-PSS-SHA256","protocol":"TLSv1.3","cert":{"subject":{"commonName":"leapfrog-ssl-30.gcs-web.com","organization":""},"issuer":{"commonName":"R10","organization":"Let's Encrypt"},"validity":{"start":"Fri, 13 Jun 2025 04:44:47 GMT","end":"Thu, 11 Sep 2025 04:44:46 GMT"},"fingerprint":{"sha1":"76:56:CB:1C:2A:EB:BC:6C:AD:AC:F9:46:52:00:98:68:6F:36:7E:4D","sha256":"2E:92:CD:78:D5:3F:E1:8C:2B:75:38:93:FD:B6:D7:66:20:2F:C1:D0:0B:A0:AE:7D:AE:10:26:7A:9B:48:60:40"}}},"request":{"raw":"GET /sites/g/files/knoqqb52941/files/css/css_aO3gfVpreLC_ok0rmlGqfTNnOYGIjQgI1drc006UnII.css?delta=5\u0026language=en\u0026theme=nir_pid2065\u0026include=eJyNj9EKwjAMRX9orCLo74TbNsxim4w0Cvt7O_eiD4Jvl8NNcpLUOGR7rKhzLqi6TFKMIjqHPZSk0r-Rq9YIe8MGu7NThoNi1XQPENStOxm8yDKmjNIN5n_VOzli5R_dxhAyTtoay-BF5WP3iuXw28M8tJ3FqW-ShoQIH8JryefT9RL0yWYl89THdW5h_-4Fhv1pRA HTTP/1.1\r\nHost: ir.serestherapeutics.com\r\nUser-Agent: Mozilla/5.0 (Windows NT 10.0; Win64; x64; rv:134.0) Gecko/20100101 Firefox/134.0\r\nAccept: text/css,*/*;q=0.1\r\nAccept-Language: en-US,en;q=0.5\r\nAccept-Encoding: gzip, deflate, br\r\nReferer: https://ir.serestherapeutics.com/news-releases/news-release-details/seres-therapeutics-reports-ser-155-phase-1b-placebo-controlled\r\nDNT: 1\r\nConnection: keep-alive\r\nCookie: bm_ss=ab8e18ef4e; ak_bmsc=8B3E3F53D6F1D551950B130550D015A2~000000000000000000000000000000~YAAQ9U0kF2FfO52YAQAAsLaDpBzYHEeJiZORhrKmMvVJl6htT4U5E/6alOnsN1WLbK0JNN0FxV6QIk3CXK6SZzJXWuElqmWB1WWYdY8quqhpWza5ivcl5im9nJoX7vrrq3G0vDVDRbOFK+CpHpJKlNA7AFE8qUMYv2oy8l08ONFK9GC3Aonufb2qXf/9ZjIkKIaaJrJwo1KUNgFeJmFTmRFsbb4oS3Jv2xmpV6uIXbaBeN9UhBTyS0HA2CF3KtgNehkaNLOEZnMBc1mLg/Q+bEEutjMUDLWyhdWbq0cnrrkhtimNWHnJcupfFzlIfpxdU3sj4xzZZ/Md5pzLYIOYZrVV2/12xnbT2CkSBSpx2FJsR/0yDsO84EToiNJUl0y3pFgjA1wezQP5EqYWYF8qXo/BI+qA; bm_s=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; bm_so=076452BA7F785C26C0D039192D414EE322EFEBEE47C9D32A826B033A65229333~YAAQ9U0kF2RfO52YAQAAsLaDpARpo2xHJdjU4Jxa73zUq51KuxsW+QSmb5iP/ENmk7iqOGRhZyjdzqR50bYOPoK0krDYMKoypGPYm3hLRIvJAjzEPSWU9v0AmtzNP00zTXG2hPxPx54udTSSuGTM2KzBDJRiwCiOkJhUWlTdDefECbi1wnKokP5hnBjxGDCQMAE2aCXe4HqNbDgvHE7G5jmtqONfD1YgD6Cw25QL5pfAPYy0BKE94QkgYz+X0zy3rLB0HCSNr0ZOGQwVNzi2iZcJKo5SMvwmYjG5K9U0kZTVIUSy4tJGLP5ot1++FSPm+vy3pNdvnFN2MubC56GIGbx4fuz6N7DiabN7PeQYi+r8MvS04Dnfb7d5OjiIIOID16B38U5M8NVX3SXmdkNgusrIqEHOgLTigWBDKbEIIu1+fexPgsghoQRNJTdw9HEjOj0FOJyf/HSuHOBqCbNWdmrBXQvBXBkw\r\nSec-Fetch-Dest: style\r\nSec-Fetch-Mode: no-cors\r\nSec-Fetch-Site: same-origin\r\nPragma: no-cache\r\nCache-Control: no-cache\r\n\r\n","headers":null,"cookies":null,"method":"GET"},"response":{"raw":"HTTP/2 200 OK\r\naccept-ranges: bytes\r\ncontent-encoding: gzip\r\ncontent-type: text/css\r\nlast-modified: Tue, 15 Jul 2025 04:37:05 GMT\r\nx-age: 24579\r\nx-cache-hits: 20\r\nx-content-type-options: nosniff\r\nx-request-id: v-813061ba-613e-11f0-853f-6fd9854c11e0\r\ncontent-length: 18963\r\nx-edgeconnect-midmile-rtt: 17, 16\r\nx-edgeconnect-origin-mex-latency: 81, 249\r\ncache-control: max-age=600\r\nexpires: Wed, 13 Aug 2025 17:49:12 GMT\r\ndate: Wed, 13 Aug 2025 17:39:12 GMT\r\nvary: Accept-Encoding\r\nX-Firefox-Spdy: h2\r\n\r\n","headers":null,"cookies":null,"status_code":"200","status_text":"OK","fingerprints":[{"name":"Akamai","description":"Akamai is global content delivery network (CDN) services provider for media and software delivery, and cloud security solutions.","website":"https://akamai.com","common_platform_enumeration":"","icon":"Akamai.svg","categories":["CDN"]}],"data":{"size":136708,"size_decoded":0,"mime_type":"text/css","magic":"ASCII text, with very long lines (42823)","md5":"f8948f83b7cc9aaea748024b2d7ba659","sha1":"60518772a2dc3d1fef763ed2a2022ba3dfadd588","sha256":"09dda277453af39793dacb98707ed918cb5aa36c890f1566fd876d19fd4323bd","sha512":"78df5ac56a55ed5e960ae6eef9a968f6c599c1e3ce53c87742954d34ceadc697415709e011f20c188dbfb594745e84e81440fd8039b87a5cdbeed00c4d9030d3","ssdeep":"1536:p69zGx7w1SardrtwlqyatyqqOu63r8d/b8:p69zg7w1SardrtwlqyatyqqOua","tlshash":"d5d320b16690244a22f5c42e53463679552fc3e2e7432dede982b96e45c9fc703f0b3a","first_seen":"2025-08-13T17:39:41.361942Z","last_seen":"2025-08-13T17:39:41.361942Z","times_seen":1,"resource_available":false,"data":null}},"time_used":405,"timings":{"blocked":-1,"dns":0,"connect":0,"send":0,"wait":404,"receive":1,"ssl":0},"alerts":{"ids":null,"analyzer":null,"urlquery":null}},{"url":{"schema":"https","addr":"ir.serestherapeutics.com/sites/g/files/knoqqb52941/themes/site/nir_pid2065/dist/img/hero/GettyImages-1097453144-Edited3.jpg","fqdn":"ir.serestherapeutics.com","domain":"serestherapeutics.com","tld":"com"},"ip":{"addr":"23.36.77.170","port":443,"asn":20940,"as":"Akamai International B.V.","country":"Norway","country_code":"NO"},"is_navigation_request":false,"resource_type":"img","requested_by":"https://ir.serestherapeutics.com/news-releases/news-release-details/seres-therapeutics-reports-ser-155-phase-1b-placebo-controlled","date":"2025-08-13T17:39:12.425Z","timestamp":0,"http_version":"","security_state":"secure","security_info":{"cipher_suite":"TLS_AES_256_GCM_SHA384","key_group_name":"x25519","signature_name":"RSA-PSS-SHA256","protocol":"TLSv1.3","cert":{"subject":{"commonName":"leapfrog-ssl-30.gcs-web.com","organization":""},"issuer":{"commonName":"R10","organization":"Let's Encrypt"},"validity":{"start":"Fri, 13 Jun 2025 04:44:47 GMT","end":"Thu, 11 Sep 2025 04:44:46 GMT"},"fingerprint":{"sha1":"76:56:CB:1C:2A:EB:BC:6C:AD:AC:F9:46:52:00:98:68:6F:36:7E:4D","sha256":"2E:92:CD:78:D5:3F:E1:8C:2B:75:38:93:FD:B6:D7:66:20:2F:C1:D0:0B:A0:AE:7D:AE:10:26:7A:9B:48:60:40"}}},"request":{"raw":"GET /sites/g/files/knoqqb52941/themes/site/nir_pid2065/dist/img/hero/GettyImages-1097453144-Edited3.jpg HTTP/1.1\r\nHost: ir.serestherapeutics.com\r\nUser-Agent: Mozilla/5.0 (Windows NT 10.0; Win64; x64; rv:134.0) Gecko/20100101 Firefox/134.0\r\nAccept: image/avif,image/webp,*/*\r\nAccept-Language: en-US,en;q=0.5\r\nAccept-Encoding: gzip, deflate, br\r\nReferer: https://ir.serestherapeutics.com/news-releases/news-release-details/seres-therapeutics-reports-ser-155-phase-1b-placebo-controlled\r\nDNT: 1\r\nConnection: keep-alive\r\nCookie: bm_ss=ab8e18ef4e; ak_bmsc=8B3E3F53D6F1D551950B130550D015A2~000000000000000000000000000000~YAAQ9U0kF2FfO52YAQAAsLaDpBzYHEeJiZORhrKmMvVJl6htT4U5E/6alOnsN1WLbK0JNN0FxV6QIk3CXK6SZzJXWuElqmWB1WWYdY8quqhpWza5ivcl5im9nJoX7vrrq3G0vDVDRbOFK+CpHpJKlNA7AFE8qUMYv2oy8l08ONFK9GC3Aonufb2qXf/9ZjIkKIaaJrJwo1KUNgFeJmFTmRFsbb4oS3Jv2xmpV6uIXbaBeN9UhBTyS0HA2CF3KtgNehkaNLOEZnMBc1mLg/Q+bEEutjMUDLWyhdWbq0cnrrkhtimNWHnJcupfFzlIfpxdU3sj4xzZZ/Md5pzLYIOYZrVV2/12xnbT2CkSBSpx2FJsR/0yDsO84EToiNJUl0y3pFgjA1wezQP5EqYWYF8qXo/BI+qA; bm_s=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; bm_so=076452BA7F785C26C0D039192D414EE322EFEBEE47C9D32A826B033A65229333~YAAQ9U0kF2RfO52YAQAAsLaDpARpo2xHJdjU4Jxa73zUq51KuxsW+QSmb5iP/ENmk7iqOGRhZyjdzqR50bYOPoK0krDYMKoypGPYm3hLRIvJAjzEPSWU9v0AmtzNP00zTXG2hPxPx54udTSSuGTM2KzBDJRiwCiOkJhUWlTdDefECbi1wnKokP5hnBjxGDCQMAE2aCXe4HqNbDgvHE7G5jmtqONfD1YgD6Cw25QL5pfAPYy0BKE94QkgYz+X0zy3rLB0HCSNr0ZOGQwVNzi2iZcJKo5SMvwmYjG5K9U0kZTVIUSy4tJGLP5ot1++FSPm+vy3pNdvnFN2MubC56GIGbx4fuz6N7DiabN7PeQYi+r8MvS04Dnfb7d5OjiIIOID16B38U5M8NVX3SXmdkNgusrIqEHOgLTigWBDKbEIIu1+fexPgsghoQRNJTdw9HEjOj0FOJyf/HSuHOBqCbNWdmrBXQvBXBkw\r\nSec-Fetch-Dest: image\r\nSec-Fetch-Mode: no-cors\r\nSec-Fetch-Site: same-origin\r\nPragma: no-cache\r\nCache-Control: no-cache\r\n\r\n","headers":null,"cookies":null,"method":"GET"},"response":{"raw":"HTTP/2 200 OK\r\naccept-ranges: bytes\r\ncontent-type: image/jpeg\r\nlast-modified: Mon, 14 Jul 2025 09:57:48 GMT\r\nx-age: 1138149\r\nx-cache-hits: 534\r\nx-content-type-options: nosniff\r\nx-request-id: v-8d54fdde-6c42-11f0-a829-cfb05386ab0b\r\ncontent-length: 442347\r\nx-edgeconnect-midmile-rtt: 16, 16\r\nx-edgeconnect-origin-mex-latency: 160, 81\r\ncache-control: max-age=600\r\nexpires: Wed, 13 Aug 2025 17:49:12 GMT\r\ndate: Wed, 13 Aug 2025 17:39:12 GMT\r\nX-Firefox-Spdy: h2\r\n\r\n","headers":null,"cookies":null,"status_code":"200","status_text":"OK","fingerprints":[{"name":"Akamai","description":"Akamai is global content delivery network (CDN) services provider for media and software delivery, and cloud security solutions.","website":"https://akamai.com","common_platform_enumeration":"","icon":"Akamai.svg","categories":["CDN"]}],"data":{"size":442347,"size_decoded":0,"mime_type":"image/jpeg","magic":"JPEG image data, JFIF standard 1.01, aspect ratio, density 1x1, segment length 16, comment: \"Compressed by jpeg-recompress\", progressive, precision 8, 1601x706, components 3","md5":"5ca7292ca7940af719087e9f907b927a","sha1":"65ffb3f00ca7d216c6d9bae1849020a549afa5cc","sha256":"ef237648037bf69de1ef6a5eb67e2c335a5609a6d2c8f9472ebffcd61478a304","sha512":"b8a0c038a7c45bda74dd112361611842ccbb92ecc93b10aad5a2bfb4925f153159be447eb3ade88a63e211483124d39ff57799cb241f51f87fe42c0d514dc285","ssdeep":"12288:FWk28iXGum/dq2c8VbaUAXVoctEaEn/tOxqm+HZ:FQ2ugp9RaUcocthI/SOZ","tlshash":"5b94239dbf0aba9984494dc24831f418b088a9e48747f27b7d74f350513e62dfdee1a8","first_seen":"2025-08-13T17:39:41.370142Z","last_seen":"2025-08-13T17:39:41.370142Z","times_seen":1,"resource_available":false,"data":null}},"time_used":253,"timings":{"blocked":-1,"dns":0,"connect":0,"send":0,"wait":238,"receive":15,"ssl":0},"alerts":{"ids":null,"analyzer":null,"urlquery":null}},{"url":{"schema":"https","addr":"ir.serestherapeutics.com/sites/g/files/knoqqb52941/files/js/js__7bTfzE6xrd_G9PQpB8LPepqiyvkIMFPsKR-TCCqRSw.js?scope=footer\u0026delta=0\u0026language=en\u0026theme=nir_pid2065\u0026include=eJyFjtsOAjEIRH_IbI2J_g6hhSiKZUNZL3_v2jXx8mJ4YGY4mVDFASvqPaS0VD_dgGSZQXGq5bCqf8HRjTqWsXEnwkwzeg_LiUnCHAhjnqzc0lt25DxpyHnGMH3bfh1xv7Q-xYBHvAESQVFsDVDZY2kZhTbr3TbZhd2FuIdXzk2Codr8MC___2TDaz8ANtZsDQ","fqdn":"ir.serestherapeutics.com","domain":"serestherapeutics.com","tld":"com"},"ip":{"addr":"23.36.77.170","port":443,"asn":20940,"as":"Akamai International B.V.","country":"Norway","country_code":"NO"},"is_navigation_request":false,"resource_type":"script","requested_by":"https://ir.serestherapeutics.com/news-releases/news-release-details/seres-therapeutics-reports-ser-155-phase-1b-placebo-controlled","date":"2025-08-13T17:39:12.429Z","timestamp":0,"http_version":"","security_state":"secure","security_info":{"cipher_suite":"TLS_AES_256_GCM_SHA384","key_group_name":"x25519","signature_name":"RSA-PSS-SHA256","protocol":"TLSv1.3","cert":{"subject":{"commonName":"leapfrog-ssl-30.gcs-web.com","organization":""},"issuer":{"commonName":"R10","organization":"Let's Encrypt"},"validity":{"start":"Fri, 13 Jun 2025 04:44:47 GMT","end":"Thu, 11 Sep 2025 04:44:46 GMT"},"fingerprint":{"sha1":"76:56:CB:1C:2A:EB:BC:6C:AD:AC:F9:46:52:00:98:68:6F:36:7E:4D","sha256":"2E:92:CD:78:D5:3F:E1:8C:2B:75:38:93:FD:B6:D7:66:20:2F:C1:D0:0B:A0:AE:7D:AE:10:26:7A:9B:48:60:40"}}},"request":{"raw":"GET /sites/g/files/knoqqb52941/files/js/js__7bTfzE6xrd_G9PQpB8LPepqiyvkIMFPsKR-TCCqRSw.js?scope=footer\u0026delta=0\u0026language=en\u0026theme=nir_pid2065\u0026include=eJyFjtsOAjEIRH_IbI2J_g6hhSiKZUNZL3_v2jXx8mJ4YGY4mVDFASvqPaS0VD_dgGSZQXGq5bCqf8HRjTqWsXEnwkwzeg_LiUnCHAhjnqzc0lt25DxpyHnGMH3bfh1xv7Q-xYBHvAESQVFsDVDZY2kZhTbr3TbZhd2FuIdXzk2Codr8MC___2TDaz8ANtZsDQ HTTP/1.1\r\nHost: ir.serestherapeutics.com\r\nUser-Agent: Mozilla/5.0 (Windows NT 10.0; Win64; x64; rv:134.0) Gecko/20100101 Firefox/134.0\r\nAccept: */*\r\nAccept-Language: en-US,en;q=0.5\r\nAccept-Encoding: gzip, deflate, br\r\nReferer: https://ir.serestherapeutics.com/news-releases/news-release-details/seres-therapeutics-reports-ser-155-phase-1b-placebo-controlled\r\nDNT: 1\r\nConnection: keep-alive\r\nCookie: bm_ss=ab8e18ef4e; ak_bmsc=8B3E3F53D6F1D551950B130550D015A2~000000000000000000000000000000~YAAQ9U0kF2FfO52YAQAAsLaDpBzYHEeJiZORhrKmMvVJl6htT4U5E/6alOnsN1WLbK0JNN0FxV6QIk3CXK6SZzJXWuElqmWB1WWYdY8quqhpWza5ivcl5im9nJoX7vrrq3G0vDVDRbOFK+CpHpJKlNA7AFE8qUMYv2oy8l08ONFK9GC3Aonufb2qXf/9ZjIkKIaaJrJwo1KUNgFeJmFTmRFsbb4oS3Jv2xmpV6uIXbaBeN9UhBTyS0HA2CF3KtgNehkaNLOEZnMBc1mLg/Q+bEEutjMUDLWyhdWbq0cnrrkhtimNWHnJcupfFzlIfpxdU3sj4xzZZ/Md5pzLYIOYZrVV2/12xnbT2CkSBSpx2FJsR/0yDsO84EToiNJUl0y3pFgjA1wezQP5EqYWYF8qXo/BI+qA; bm_s=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; bm_so=076452BA7F785C26C0D039192D414EE322EFEBEE47C9D32A826B033A65229333~YAAQ9U0kF2RfO52YAQAAsLaDpARpo2xHJdjU4Jxa73zUq51KuxsW+QSmb5iP/ENmk7iqOGRhZyjdzqR50bYOPoK0krDYMKoypGPYm3hLRIvJAjzEPSWU9v0AmtzNP00zTXG2hPxPx54udTSSuGTM2KzBDJRiwCiOkJhUWlTdDefECbi1wnKokP5hnBjxGDCQMAE2aCXe4HqNbDgvHE7G5jmtqONfD1YgD6Cw25QL5pfAPYy0BKE94QkgYz+X0zy3rLB0HCSNr0ZOGQwVNzi2iZcJKo5SMvwmYjG5K9U0kZTVIUSy4tJGLP5ot1++FSPm+vy3pNdvnFN2MubC56GIGbx4fuz6N7DiabN7PeQYi+r8MvS04Dnfb7d5OjiIIOID16B38U5M8NVX3SXmdkNgusrIqEHOgLTigWBDKbEIIu1+fexPgsghoQRNJTdw9HEjOj0FOJyf/HSuHOBqCbNWdmrBXQvBXBkw\r\nSec-Fetch-Dest: script\r\nSec-Fetch-Mode: no-cors\r\nSec-Fetch-Site: same-origin\r\nPragma: no-cache\r\nCache-Control: no-cache\r\n\r\n","headers":null,"cookies":null,"method":"GET"},"response":{"raw":"HTTP/2 200 OK\r\naccept-ranges: bytes\r\ncontent-encoding: gzip\r\ncontent-type: text/javascript\r\nlast-modified: Tue, 15 Jul 2025 04:13:19 GMT\r\nx-age: 27709\r\nx-cache-hits: 11\r\nx-content-type-options: nosniff\r\nx-request-id: v-3c2c5544-6137-11f0-bb19-cfd63ba47a2a\r\ncontent-length: 71750\r\nx-edgeconnect-midmile-rtt: 20, 17\r\nx-edgeconnect-origin-mex-latency: 90, 82\r\ncache-control: max-age=600\r\nexpires: Wed, 13 Aug 2025 17:49:12 GMT\r\ndate: Wed, 13 Aug 2025 17:39:12 GMT\r\nvary: Accept-Encoding\r\nX-Firefox-Spdy: h2\r\n\r\n","headers":null,"cookies":null,"status_code":"200","status_text":"OK","fingerprints":[{"name":"Akamai","description":"Akamai is global content delivery network (CDN) services provider for media and software delivery, and cloud security solutions.","website":"https://akamai.com","common_platform_enumeration":"","icon":"Akamai.svg","categories":["CDN"]}],"data":{"size":233109,"size_decoded":0,"mime_type":"text/javascript","magic":"JavaScript source, ASCII text, with very long lines (32065)","md5":"cda6470aaea01f51c089d2d264a28fd7","sha1":"b63db927443c4dcc0e0b97643dcd8a0bef43a646","sha256":"c260e42e0e75120b28dafa258797cd03bbfa5ad83b01fc481b5ebb33e6c9150d","sha512":"c19d416cc73e4eefab49e760a9b1f3f0104bee58dc066959e06780636fb1ded95eb824a81cfd135a080a4da38416e0697e0215747ec80ab49fc159edc9f8fead","ssdeep":"3072:D4J+OlfOhWppCW6G9a98HrB3oACp44zi0Wrxghhgw9km8kv6:TOFpqG9a98Hr1K4vgHODkv6","tlshash":"163408cd7292712296eb71b8407f560bb23b9959b4088858f168c8d97dbce4d607bf3c","first_seen":"2025-06-21T18:39:44.496604Z","last_seen":"2025-11-12T20:41:57.057897Z","times_seen":10,"resource_available":true,"data":null}},"time_used":259,"timings":{"blocked":-1,"dns":0,"connect":0,"send":0,"wait":257,"receive":2,"ssl":0},"alerts":{"ids":null,"analyzer":null,"urlquery":null}},{"url":{"schema":"https","addr":"ir.serestherapeutics.com/sites/g/files/knoqqb52941/files/css/css_m5b5sjuSm0MakBWlGtxj8fJgdkqcBh_F0-ffWzbfRdA.css?delta=3\u0026language=en\u0026theme=nir_pid2065\u0026include=eJyNj9EKwjAMRX9orCLo74TbNsxim4w0Cvt7O_eiD4Jvl8NNcpLUOGR7rKhzLqi6TFKMIjqHPZSk0r-Rq9YIe8MGu7NThoNi1XQPENStOxm8yDKmjNIN5n_VOzli5R_dxhAyTtoay-BF5WP3iuXw28M8tJ3FqW-ShoQIH8JryefT9RL0yWYl89THdW5h_-4Fhv1pRA","fqdn":"ir.serestherapeutics.com","domain":"serestherapeutics.com","tld":"com"},"ip":{"addr":"23.36.77.170","port":443,"asn":20940,"as":"Akamai International B.V.","country":"Norway","country_code":"NO"},"is_navigation_request":false,"resource_type":"stylesheet","requested_by":"https://ir.serestherapeutics.com/news-releases/news-release-details/seres-therapeutics-reports-ser-155-phase-1b-placebo-controlled","date":"2025-08-13T17:39:12.418Z","timestamp":0,"http_version":"","security_state":"secure","security_info":{"cipher_suite":"TLS_AES_256_GCM_SHA384","key_group_name":"x25519","signature_name":"RSA-PSS-SHA256","protocol":"TLSv1.3","cert":{"subject":{"commonName":"leapfrog-ssl-30.gcs-web.com","organization":""},"issuer":{"commonName":"R10","organization":"Let's Encrypt"},"validity":{"start":"Fri, 13 Jun 2025 04:44:47 GMT","end":"Thu, 11 Sep 2025 04:44:46 GMT"},"fingerprint":{"sha1":"76:56:CB:1C:2A:EB:BC:6C:AD:AC:F9:46:52:00:98:68:6F:36:7E:4D","sha256":"2E:92:CD:78:D5:3F:E1:8C:2B:75:38:93:FD:B6:D7:66:20:2F:C1:D0:0B:A0:AE:7D:AE:10:26:7A:9B:48:60:40"}}},"request":{"raw":"GET /sites/g/files/knoqqb52941/files/css/css_m5b5sjuSm0MakBWlGtxj8fJgdkqcBh_F0-ffWzbfRdA.css?delta=3\u0026language=en\u0026theme=nir_pid2065\u0026include=eJyNj9EKwjAMRX9orCLo74TbNsxim4w0Cvt7O_eiD4Jvl8NNcpLUOGR7rKhzLqi6TFKMIjqHPZSk0r-Rq9YIe8MGu7NThoNi1XQPENStOxm8yDKmjNIN5n_VOzli5R_dxhAyTtoay-BF5WP3iuXw28M8tJ3FqW-ShoQIH8JryefT9RL0yWYl89THdW5h_-4Fhv1pRA HTTP/1.1\r\nHost: ir.serestherapeutics.com\r\nUser-Agent: Mozilla/5.0 (Windows NT 10.0; Win64; x64; rv:134.0) Gecko/20100101 Firefox/134.0\r\nAccept: text/css,*/*;q=0.1\r\nAccept-Language: en-US,en;q=0.5\r\nAccept-Encoding: gzip, deflate, br\r\nReferer: https://ir.serestherapeutics.com/news-releases/news-release-details/seres-therapeutics-reports-ser-155-phase-1b-placebo-controlled\r\nDNT: 1\r\nConnection: keep-alive\r\nCookie: bm_ss=ab8e18ef4e; ak_bmsc=8B3E3F53D6F1D551950B130550D015A2~000000000000000000000000000000~YAAQ9U0kF2FfO52YAQAAsLaDpBzYHEeJiZORhrKmMvVJl6htT4U5E/6alOnsN1WLbK0JNN0FxV6QIk3CXK6SZzJXWuElqmWB1WWYdY8quqhpWza5ivcl5im9nJoX7vrrq3G0vDVDRbOFK+CpHpJKlNA7AFE8qUMYv2oy8l08ONFK9GC3Aonufb2qXf/9ZjIkKIaaJrJwo1KUNgFeJmFTmRFsbb4oS3Jv2xmpV6uIXbaBeN9UhBTyS0HA2CF3KtgNehkaNLOEZnMBc1mLg/Q+bEEutjMUDLWyhdWbq0cnrrkhtimNWHnJcupfFzlIfpxdU3sj4xzZZ/Md5pzLYIOYZrVV2/12xnbT2CkSBSpx2FJsR/0yDsO84EToiNJUl0y3pFgjA1wezQP5EqYWYF8qXo/BI+qA; bm_s=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; bm_so=076452BA7F785C26C0D039192D414EE322EFEBEE47C9D32A826B033A65229333~YAAQ9U0kF2RfO52YAQAAsLaDpARpo2xHJdjU4Jxa73zUq51KuxsW+QSmb5iP/ENmk7iqOGRhZyjdzqR50bYOPoK0krDYMKoypGPYm3hLRIvJAjzEPSWU9v0AmtzNP00zTXG2hPxPx54udTSSuGTM2KzBDJRiwCiOkJhUWlTdDefECbi1wnKokP5hnBjxGDCQMAE2aCXe4HqNbDgvHE7G5jmtqONfD1YgD6Cw25QL5pfAPYy0BKE94QkgYz+X0zy3rLB0HCSNr0ZOGQwVNzi2iZcJKo5SMvwmYjG5K9U0kZTVIUSy4tJGLP5ot1++FSPm+vy3pNdvnFN2MubC56GIGbx4fuz6N7DiabN7PeQYi+r8MvS04Dnfb7d5OjiIIOID16B38U5M8NVX3SXmdkNgusrIqEHOgLTigWBDKbEIIu1+fexPgsghoQRNJTdw9HEjOj0FOJyf/HSuHOBqCbNWdmrBXQvBXBkw\r\nSec-Fetch-Dest: style\r\nSec-Fetch-Mode: no-cors\r\nSec-Fetch-Site: same-origin\r\nPragma: no-cache\r\nCache-Control: no-cache\r\n\r\n","headers":null,"cookies":null,"method":"GET"},"response":{"raw":"HTTP/2 200 OK\r\naccept-ranges: bytes\r\ncontent-encoding: gzip\r\ncontent-type: text/css\r\nlast-modified: Tue, 15 Jul 2025 04:37:05 GMT\r\nx-age: 24578\r\nx-cache-hits: 18\r\nx-content-type-options: nosniff\r\nx-request-id: v-814e7920-613e-11f0-8f6a-43a31824329b\r\ncontent-length: 2186\r\nx-edgeconnect-midmile-rtt: 0, 17, 16\r\nx-edgeconnect-origin-mex-latency: 87, 90, 268\r\ncache-control: max-age=600\r\nexpires: Wed, 13 Aug 2025 17:49:12 GMT\r\ndate: Wed, 13 Aug 2025 17:39:12 GMT\r\nvary: Accept-Encoding\r\nX-Firefox-Spdy: h2\r\n\r\n","headers":null,"cookies":null,"status_code":"200","status_text":"OK","fingerprints":[{"name":"Akamai","description":"Akamai is global content delivery network (CDN) services provider for media and software delivery, and cloud security solutions.","website":"https://akamai.com","common_platform_enumeration":"","icon":"Akamai.svg","categories":["CDN"]}],"data":{"size":13254,"size_decoded":0,"mime_type":"text/css","magic":"ASCII text, with very long lines (13184)","md5":"fb6bbdd172404ea37022eb98117aedc9","sha1":"1082f1bb7cb92a42ebcf45882e73dd313abea9e0","sha256":"dffdb7c260b4e49e529b63806c3b94499069e879c89bcdd25452a357d1ddc29f","sha512":"e4d2e78b3d2e394c9d69831e5483382a3cd98a34a4d927d437aaaa5c327571f89a144fbd6cb8571db004f3ec11f817abaa1e85623453102f4864e4b0c15b7dd0","ssdeep":"192:HERRnliH2vkTa0OPr2Zc1f057NK1K/MeACD:ynliHUkTa0OPr2Zv5yoACD","tlshash":"2852eca4e48c00e77322c4978b55f32966adb2a1c9815e51f12fe45c5fe2a1362c6b3e","first_seen":"2025-08-13T17:39:41.380522Z","last_seen":"2025-08-13T17:39:41.380522Z","times_seen":1,"resource_available":false,"data":null}},"time_used":427,"timings":{"blocked":-1,"dns":0,"connect":0,"send":0,"wait":427,"receive":0,"ssl":0},"alerts":{"ids":null,"analyzer":null,"urlquery":null}},{"url":{"schema":"https","addr":"ir.serestherapeutics.com/sites/g/files/knoqqb52941/files/css/css_O6nmAtPt48xPr5RpXhUaKhKCgQm8nsiL7zKP7TcZBj8.css?delta=4\u0026language=en\u0026theme=nir_pid2065\u0026include=eJyNj9EKwjAMRX9orCLo74TbNsxim4w0Cvt7O_eiD4Jvl8NNcpLUOGR7rKhzLqi6TFKMIjqHPZSk0r-Rq9YIe8MGu7NThoNi1XQPENStOxm8yDKmjNIN5n_VOzli5R_dxhAyTtoay-BF5WP3iuXw28M8tJ3FqW-ShoQIH8JryefT9RL0yWYl89THdW5h_-4Fhv1pRA","fqdn":"ir.serestherapeutics.com","domain":"serestherapeutics.com","tld":"com"},"ip":{"addr":"23.36.77.170","port":443,"asn":20940,"as":"Akamai International B.V.","country":"Norway","country_code":"NO"},"is_navigation_request":false,"resource_type":"stylesheet","requested_by":"https://ir.serestherapeutics.com/news-releases/news-release-details/seres-therapeutics-reports-ser-155-phase-1b-placebo-controlled","date":"2025-08-13T17:39:12.966Z","timestamp":0,"http_version":"","security_state":"secure","security_info":{"cipher_suite":"TLS_AES_256_GCM_SHA384","key_group_name":"x25519","signature_name":"RSA-PSS-SHA256","protocol":"TLSv1.3","cert":{"subject":{"commonName":"leapfrog-ssl-30.gcs-web.com","organization":""},"issuer":{"commonName":"R10","organization":"Let's Encrypt"},"validity":{"start":"Fri, 13 Jun 2025 04:44:47 GMT","end":"Thu, 11 Sep 2025 04:44:46 GMT"},"fingerprint":{"sha1":"76:56:CB:1C:2A:EB:BC:6C:AD:AC:F9:46:52:00:98:68:6F:36:7E:4D","sha256":"2E:92:CD:78:D5:3F:E1:8C:2B:75:38:93:FD:B6:D7:66:20:2F:C1:D0:0B:A0:AE:7D:AE:10:26:7A:9B:48:60:40"}}},"request":{"raw":"GET /sites/g/files/knoqqb52941/files/css/css_O6nmAtPt48xPr5RpXhUaKhKCgQm8nsiL7zKP7TcZBj8.css?delta=4\u0026language=en\u0026theme=nir_pid2065\u0026include=eJyNj9EKwjAMRX9orCLo74TbNsxim4w0Cvt7O_eiD4Jvl8NNcpLUOGR7rKhzLqi6TFKMIjqHPZSk0r-Rq9YIe8MGu7NThoNi1XQPENStOxm8yDKmjNIN5n_VOzli5R_dxhAyTtoay-BF5WP3iuXw28M8tJ3FqW-ShoQIH8JryefT9RL0yWYl89THdW5h_-4Fhv1pRA HTTP/1.1\r\nHost: ir.serestherapeutics.com\r\nUser-Agent: Mozilla/5.0 (Windows NT 10.0; Win64; x64; rv:134.0) Gecko/20100101 Firefox/134.0\r\nAccept: text/css,*/*;q=0.1\r\nAccept-Language: en-US,en;q=0.5\r\nAccept-Encoding: gzip, deflate, br\r\nReferer: https://ir.serestherapeutics.com/news-releases/news-release-details/seres-therapeutics-reports-ser-155-phase-1b-placebo-controlled\r\nDNT: 1\r\nConnection: keep-alive\r\nCookie: bm_ss=ab8e18ef4e; ak_bmsc=4E19C384354D9168EC037A0AE57F6E73~000000000000000000000000000000~YAAQ9U0kF3FfO52YAQAAoLiDpBzRDcrnH6JVmuZe+X7eJCmtLVP5oR5k3kXGARYJJVBAsw+q81DIcLQmOV8N1ujMBrXUamJHnJS7hNYlYdEDIAeNK/IANgppOIGPWSD30vdHue4X8W3dI7qdSkeDiXL8vWDfixSOhBbxDuqdFA/9Cv2o/FiNUUfmV6SuQVibYQXOJ+wagXSrei1Zkl9X2gVN/Gwom++A8v7BTG4rDWjjmLmzRJy6d4g31vDW+5uTeETmQZZUc4HHnbyxlOBP+//XhF7R8CFq5vH1FQ8GKtDX34wS1DW4XlTLGeAmusrcuOEBmNIflJmGwJOrY5EqLZDfcLRBdsHSY8BlxpWAWSyb+95E1IMm49gqrCGvKrPaRuI94Gf0m5uZE3N19M9ZYvwmQHv+8eP0+Cgn1KAO8sB4ofSwMJovneYg1yUOVzgENB4=; bm_s=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; bm_so=076452BA7F785C26C0D039192D414EE322EFEBEE47C9D32A826B033A65229333~YAAQ9U0kF2RfO52YAQAAsLaDpARpo2xHJdjU4Jxa73zUq51KuxsW+QSmb5iP/ENmk7iqOGRhZyjdzqR50bYOPoK0krDYMKoypGPYm3hLRIvJAjzEPSWU9v0AmtzNP00zTXG2hPxPx54udTSSuGTM2KzBDJRiwCiOkJhUWlTdDefECbi1wnKokP5hnBjxGDCQMAE2aCXe4HqNbDgvHE7G5jmtqONfD1YgD6Cw25QL5pfAPYy0BKE94QkgYz+X0zy3rLB0HCSNr0ZOGQwVNzi2iZcJKo5SMvwmYjG5K9U0kZTVIUSy4tJGLP5ot1++FSPm+vy3pNdvnFN2MubC56GIGbx4fuz6N7DiabN7PeQYi+r8MvS04Dnfb7d5OjiIIOID16B38U5M8NVX3SXmdkNgusrIqEHOgLTigWBDKbEIIu1+fexPgsghoQRNJTdw9HEjOj0FOJyf/HSuHOBqCbNWdmrBXQvBXBkw\r\nSec-Fetch-Dest: style\r\nSec-Fetch-Mode: no-cors\r\nSec-Fetch-Site: same-origin\r\nPragma: no-cache\r\nCache-Control: no-cache\r\n\r\n","headers":null,"cookies":null,"method":"GET"},"response":{"raw":"HTTP/2 200 OK\r\naccept-ranges: bytes\r\ncontent-encoding: gzip\r\ncontent-type: text/css\r\nlast-modified: Tue, 15 Jul 2025 04:37:09 GMT\r\nx-age: 27954\r\nx-cache-hits: 20\r\nx-content-type-options: nosniff\r\nx-request-id: v-a58dac6e-6136-11f0-aadd-1b7695d16758\r\ncontent-length: 258\r\nx-edgeconnect-midmile-rtt: 17, 25\r\nx-edgeconnect-origin-mex-latency: 89, 90\r\ncache-control: max-age=600\r\nexpires: Wed, 13 Aug 2025 17:49:13 GMT\r\ndate: Wed, 13 Aug 2025 17:39:13 GMT\r\nvary: Accept-Encoding\r\nset-cookie: ak_bmsc=4E19C384354D9168EC037A0AE57F6E73~000000000000000000000000000000~YAAQ9U0kF3NfO52YAQAAZ7qDpBwgNXz/plqfOUrKcZxl/8/jLs0BZjTiGad9fubqep1PBR6TuT7eoS9ivFyGBgRzrGQWF+OBSHtVgLafooQLot3cK3eezBYqhwuZBp60UJDo319KqK7SfB8FgmVkwNbVYlIDlsEgfpw7bdbp9hS0oBRaYeaUSPKk39j7Gmilc0cmMshQh/BQu80O/UWNVHW7CkbVhOz3SLAn5tBjASZ+jn18cbFWkoyuWTBa/dQjTn/aavwftjNgkW3d2bTFZARwTe3UrXrCPxkVB8Sm7zojstnXl/84HqoGfCt2oqkyNXLjiQdMJobLgk4CtWgQIUQ9WEDtD4TJ6vlsD20rhO1aABOGvIXDy/aYhqkvM/ESY1Rw37795hHinrwVsa0NuVR4v4QGZRwY6ELREaxlzExZWRRD9EWFrZEhzNcZMm5ca0+ZWRyo5Xkkffzq; Domain=.serestherapeutics.com; Path=/; Expires=Wed, 13 Aug 2025 19:39:11 GMT; Max-Age=7198\r\nX-Firefox-Spdy: h2\r\n\r\n","headers":null,"cookies":null,"status_code":"200","status_text":"OK","fingerprints":[{"name":"Akamai Bot Manager","description":"Akamai Bot Manager detect bots using device fingerprinting bot signatures.","website":"https://www.akamai.com/us/en/products/security/bot-manager.jsp","common_platform_enumeration":"","icon":"Akamai.svg","categories":["Security"]},{"name":"Akamai","description":"Akamai is global content delivery network (CDN) services provider for media and software delivery, and cloud security solutions.","website":"https://akamai.com","common_platform_enumeration":"","icon":"Akamai.svg","categories":["CDN"]}],"data":{"size":404,"size_decoded":0,"mime_type":"text/css","magic":"ASCII text, with very long lines (334)","md5":"d70d31a59255ff233fa52ce0defa3cf3","sha1":"9cdc343881e80b447c92ece5ac195e5c740c7e16","sha256":"98965226750d0e733bf319bfe96fdcb030c8c3fd7bfa89afdcc21906db03724d","sha512":"6ff53c0cfbc2fb71a93f92a40298a2e546f0582aba51f7147d8dea35e13e74675c73a6d031a4120c0c6f9d7b96ab7c001be3c7904b1f0c1b65066ac9e378aa67","ssdeep":"","tlshash":"f0e06169f230145717d1c219cf41772c05665b1cc3f239f0d886a4be249aa7342b4e7e","first_seen":"2025-08-13T17:39:41.390302Z","last_seen":"2025-08-13T17:39:41.390302Z","times_seen":1,"resource_available":false,"data":null}},"time_used":164,"timings":{"blocked":0,"dns":0,"connect":0,"send":0,"wait":163,"receive":1,"ssl":0},"alerts":{"ids":null,"analyzer":null,"urlquery":null}},{"url":{"schema":"https","addr":"ir.serestherapeutics.com/sites/g/files/knoqqb52941/themes/site/nir_pid2065/dist/fonts/lato-v16-latin-regular.woff2","fqdn":"ir.serestherapeutics.com","domain":"serestherapeutics.com","tld":"com"},"ip":{"addr":"23.36.77.170","port":443,"asn":20940,"as":"Akamai International B.V.","country":"Norway","country_code":"NO"},"is_navigation_request":false,"resource_type":"font","requested_by":"https://ir.serestherapeutics.com/news-releases/news-release-details/seres-therapeutics-reports-ser-155-phase-1b-placebo-controlled","date":"2025-08-13T17:39:13.007Z","timestamp":0,"http_version":"","security_state":"secure","security_info":{"cipher_suite":"TLS_AES_256_GCM_SHA384","key_group_name":"x25519","signature_name":"RSA-PSS-SHA256","protocol":"TLSv1.3","cert":{"subject":{"commonName":"leapfrog-ssl-30.gcs-web.com","organization":""},"issuer":{"commonName":"R10","organization":"Let's Encrypt"},"validity":{"start":"Fri, 13 Jun 2025 04:44:47 GMT","end":"Thu, 11 Sep 2025 04:44:46 GMT"},"fingerprint":{"sha1":"76:56:CB:1C:2A:EB:BC:6C:AD:AC:F9:46:52:00:98:68:6F:36:7E:4D","sha256":"2E:92:CD:78:D5:3F:E1:8C:2B:75:38:93:FD:B6:D7:66:20:2F:C1:D0:0B:A0:AE:7D:AE:10:26:7A:9B:48:60:40"}}},"request":{"raw":"GET /sites/g/files/knoqqb52941/themes/site/nir_pid2065/dist/fonts/lato-v16-latin-regular.woff2 HTTP/1.1\r\nHost: ir.serestherapeutics.com\r\nUser-Agent: Mozilla/5.0 (Windows NT 10.0; Win64; x64; rv:134.0) Gecko/20100101 Firefox/134.0\r\nAccept: application/font-woff2;q=1.0,application/font-woff;q=0.9,*/*;q=0.8\r\nAccept-Language: en-US,en;q=0.5\r\nAccept-Encoding: identity\r\nDNT: 1\r\nConnection: keep-alive\r\nReferer: https://ir.serestherapeutics.com/sites/g/files/knoqqb52941/files/css/css_kzaM5d7Hf_D4urQRrPnMNG7ZSmDxlul3AoaRuCcLFBg.css?delta=1\u0026language=en\u0026theme=nir_pid2065\u0026include=eJyNj9EKwjAMRX9orCLo74TbNsxim4w0Cvt7O_eiD4Jvl8NNcpLUOGR7rKhzLqi6TFKMIjqHPZSk0r-Rq9YIe8MGu7NThoNi1XQPENStOxm8yDKmjNIN5n_VOzli5R_dxhAyTtoay-BF5WP3iuXw28M8tJ3FqW-ShoQIH8JryefT9RL0yWYl89THdW5h_-4Fhv1pRA\r\nCookie: bm_ss=ab8e18ef4e; ak_bmsc=4E19C384354D9168EC037A0AE57F6E73~000000000000000000000000000000~YAAQ9U0kF3FfO52YAQAAoLiDpBzRDcrnH6JVmuZe+X7eJCmtLVP5oR5k3kXGARYJJVBAsw+q81DIcLQmOV8N1ujMBrXUamJHnJS7hNYlYdEDIAeNK/IANgppOIGPWSD30vdHue4X8W3dI7qdSkeDiXL8vWDfixSOhBbxDuqdFA/9Cv2o/FiNUUfmV6SuQVibYQXOJ+wagXSrei1Zkl9X2gVN/Gwom++A8v7BTG4rDWjjmLmzRJy6d4g31vDW+5uTeETmQZZUc4HHnbyxlOBP+//XhF7R8CFq5vH1FQ8GKtDX34wS1DW4XlTLGeAmusrcuOEBmNIflJmGwJOrY5EqLZDfcLRBdsHSY8BlxpWAWSyb+95E1IMm49gqrCGvKrPaRuI94Gf0m5uZE3N19M9ZYvwmQHv+8eP0+Cgn1KAO8sB4ofSwMJovneYg1yUOVzgENB4=; bm_s=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; bm_so=076452BA7F785C26C0D039192D414EE322EFEBEE47C9D32A826B033A65229333~YAAQ9U0kF2RfO52YAQAAsLaDpARpo2xHJdjU4Jxa73zUq51KuxsW+QSmb5iP/ENmk7iqOGRhZyjdzqR50bYOPoK0krDYMKoypGPYm3hLRIvJAjzEPSWU9v0AmtzNP00zTXG2hPxPx54udTSSuGTM2KzBDJRiwCiOkJhUWlTdDefECbi1wnKokP5hnBjxGDCQMAE2aCXe4HqNbDgvHE7G5jmtqONfD1YgD6Cw25QL5pfAPYy0BKE94QkgYz+X0zy3rLB0HCSNr0ZOGQwVNzi2iZcJKo5SMvwmYjG5K9U0kZTVIUSy4tJGLP5ot1++FSPm+vy3pNdvnFN2MubC56GIGbx4fuz6N7DiabN7PeQYi+r8MvS04Dnfb7d5OjiIIOID16B38U5M8NVX3SXmdkNgusrIqEHOgLTigWBDKbEIIu1+fexPgsghoQRNJTdw9HEjOj0FOJyf/HSuHOBqCbNWdmrBXQvBXBkw\r\nSec-Fetch-Dest: font\r\nSec-Fetch-Mode: cors\r\nSec-Fetch-Site: same-origin\r\nPragma: no-cache\r\nCache-Control: no-cache\r\n\r\n","headers":null,"cookies":null,"method":"GET"},"response":{"raw":"HTTP/2 200 OK\r\naccept-ranges: bytes\r\nlast-modified: Mon, 14 Jul 2025 09:57:48 GMT\r\nx-age: 1140847\r\nx-cache-hits: 446\r\nx-content-type-options: nosniff\r\nx-request-id: v-4586e2a2-6c3c-11f0-af3c-1fbf4cbabb80\r\ncontent-length: 23484\r\nx-edgeconnect-midmile-rtt: 17, 21\r\nx-edgeconnect-origin-mex-latency: 167, 89\r\ncache-control: max-age=600\r\nexpires: Wed, 13 Aug 2025 17:49:13 GMT\r\ndate: Wed, 13 Aug 2025 17:39:13 GMT\r\nset-cookie: ak_bmsc=4E19C384354D9168EC037A0AE57F6E73~000000000000000000000000000000~YAAQ9U0kF3RfO52YAQAAd7qDpBw5F+q3Uc5v0N7+PDFzsbd7US5lA8rWlWvLno9HKg/X2sIOTfJntg/q7EBuiT+pIEeaFH/wg4KzFCU93Nv0olc9dX8xpQR06oZ3gERte/SdeorndYWd9RFZdhQM80Cu2pDypc8UhsWbGf8lr+/knh7ONEmk3ShcQA9PRLImzOypnFuQBCHv4jsuACpevJmiCZzQp847Myc0lvKkgtrRbHt/L5zRZT+X5L19GrQ1s+sD2U4aOOCiVvPRMkyzlLvUSizr+fmrE44xCqQeIlumDAkPO5fqUBDjdLB0o5nu7EWc8K9g2uUTkBxB1H/UALUHDyTQgbbIc0iGmdA4jDi7n8u9NyBxGZz0K8wryScePwIL3i++X2T+1NWhj13wA4+10C0x6g/ihykRb9J+Xxln9gUF/CNPH7RZsRuMvkYuCrpQI4xb0TLRAX4A; Domain=.serestherapeutics.com; Path=/; Expires=Wed, 13 Aug 2025 19:39:11 GMT; Max-Age=7198\r\nX-Firefox-Spdy: h2\r\n\r\n","headers":null,"cookies":null,"status_code":"200","status_text":"OK","fingerprints":[{"name":"Akamai Bot Manager","description":"Akamai Bot Manager detect bots using device fingerprinting bot signatures.","website":"https://www.akamai.com/us/en/products/security/bot-manager.jsp","common_platform_enumeration":"","icon":"Akamai.svg","categories":["Security"]},{"name":"Akamai","description":"Akamai is global content delivery network (CDN) services provider for media and software delivery, and cloud security solutions.","website":"https://akamai.com","common_platform_enumeration":"","icon":"Akamai.svg","categories":["CDN"]}],"data":{"size":23484,"size_decoded":0,"mime_type":"font/woff2","magic":"Web Open Font Format (Version 2), TrueType, length 23484, version 1.0","md5":"b4d2c4c39853ee244272c04999b230ba","sha1":"c82e22dde9716c40ba20e6c7ed03a1b66556de15","sha256":"c3c0d3f472358aac78455515c4800771426770c22698e2486d39fdb5505634e1","sha512":"d315d6a4e28bb125128d3a4d99fe120e383061d367341f06c4b74a589b4ca29c516cbc8d23ddd37267a1e4497c74fd58b1dffd39cb70348b8a3ea3d48237f8ef","ssdeep":"384:iXFbv7T+soFz7IbR/aBa639y2FNedPuzHQ1eGcYe3mkGtapwx/vX5htghzvcjvm:iXFzP+soFP8RQty2FNedmzocYe3DqapT","tlshash":"40b2e1778269aa70d6d01bb5ffc112a73a79589245d5e3a34e409b02442c73f7eadf40","first_seen":"2023-04-07T01:34:48Z","last_seen":"2026-04-03T16:56:39.518452Z","times_seen":3003,"resource_available":false,"data":null}},"time_used":138,"timings":{"blocked":0,"dns":0,"connect":0,"send":0,"wait":137,"receive":1,"ssl":0},"alerts":{"ids":null,"analyzer":null,"urlquery":null}},{"url":{"schema":"https","addr":"ir.serestherapeutics.com/sites/g/files/knoqqb52941/themes/site/nir_pid2065/fonts/ndqfonticons.woff","fqdn":"ir.serestherapeutics.com","domain":"serestherapeutics.com","tld":"com"},"ip":{"addr":"23.36.77.170","port":443,"asn":20940,"as":"Akamai International B.V.","country":"Norway","country_code":"NO"},"is_navigation_request":false,"resource_type":"font","requested_by":"https://ir.serestherapeutics.com/news-releases/news-release-details/seres-therapeutics-reports-ser-155-phase-1b-placebo-controlled","date":"2025-08-13T17:39:13.094Z","timestamp":0,"http_version":"","security_state":"secure","security_info":{"cipher_suite":"TLS_AES_256_GCM_SHA384","key_group_name":"x25519","signature_name":"RSA-PSS-SHA256","protocol":"TLSv1.3","cert":{"subject":{"commonName":"leapfrog-ssl-30.gcs-web.com","organization":""},"issuer":{"commonName":"R10","organization":"Let's Encrypt"},"validity":{"start":"Fri, 13 Jun 2025 04:44:47 GMT","end":"Thu, 11 Sep 2025 04:44:46 GMT"},"fingerprint":{"sha1":"76:56:CB:1C:2A:EB:BC:6C:AD:AC:F9:46:52:00:98:68:6F:36:7E:4D","sha256":"2E:92:CD:78:D5:3F:E1:8C:2B:75:38:93:FD:B6:D7:66:20:2F:C1:D0:0B:A0:AE:7D:AE:10:26:7A:9B:48:60:40"}}},"request":{"raw":"GET /sites/g/files/knoqqb52941/themes/site/nir_pid2065/fonts/ndqfonticons.woff HTTP/1.1\r\nHost: ir.serestherapeutics.com\r\nUser-Agent: Mozilla/5.0 (Windows NT 10.0; Win64; x64; rv:134.0) Gecko/20100101 Firefox/134.0\r\nAccept: application/font-woff2;q=1.0,application/font-woff;q=0.9,*/*;q=0.8\r\nAccept-Language: en-US,en;q=0.5\r\nAccept-Encoding: identity\r\nDNT: 1\r\nConnection: keep-alive\r\nReferer: https://ir.serestherapeutics.com/sites/g/files/knoqqb52941/files/css/css_aO3gfVpreLC_ok0rmlGqfTNnOYGIjQgI1drc006UnII.css?delta=5\u0026language=en\u0026theme=nir_pid2065\u0026include=eJyNj9EKwjAMRX9orCLo74TbNsxim4w0Cvt7O_eiD4Jvl8NNcpLUOGR7rKhzLqi6TFKMIjqHPZSk0r-Rq9YIe8MGu7NThoNi1XQPENStOxm8yDKmjNIN5n_VOzli5R_dxhAyTtoay-BF5WP3iuXw28M8tJ3FqW-ShoQIH8JryefT9RL0yWYl89THdW5h_-4Fhv1pRA\r\nCookie: bm_ss=ab8e18ef4e; ak_bmsc=4E19C384354D9168EC037A0AE57F6E73~000000000000000000000000000000~YAAQ9U0kF3FfO52YAQAAoLiDpBzRDcrnH6JVmuZe+X7eJCmtLVP5oR5k3kXGARYJJVBAsw+q81DIcLQmOV8N1ujMBrXUamJHnJS7hNYlYdEDIAeNK/IANgppOIGPWSD30vdHue4X8W3dI7qdSkeDiXL8vWDfixSOhBbxDuqdFA/9Cv2o/FiNUUfmV6SuQVibYQXOJ+wagXSrei1Zkl9X2gVN/Gwom++A8v7BTG4rDWjjmLmzRJy6d4g31vDW+5uTeETmQZZUc4HHnbyxlOBP+//XhF7R8CFq5vH1FQ8GKtDX34wS1DW4XlTLGeAmusrcuOEBmNIflJmGwJOrY5EqLZDfcLRBdsHSY8BlxpWAWSyb+95E1IMm49gqrCGvKrPaRuI94Gf0m5uZE3N19M9ZYvwmQHv+8eP0+Cgn1KAO8sB4ofSwMJovneYg1yUOVzgENB4=; bm_s=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; bm_so=076452BA7F785C26C0D039192D414EE322EFEBEE47C9D32A826B033A65229333~YAAQ9U0kF2RfO52YAQAAsLaDpARpo2xHJdjU4Jxa73zUq51KuxsW+QSmb5iP/ENmk7iqOGRhZyjdzqR50bYOPoK0krDYMKoypGPYm3hLRIvJAjzEPSWU9v0AmtzNP00zTXG2hPxPx54udTSSuGTM2KzBDJRiwCiOkJhUWlTdDefECbi1wnKokP5hnBjxGDCQMAE2aCXe4HqNbDgvHE7G5jmtqONfD1YgD6Cw25QL5pfAPYy0BKE94QkgYz+X0zy3rLB0HCSNr0ZOGQwVNzi2iZcJKo5SMvwmYjG5K9U0kZTVIUSy4tJGLP5ot1++FSPm+vy3pNdvnFN2MubC56GIGbx4fuz6N7DiabN7PeQYi+r8MvS04Dnfb7d5OjiIIOID16B38U5M8NVX3SXmdkNgusrIqEHOgLTigWBDKbEIIu1+fexPgsghoQRNJTdw9HEjOj0FOJyf/HSuHOBqCbNWdmrBXQvBXBkw\r\nSec-Fetch-Dest: font\r\nSec-Fetch-Mode: cors\r\nSec-Fetch-Site: same-origin\r\nPragma: no-cache\r\nCache-Control: no-cache\r\n\r\n","headers":null,"cookies":null,"method":"GET"},"response":{"raw":"HTTP/2 200 OK\r\naccept-ranges: bytes\r\nlast-modified: Mon, 14 Jul 2025 09:43:39 GMT\r\nx-age: 1123114\r\nx-cache-hits: 419\r\nx-content-type-options: nosniff\r\nx-request-id: v-8d5a672e-6c42-11f0-afb8-dfa27369db55\r\ncontent-length: 34147\r\nx-edgeconnect-midmile-rtt: 16, 21\r\nx-edgeconnect-origin-mex-latency: 83, 82\r\ncache-control: max-age=600\r\nexpires: Wed, 13 Aug 2025 17:49:13 GMT\r\ndate: Wed, 13 Aug 2025 17:39:13 GMT\r\nset-cookie: ak_bmsc=4E19C384354D9168EC037A0AE57F6E73~000000000000000000000000000000~YAAQ9U0kF3hfO52YAQAAwrqDpByk5fp5hgoTWnAnWzCW2u5HoJb3EMU2VZqOSwBJjFP2i2BTIg+15y5iVAo9e/6UDdExzRg7KGE3clEGRB/afIoQnVZEemA7ZHxmWMvxei7i/LCwHm5OOQNf1GUlRLXJYSwMGvOKRlMX4aJVVum25ZVrwB8nLFMSODqP/Bp3V/mMYhZoJBZ/pZJB0R0qzJJhe3g5+PpAZZAV9gIPyevTuzVlHW9CnFjHwsX551T24brIKfwbDcFKothT+7vD/6QIUIdqLDp0bYJ04TRy8X8DAtCC72f9bzAIibghLwMbvXv3m2Va7vNsa3uwJKwvwhbhWs8xlZhWIegR02IbFKZ8YhpznxSCKPrnhuQGWu2UhJl4bNqIK0Q8VAgWWtmj8mAyjATF3XoryjBbac9q/jYW3bMzv58vagHRZnGMVPIwKaYVxoshc8lEDiH3; Domain=.serestherapeutics.com; Path=/; Expires=Wed, 13 Aug 2025 19:39:11 GMT; Max-Age=7198\r\nX-Firefox-Spdy: h2\r\n\r\n","headers":null,"cookies":null,"status_code":"200","status_text":"OK","fingerprints":[{"name":"Akamai Bot Manager","description":"Akamai Bot Manager detect bots using device fingerprinting bot signatures.","website":"https://www.akamai.com/us/en/products/security/bot-manager.jsp","common_platform_enumeration":"","icon":"Akamai.svg","categories":["Security"]},{"name":"Akamai","description":"Akamai is global content delivery network (CDN) services provider for media and software delivery, and cloud security solutions.","website":"https://akamai.com","common_platform_enumeration":"","icon":"Akamai.svg","categories":["CDN"]}],"data":{"size":34147,"size_decoded":0,"mime_type":"font/woff","magic":"Web Open Font Format, CFF, length 34148, version 1.0","md5":"8bbd17f9849632de7a9c91125b054d4e","sha1":"dfcb147557ff0837d02e401dc7532d5528af8ec9","sha256":"976d22490288a04d5bc7edaa827b729f8d7df858b1df77b1aed89675eb2539ca","sha512":"5b67e72e80560f41905bad7db3eaf4763999156d6cca60c2861a3eec5e9b045d156f4dede8f92c04e38ae43c0f9a1d72b4bee1d3a9e497a92f7f2d7e9649f546","ssdeep":"768:2fVSezQ9dL6g79yukVIp227G5RKF5BZj9FCx4NUh8dWSlN/:29SeYdLDxyuaC7IY3BZ6vSD","tlshash":"46e2f1b8ff7a472cc29c6e7230d235c66510c1c3475aa6efb059aadf1160c1a8768a39","first_seen":"2024-10-14T13:57:00.0549Z","last_seen":"2025-11-28T03:39:16.556263Z","times_seen":9,"resource_available":false,"data":null}},"time_used":146,"timings":{"blocked":-1,"dns":0,"connect":0,"send":0,"wait":142,"receive":4,"ssl":0},"alerts":{"ids":null,"analyzer":null,"urlquery":null}},{"url":{"schema":"https","addr":"ir.serestherapeutics.com/sites/g/files/knoqqb52941/themes/site/nir_pid2065/dist/fonts/lato-v16-latin-300.woff2","fqdn":"ir.serestherapeutics.com","domain":"serestherapeutics.com","tld":"com"},"ip":{"addr":"23.36.77.170","port":443,"asn":20940,"as":"Akamai International B.V.","country":"Norway","country_code":"NO"},"is_navigation_request":false,"resource_type":"font","requested_by":"https://ir.serestherapeutics.com/news-releases/news-release-details/seres-therapeutics-reports-ser-155-phase-1b-placebo-controlled","date":"2025-08-13T17:39:13.093Z","timestamp":0,"http_version":"","security_state":"secure","security_info":{"cipher_suite":"TLS_AES_256_GCM_SHA384","key_group_name":"x25519","signature_name":"RSA-PSS-SHA256","protocol":"TLSv1.3","cert":{"subject":{"commonName":"leapfrog-ssl-30.gcs-web.com","organization":""},"issuer":{"commonName":"R10","organization":"Let's Encrypt"},"validity":{"start":"Fri, 13 Jun 2025 04:44:47 GMT","end":"Thu, 11 Sep 2025 04:44:46 GMT"},"fingerprint":{"sha1":"76:56:CB:1C:2A:EB:BC:6C:AD:AC:F9:46:52:00:98:68:6F:36:7E:4D","sha256":"2E:92:CD:78:D5:3F:E1:8C:2B:75:38:93:FD:B6:D7:66:20:2F:C1:D0:0B:A0:AE:7D:AE:10:26:7A:9B:48:60:40"}}},"request":{"raw":"GET /sites/g/files/knoqqb52941/themes/site/nir_pid2065/dist/fonts/lato-v16-latin-300.woff2 HTTP/1.1\r\nHost: ir.serestherapeutics.com\r\nUser-Agent: Mozilla/5.0 (Windows NT 10.0; Win64; x64; rv:134.0) Gecko/20100101 Firefox/134.0\r\nAccept: application/font-woff2;q=1.0,application/font-woff;q=0.9,*/*;q=0.8\r\nAccept-Language: en-US,en;q=0.5\r\nAccept-Encoding: identity\r\nDNT: 1\r\nConnection: keep-alive\r\nReferer: https://ir.serestherapeutics.com/sites/g/files/knoqqb52941/files/css/css_kzaM5d7Hf_D4urQRrPnMNG7ZSmDxlul3AoaRuCcLFBg.css?delta=1\u0026language=en\u0026theme=nir_pid2065\u0026include=eJyNj9EKwjAMRX9orCLo74TbNsxim4w0Cvt7O_eiD4Jvl8NNcpLUOGR7rKhzLqi6TFKMIjqHPZSk0r-Rq9YIe8MGu7NThoNi1XQPENStOxm8yDKmjNIN5n_VOzli5R_dxhAyTtoay-BF5WP3iuXw28M8tJ3FqW-ShoQIH8JryefT9RL0yWYl89THdW5h_-4Fhv1pRA\r\nCookie: bm_ss=ab8e18ef4e; ak_bmsc=4E19C384354D9168EC037A0AE57F6E73~000000000000000000000000000000~YAAQ9U0kF3FfO52YAQAAoLiDpBzRDcrnH6JVmuZe+X7eJCmtLVP5oR5k3kXGARYJJVBAsw+q81DIcLQmOV8N1ujMBrXUamJHnJS7hNYlYdEDIAeNK/IANgppOIGPWSD30vdHue4X8W3dI7qdSkeDiXL8vWDfixSOhBbxDuqdFA/9Cv2o/FiNUUfmV6SuQVibYQXOJ+wagXSrei1Zkl9X2gVN/Gwom++A8v7BTG4rDWjjmLmzRJy6d4g31vDW+5uTeETmQZZUc4HHnbyxlOBP+//XhF7R8CFq5vH1FQ8GKtDX34wS1DW4XlTLGeAmusrcuOEBmNIflJmGwJOrY5EqLZDfcLRBdsHSY8BlxpWAWSyb+95E1IMm49gqrCGvKrPaRuI94Gf0m5uZE3N19M9ZYvwmQHv+8eP0+Cgn1KAO8sB4ofSwMJovneYg1yUOVzgENB4=; bm_s=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; bm_so=076452BA7F785C26C0D039192D414EE322EFEBEE47C9D32A826B033A65229333~YAAQ9U0kF2RfO52YAQAAsLaDpARpo2xHJdjU4Jxa73zUq51KuxsW+QSmb5iP/ENmk7iqOGRhZyjdzqR50bYOPoK0krDYMKoypGPYm3hLRIvJAjzEPSWU9v0AmtzNP00zTXG2hPxPx54udTSSuGTM2KzBDJRiwCiOkJhUWlTdDefECbi1wnKokP5hnBjxGDCQMAE2aCXe4HqNbDgvHE7G5jmtqONfD1YgD6Cw25QL5pfAPYy0BKE94QkgYz+X0zy3rLB0HCSNr0ZOGQwVNzi2iZcJKo5SMvwmYjG5K9U0kZTVIUSy4tJGLP5ot1++FSPm+vy3pNdvnFN2MubC56GIGbx4fuz6N7DiabN7PeQYi+r8MvS04Dnfb7d5OjiIIOID16B38U5M8NVX3SXmdkNgusrIqEHOgLTigWBDKbEIIu1+fexPgsghoQRNJTdw9HEjOj0FOJyf/HSuHOBqCbNWdmrBXQvBXBkw\r\nSec-Fetch-Dest: font\r\nSec-Fetch-Mode: cors\r\nSec-Fetch-Site: same-origin\r\nPragma: no-cache\r\nCache-Control: no-cache\r\n\r\n","headers":null,"cookies":null,"method":"GET"},"response":{"raw":"HTTP/2 200 OK\r\naccept-ranges: bytes\r\nlast-modified: Mon, 14 Jul 2025 09:43:39 GMT\r\nx-age: 865651\r\nx-cache-hits: 379\r\nx-content-type-options: nosniff\r\nx-request-id: v-4548b57a-6c3e-11f0-8661-cf8d713a140f\r\ncontent-length: 23248\r\nx-edgeconnect-midmile-rtt: 18, 22\r\nx-edgeconnect-origin-mex-latency: 81, 90\r\ncache-control: max-age=600\r\nexpires: Wed, 13 Aug 2025 17:49:13 GMT\r\ndate: Wed, 13 Aug 2025 17:39:13 GMT\r\nset-cookie: ak_bmsc=4E19C384354D9168EC037A0AE57F6E73~000000000000000000000000000000~YAAQ9U0kF3pfO52YAQAAyrqDpBxZNiQhgQ/mLbHzuEyKUI1B5Q02Uo0y/Q8t/RN651uf3zXQrlH74xzEGFZJh8Z3EipvPaPk8w7Is198IT9ERHRfRPKa2M7lbnLucg3cEIMP0T5Us1UtqKrkD4IyfMWS5Il+7GYb/LonOBcDcZfDHDidfuuSIQ6TrFLomDSIbFN39zhVmt4CPEAYeJCFpnrqAGm+u+JZOxVfbd6hq2X8CRbwAnpU/qIeEkfJZTcbdrKuCAfQd9nnNvAIY60IM359bhv/qJQdbTtF9ptE/8TrJUyq6y1eZieW7441XaaLDTJjdbbmD+kIh76nTK2tFfqRYBRM+LJxo4h7ROy+Jg0nL8xfVSOAHRJQZeKb/jZ7i3pBOoDbq2YYcEhFDfwAdJJtM3L3MIx/VHn8srwrv/OxDJmiCmO13LX5jQfOZxx+mwR2mwpsu1ypGLyV; Domain=.serestherapeutics.com; Path=/; Expires=Wed, 13 Aug 2025 19:39:11 GMT; Max-Age=7198\r\nX-Firefox-Spdy: h2\r\n\r\n","headers":null,"cookies":null,"status_code":"200","status_text":"OK","fingerprints":[{"name":"Akamai Bot Manager","description":"Akamai Bot Manager detect bots using device fingerprinting bot signatures.","website":"https://www.akamai.com/us/en/products/security/bot-manager.jsp","common_platform_enumeration":"","icon":"Akamai.svg","categories":["Security"]},{"name":"Akamai","description":"Akamai is global content delivery network (CDN) services provider for media and software delivery, and cloud security solutions.","website":"https://akamai.com","common_platform_enumeration":"","icon":"Akamai.svg","categories":["CDN"]}],"data":{"size":23248,"size_decoded":0,"mime_type":"font/woff2","magic":"Web Open Font Format (Version 2), TrueType, length 23248, version 1.0","md5":"98d8cf792834c0bef59c2be99dc3533d","sha1":"f48e6d698147781b82f573a71f904355274015cd","sha256":"9194059997d722ec01e41980dffbff03ebe00808b1cdd164a7fd18a561bc312a","sha512":"d6877b880861a94a9c5798c764d14f2762fa4e1e4c61e24000c0fe74052e519d8efa9b4a12ee6f438d6acd814efb03714568c405ac37000983dcbab978db1570","ssdeep":"384:/lH2SiZYjzY0O/TlG0biKGhvw5XMOvgHpTR8VNUNj0kjorfTDQ0pFRVOjxrqbDq0:/lHjjCGUiKGCupN87U9jorfT80XRVOj8","tlshash":"3aa2d08038dbd09be0bd52756e3bd80fcb625f6892607c905b371c6e2c58254424defb","first_seen":"2023-04-10T09:56:19Z","last_seen":"2026-04-02T04:41:21.335741Z","times_seen":383,"resource_available":false,"data":null}},"time_used":150,"timings":{"blocked":-1,"dns":0,"connect":0,"send":0,"wait":149,"receive":1,"ssl":0},"alerts":{"ids":null,"analyzer":null,"urlquery":null}},{"url":{"schema":"https","addr":"assets.adobedtm.com/898335afd880/c52ee8aa1e90/a9a9246fcf93/EX9f1ce69e4b404891b885911666e7b92a-libraryCode_source.min.js","fqdn":"assets.adobedtm.com","domain":"adobedtm.com","tld":"com"},"ip":{"addr":"96.6.17.25","port":443,"asn":16625,"as":"AKAMAI-AS","country":"Norway","country_code":"NO"},"is_navigation_request":false,"resource_type":"script","requested_by":"https://ir.serestherapeutics.com/news-releases/news-release-details/seres-therapeutics-reports-ser-155-phase-1b-placebo-controlled","date":"2025-08-13T17:39:14.325Z","timestamp":0,"http_version":"","security_state":"secure","security_info":{"cipher_suite":"TLS_AES_256_GCM_SHA384","key_group_name":"x25519","signature_name":"ECDSA-P256-SHA256","protocol":"TLSv1.3","cert":{"subject":{"commonName":"assets.adobedtm.com","organization":"Adobe Inc."},"issuer":{"commonName":"DigiCert Global G2 TLS RSA SHA256 2020 CA1","organization":"DigiCert Inc"},"validity":{"start":"Tue, 24 Jun 2025 00:00:00 GMT","end":"Sat, 25 Jul 2026 23:59:59 GMT"},"fingerprint":{"sha1":"2F:BD:F6:81:46:EE:C6:68:47:14:7F:F0:63:9A:CA:DE:F6:5D:C7:80","sha256":"F0:43:20:D8:ED:30:30:7B:92:0C:29:1B:07:12:29:EE:72:B4:10:4C:38:64:3C:9A:AD:BF:70:A4:DC:CE:5B:8E"}}},"request":{"raw":"GET /898335afd880/c52ee8aa1e90/a9a9246fcf93/EX9f1ce69e4b404891b885911666e7b92a-libraryCode_source.min.js HTTP/1.1\r\nHost: assets.adobedtm.com\r\nUser-Agent: Mozilla/5.0 (Windows NT 10.0; Win64; x64; rv:134.0) Gecko/20100101 Firefox/134.0\r\nAccept: */*\r\nAccept-Language: en-US,en;q=0.5\r\nAccept-Encoding: gzip, deflate, br\r\nDNT: 1\r\nConnection: keep-alive\r\nReferer: https://ir.serestherapeutics.com/\r\nSec-Fetch-Dest: script\r\nSec-Fetch-Mode: no-cors\r\nSec-Fetch-Site: cross-site\r\nPragma: no-cache\r\nCache-Control: no-cache\r\n\r\n","headers":null,"cookies":null,"method":"GET"},"response":{"raw":"HTTP/2 200 OK\r\naccept-ranges: bytes\r\ncontent-type: application/x-javascript\r\netag: \"fa4a382999ecbaa870ece29003fe5cd0:1675447238.121712\"\r\nlast-modified: Fri, 03 Feb 2023 18:00:38 GMT\r\nserver: AkamaiNetStorage\r\nvary: Accept-Encoding\r\ncontent-encoding: gzip\r\ncontent-length: 13535\r\ncache-control: max-age=3600\r\nexpires: Wed, 13 Aug 2025 18:39:14 GMT\r\ndate: Wed, 13 Aug 2025 17:39:14 GMT\r\naccess-control-allow-origin: https://ir.serestherapeutics.com\r\nx-content-type-options: nosniff\r\ntiming-allow-origin: *\r\nX-Firefox-Spdy: h2\r\n\r\n","headers":null,"cookies":null,"status_code":"200","status_text":"OK","fingerprints":null,"data":{"size":37000,"size_decoded":0,"mime_type":"application/x-javascript","magic":"JavaScript source, ASCII text, with very long lines (32176)","md5":"f89b497f4495320cabaa3adbb2c2a0d5","sha1":"69275e61906377fe8122fe44c5ef9e5292465271","sha256":"f2d45bebe310e6913fb1846dd661fc9fad22185c8b06e499feae67726fc5ab17","sha512":"d4794cfc74191f2c9b662dcba806b0eb1b2213d3c3e6a13a3b344307905c201364dd3b4fac1a1cf6d15b18c4ff0acce7e36fdd0d7d06cc8646100b9da266ebe5","ssdeep":"768:Qa6IY9mkYhhm7S/5I0XlTCrOoboxI5WdfD6DrVySyEmy/I6/k:Xh0bYhhYS/y+VCdsHWISPI6/k","tlshash":"bef22dc531eab47f165271f42c6f080ee139cf5a888994b4e081c9e16878ed651affb7","first_seen":"2023-03-13T20:39:53Z","last_seen":"2026-04-02T06:14:20.721378Z","times_seen":65,"resource_available":true,"data":null}},"time_used":40,"timings":{"blocked":12,"dns":2,"connect":1,"send":0,"wait":16,"receive":1,"ssl":6},"alerts":{"ids":null,"analyzer":null,"urlquery":null}},{"url":{"schema":"https","addr":"analytics.imirwin.com/matomo.php?action_name=Seres%20Therapeutics%20Reports%20SER-155%20Phase%201b%20Placebo-Controlled%20Cohort%202%20Study%20Safety%20and%20Clinical%20Results%20in%20Patients%20Undergoing%20Allogeneic%20Hematopoietic%20Stem%20Cell%20Transplant%20(allo-HSCT)%20%7C%20Seres%20Therapeutics\u0026idsite=310\u0026rec=1\u0026r=594286\u0026h=17\u0026m=39\u0026s=14\u0026url=https%3A%2F%2Fir.serestherapeutics.com%2Fnews-releases%2Fnews-release-details%2Fseres-therapeutics-reports-ser-155-phase-1b-placebo-controlled\u0026_id=2c4a18add8648920\u0026_idn=1\u0026send_image=0\u0026_refts=0\u0026pv_id=iAx4rZ\u0026pf_net=355\u0026pf_srv=184\u0026pf_tfr=1\u0026pf_dm1=1291\u0026uadata=%7B%7D\u0026pdf=1\u0026qt=0\u0026realp=0\u0026wma=0\u0026fla=0\u0026java=0\u0026ag=0\u0026cookie=1\u0026res=1280x1024","fqdn":"analytics.imirwin.com","domain":"imirwin.com","tld":"com"},"ip":{"addr":"3.20.69.173","port":443,"asn":16509,"as":"AMAZON-02","country":"United States","country_code":"US"},"is_navigation_request":false,"resource_type":"beacon","requested_by":"https://ir.serestherapeutics.com/news-releases/news-release-details/seres-therapeutics-reports-ser-155-phase-1b-placebo-controlled","date":"2025-08-13T17:39:14.396Z","timestamp":0,"http_version":"","security_state":"secure","security_info":{"cipher_suite":"TLS_ECDHE_RSA_WITH_AES_128_GCM_SHA256","key_group_name":"P256","signature_name":"RSA-PKCS1-SHA256","protocol":"TLSv1.2","cert":{"subject":{"commonName":"analytics.imirwin.com","organization":""},"issuer":{"commonName":"Amazon RSA 2048 M04","organization":"Amazon"},"validity":{"start":"Mon, 19 May 2025 00:00:00 GMT","end":"Wed, 17 Jun 2026 23:59:59 GMT"},"fingerprint":{"sha1":"16:AE:C9:5B:15:E9:8D:4C:8E:FE:FD:30:19:4F:64:13:35:0C:E2:96","sha256":"53:75:12:9A:25:BD:14:3D:DC:A6:7E:44:7E:4B:69:48:EB:D8:28:7D:99:33:B5:94:B9:6F:F6:31:60:7E:0B:2E"}}},"request":{"raw":"POST /matomo.php?action_name=Seres%20Therapeutics%20Reports%20SER-155%20Phase%201b%20Placebo-Controlled%20Cohort%202%20Study%20Safety%20and%20Clinical%20Results%20in%20Patients%20Undergoing%20Allogeneic%20Hematopoietic%20Stem%20Cell%20Transplant%20(allo-HSCT)%20%7C%20Seres%20Therapeutics\u0026idsite=310\u0026rec=1\u0026r=594286\u0026h=17\u0026m=39\u0026s=14\u0026url=https%3A%2F%2Fir.serestherapeutics.com%2Fnews-releases%2Fnews-release-details%2Fseres-therapeutics-reports-ser-155-phase-1b-placebo-controlled\u0026_id=2c4a18add8648920\u0026_idn=1\u0026send_image=0\u0026_refts=0\u0026pv_id=iAx4rZ\u0026pf_net=355\u0026pf_srv=184\u0026pf_tfr=1\u0026pf_dm1=1291\u0026uadata=%7B%7D\u0026pdf=1\u0026qt=0\u0026realp=0\u0026wma=0\u0026fla=0\u0026java=0\u0026ag=0\u0026cookie=1\u0026res=1280x1024 HTTP/1.1\r\nHost: analytics.imirwin.com\r\nUser-Agent: Mozilla/5.0 (Windows NT 10.0; Win64; x64; rv:134.0) Gecko/20100101 Firefox/134.0\r\nAccept: */*\r\nAccept-Language: en-US,en;q=0.5\r\nAccept-Encoding: gzip, deflate, br\r\nContent-Type: application/x-www-form-urlencoded; charset=utf-8\r\nContent-Length: 0\r\nOrigin: https://ir.serestherapeutics.com\r\nDNT: 1\r\nConnection: keep-alive\r\nReferer: https://ir.serestherapeutics.com/\r\nSec-Fetch-Dest: empty\r\nSec-Fetch-Mode: no-cors\r\nSec-Fetch-Site: cross-site\r\n\r\n","headers":null,"cookies":null,"method":"POST"},"response":{"raw":"HTTP/2 204 No Content\r\ndate: Wed, 13 Aug 2025 17:39:14 GMT\r\nserver: nginx/1.27.5\r\nx-powered-by: PHP/8.3.19\r\ntk: N\r\naccess-control-allow-origin: https://ir.serestherapeutics.com\r\naccess-control-allow-credentials: true\r\nreferrer-policy: origin\r\nstrict-transport-security: max-age=31536000; includeSubDomains\r\nx-frame-options: deny\r\nX-Firefox-Spdy: h2\r\n\r\n","headers":null,"cookies":null,"status_code":"204","status_text":"No Content","fingerprints":[{"name":"PHP:8.3.19","description":"PHP is a general-purpose scripting language used for web development.","website":"https://php.net","common_platform_enumeration":"cpe:2.3:a:php:php:*:*:*:*:*:*:*:*","icon":"PHP.svg","categories":["Programming languages"]},{"name":"HSTS","description":"HTTP Strict Transport Security (HSTS) informs browsers that the site should only be accessed using HTTPS.","website":"https://www.rfc-editor.org/rfc/rfc6797#section-6.1","common_platform_enumeration":"","icon":"","categories":["Security"]},{"name":"Nginx:1.27.5","description":"Nginx is a web server that can also be used as a reverse proxy, load balancer, mail proxy and HTTP cache.","website":"https://nginx.org/en","common_platform_enumeration":"cpe:2.3:a:f5:nginx:*:*:*:*:*:*:*:*","icon":"Nginx.svg","categories":["Web servers","Reverse proxies"]}],"data":{"size":0,"size_decoded":0,"mime_type":"text/plain","magic":"","md5":"d41d8cd98f00b204e9800998ecf8427e","sha1":"da39a3ee5e6b4b0d3255bfef95601890afd80709","sha256":"e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855","sha512":"cf83e1357eefb8bdf1542850d66d8007d620e4050b5715dc83f4a921d36ce9ce47d0d13c5d85f2b0ff8318d2877eec2f63b931bd47417a81a538327af927da3e","ssdeep":"","tlshash":"","first_seen":"0001-01-01T00:00:00Z","last_seen":"2026-04-03T18:31:03.533086Z","times_seen":13299059,"resource_available":true,"data":null}},"time_used":123,"timings":{"blocked":0,"dns":0,"connect":0,"send":0,"wait":123,"receive":0,"ssl":0},"alerts":{"ids":null,"analyzer":null,"urlquery":null}},{"url":{"schema":"https","addr":"ir.serestherapeutics.com/news-releases/news-release-details/seres-therapeutics-reports-ser-155-phase-1b-placebo-controlled","fqdn":"ir.serestherapeutics.com","domain":"serestherapeutics.com","tld":"com"},"ip":{"addr":"23.36.77.170","port":443,"asn":20940,"as":"Akamai International B.V.","country":"Norway","country_code":"NO"},"is_navigation_request":true,"resource_type":"document","requested_by":"","date":"2025-08-13T17:39:11.642Z","timestamp":0,"http_version":"","security_state":"secure","security_info":{"cipher_suite":"TLS_AES_256_GCM_SHA384","key_group_name":"x25519","signature_name":"RSA-PSS-SHA256","protocol":"TLSv1.3","cert":{"subject":{"commonName":"leapfrog-ssl-30.gcs-web.com","organization":""},"issuer":{"commonName":"R10","organization":"Let's Encrypt"},"validity":{"start":"Fri, 13 Jun 2025 04:44:47 GMT","end":"Thu, 11 Sep 2025 04:44:46 GMT"},"fingerprint":{"sha1":"76:56:CB:1C:2A:EB:BC:6C:AD:AC:F9:46:52:00:98:68:6F:36:7E:4D","sha256":"2E:92:CD:78:D5:3F:E1:8C:2B:75:38:93:FD:B6:D7:66:20:2F:C1:D0:0B:A0:AE:7D:AE:10:26:7A:9B:48:60:40"}}},"request":{"raw":"GET /news-releases/news-release-details/seres-therapeutics-reports-ser-155-phase-1b-placebo-controlled HTTP/1.1\r\nHost: ir.serestherapeutics.com\r\nUser-Agent: Mozilla/5.0 (Windows NT 10.0; Win64; x64; rv:134.0) Gecko/20100101 Firefox/134.0\r\nAccept: text/html,application/xhtml+xml,application/xml;q=0.9,image/avif,image/webp,*/*;q=0.8\r\nAccept-Language: en-US,en;q=0.5\r\nAccept-Encoding: gzip, deflate, br\r\nDNT: 1\r\nUpgrade-Insecure-Requests: 1\r\nConnection: keep-alive\r\nSec-Fetch-Dest: document\r\nSec-Fetch-Mode: navigate\r\nSec-Fetch-Site: cross-site\r\nPragma: no-cache\r\nCache-Control: no-cache\r\n\r\n","headers":null,"cookies":null,"method":"GET"},"response":{"raw":"HTTP/2 200 OK\r\naccept-ranges: bytes\r\ncontent-language: en\r\ncontent-type: text/html; charset=UTF-8\r\netag: \"1755106746\"\r\nexpect-ct: max-age=0, report-uri=\"/report-expect-ct-violation\"\r\nfeature-policy: accelerometer 'none';ambient-light-sensor 'none';autoplay 'self';camera 'none';encrypted-media 'none';fullscreen 'self';geolocation 'self';gyroscope 'none';magnetometer 'none';microphone 'none';midi 'none';payment 'none';picture-in-picture 'none';speaker 'self';sync-xhr 'self';usb 'none';vibrate 'none';vr 'none'\r\nfrom-origin: same\r\nlast-modified: Wed, 13 Aug 2025 17:39:06 GMT\r\nreferrer-policy: no-referrer-when-downgrade\r\nstrict-transport-security: max-age=31536000\r\nx-age: 5\r\nx-cache-hits: 1\r\nx-content-type-options: nosniff\r\nx-drupal-dynamic-cache: UNCACHEABLE (poor cacheability)\r\nx-frame-options: SAMEORIGIN\r\nx-request-id: v-69393c72-786c-11f0-9e37-0bf29cdc7727\r\nx-xss-protection: 1; mode=block\r\nx-edgeconnect-midmile-rtt: 1, 18\r\nx-edgeconnect-origin-mex-latency: 84, 84\r\nx-akamai-transformed: 9 14442 0 pmb=mTOE,2\r\ncontent-encoding: gzip\r\ncache-control: public, max-age=0, s-maxage=2700\r\nexpires: Wed, 13 Aug 2025 17:39:12 GMT\r\ndate: Wed, 13 Aug 2025 17:39:12 GMT\r\ncontent-length: 14704\r\nvary: Accept-Encoding\r\nset-cookie: bm_ss=ab8e18ef4e; Secure; SameSite=None; Domain=.serestherapeutics.com; Path=/; HttpOnly; Max-Age=3600\nak_bmsc=8B3E3F53D6F1D551950B130550D015A2~000000000000000000000000000000~YAAQ9U0kF2FfO52YAQAAsLaDpBzYHEeJiZORhrKmMvVJl6htT4U5E/6alOnsN1WLbK0JNN0FxV6QIk3CXK6SZzJXWuElqmWB1WWYdY8quqhpWza5ivcl5im9nJoX7vrrq3G0vDVDRbOFK+CpHpJKlNA7AFE8qUMYv2oy8l08ONFK9GC3Aonufb2qXf/9ZjIkKIaaJrJwo1KUNgFeJmFTmRFsbb4oS3Jv2xmpV6uIXbaBeN9UhBTyS0HA2CF3KtgNehkaNLOEZnMBc1mLg/Q+bEEutjMUDLWyhdWbq0cnrrkhtimNWHnJcupfFzlIfpxdU3sj4xzZZ/Md5pzLYIOYZrVV2/12xnbT2CkSBSpx2FJsR/0yDsO84EToiNJUl0y3pFgjA1wezQP5EqYWYF8qXo/BI+qA; Domain=.serestherapeutics.com; Path=/; Expires=Wed, 13 Aug 2025 19:39:11 GMT; Max-Age=7199\nbm_mi=FA27DCBA53649A6151F2E389CA296CEF~YAAQ9U0kF2JfO52YAQAAsLaDpBwggx08NHl/O9WlljlMZtHG3Ml6teZdgRcPjKysuh4McUVdN+k2G9UXIXUehMgrQgTpKg73dDZYj+Jj17U2HerHmdUV23qBOELWIGCVsmC1WYHe9sUD767BclcWXAngFLKwV0ZE8AjhjbJ1oL5+osC1iBKA1khE1CR8iTs/WNrnQVNjHK+gJBaFzlR5olwsIuTPG3Vk/JE1qfnDkCdqvMxKzPdid3lx3Dyx+zvxUenBzIzHVSXE9KxVzr0j/MYoAV5lhyD+1VGEtOqBgosIy90KbYZh5ANs93RGB0J5O/bz3ikIJoxG6OW9x3mKpeeQhne6NhsUp7pAv66dFgQyUmTHxhx7it8trrI3oF75hYecLXP9E5j26V9qWFvJ+rkBH10euz64f4LIj1cApGBCKh9/3rlgQfZiHetqAOgkZ76IQUxiqHAlkw==~1; Domain=.serestherapeutics.com; Path=/; Expires=Wed, 13 Aug 2025 17:39:12 GMT; Max-Age=0; Secure\nbm_s=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; Domain=.serestherapeutics.com; Path=/; Expires=Sat, 13 Sep 2025 17:39:12 GMT; Max-Age=2678400; Secure; HttpOnly\nbm_so=076452BA7F785C26C0D039192D414EE322EFEBEE47C9D32A826B033A65229333~YAAQ9U0kF2RfO52YAQAAsLaDpARpo2xHJdjU4Jxa73zUq51KuxsW+QSmb5iP/ENmk7iqOGRhZyjdzqR50bYOPoK0krDYMKoypGPYm3hLRIvJAjzEPSWU9v0AmtzNP00zTXG2hPxPx54udTSSuGTM2KzBDJRiwCiOkJhUWlTdDefECbi1wnKokP5hnBjxGDCQMAE2aCXe4HqNbDgvHE7G5jmtqONfD1YgD6Cw25QL5pfAPYy0BKE94QkgYz+X0zy3rLB0HCSNr0ZOGQwVNzi2iZcJKo5SMvwmYjG5K9U0kZTVIUSy4tJGLP5ot1++FSPm+vy3pNdvnFN2MubC56GIGbx4fuz6N7DiabN7PeQYi+r8MvS04Dnfb7d5OjiIIOID16B38U5M8NVX3SXmdkNgusrIqEHOgLTigWBDKbEIIu1+fexPgsghoQRNJTdw9HEjOj0FOJyf/HSuHOBqCbNWdmrBXQvBXBkw; Domain=.serestherapeutics.com; Path=/; Expires=Thu, 14 Aug 2025 17:39:12 GMT; Max-Age=86400; Secure\r\nX-Firefox-Spdy: h2\r\n\r\n","headers":null,"cookies":null,"status_code":"200","status_text":"OK","fingerprints":[{"name":"Akamai","description":"Akamai is global content delivery network (CDN) services provider for media and software delivery, and cloud security solutions.","website":"https://akamai.com","common_platform_enumeration":"","icon":"Akamai.svg","categories":["CDN"]},{"name":"Modernizr","description":"Modernizr is a JavaScript library that detects the features available in a user's browser.","website":"https://modernizr.com","common_platform_enumeration":"","icon":"Modernizr.svg","categories":["JavaScript libraries"]},{"name":"Drupal Multisite","description":"Drupal Multisite enables separate, independent sites to be served from a single codebase.","website":"https://www.drupal.org/docs/multisite-drupal","common_platform_enumeration":"","icon":"Drupal.svg","categories":["Hosting"]},{"name":"Drupal:10","description":"Drupal is a free and open-source web content management framework.","website":"https://www.drupal.org/","common_platform_enumeration":"cpe:2.3:a:drupal:drupal:*:*:*:*:*:*:*:*","icon":"Drupal.svg","categories":["CMS"]},{"name":"jQuery","description":"jQuery is a JavaScript library which is a free, open-source software designed to simplify HTML DOM tree traversal and manipulation, as well as event handling, CSS animation, and Ajax.","website":"https://jquery.com","common_platform_enumeration":"cpe:2.3:a:jquery:jquery:*:*:*:*:*:*:*:*","icon":"jQuery.svg","categories":["JavaScript libraries"]},{"name":"Typekit","description":"Typekit is an online service which offers a subscription library of fonts.","website":"https://typekit.com","common_platform_enumeration":"","icon":"Typekit.png","categories":["Font scripts"]},{"name":"DataTables","description":"DataTables is a plug-in for the jQuery Javascript library adding advanced features like pagination, instant search, themes, and more to any HTML table.","website":"https://datatables.net","common_platform_enumeration":"cpe:2.3:a:datatables:datatables.net:*:*:*:*:*:*:*:*","icon":"DataTables.png","categories":["JavaScript libraries"]},{"name":"PHP","description":"PHP is a general-purpose scripting language used for web development.","website":"https://php.net","common_platform_enumeration":"cpe:2.3:a:php:php:*:*:*:*:*:*:*:*","icon":"PHP.svg","categories":["Programming languages"]},{"name":"Acquia Cloud Site Factory","description":"Acquia Site Factory is a multisite platform for Drupal.","website":"https://www.acquia.com/products/drupal-cloud/site-factory","common_platform_enumeration":"","icon":"acquia-site-factory.png","categories":["Hosting"]},{"name":"HSTS","description":"HTTP Strict Transport Security (HSTS) informs browsers that the site should only be accessed using HTTPS.","website":"https://www.rfc-editor.org/rfc/rfc6797#section-6.1","common_platform_enumeration":"","icon":"","categories":["Security"]},{"name":"Adobe Fonts","description":"Adobe Fonts is a web-based service providing access to a vast library of high-quality fonts for web and print design.","website":"https://fonts.adobe.com","common_platform_enumeration":"","icon":"Adobe Fonts.svg","categories":["Font scripts"]},{"name":"Acquia Cloud Platform","description":"Acquia Cloud Platform is a Drupal-tuned application lifecycle management suite with an infrastructure to support Drupal deployment workflow processes.","website":"https://www.acquia.com/products/drupal-cloud/cloud-platform","common_platform_enumeration":"","icon":"acquia-cloud.png","categories":["PaaS"]}],"data":{"size":47303,"size_decoded":0,"mime_type":"text/html; charset=UTF-8","magic":"HTML document, Unicode text, UTF-8 text, with very long lines (2064), with CRLF, LF line terminators","md5":"0b1b4d2da50341901bb93c6701754a0d","sha1":"3637ce5d2c7e485c0b9bd8c852219cbcbb045170","sha256":"b35b85d3e2861d4dc314167b3eef787ec4a19d6a033ca89006028ab554492911","sha512":"d52421613a16d3086aff6c1bcb3dc0e1da487d544ff034da5898e92a978ee3590b43b4e26fccbf7657349f76283ba8a3fa67d8a3485a5b49849c221d83f90e77","ssdeep":"768:HQpm/kwBVQ769ZF2v4GQMq2nJGhmDdWI7gIGzFyZ7wnLPypuqmj:wpmMwBHDFAQMq2ndngdzFyZ7wnLPyBmj","tlshash":"bf232b42b9d02337021751a563a252a6f36ee447e7004856f8ec420cbf9be6acfbf15d","first_seen":"2025-08-13T17:39:41.400545Z","last_seen":"2025-08-13T17:39:41.400545Z","times_seen":1,"resource_available":false,"data":null}},"time_used":888,"timings":{"blocked":351,"dns":325,"connect":1,"send":0,"wait":184,"receive":1,"ssl":23},"alerts":{"ids":null,"analyzer":null,"urlquery":null}},{"url":{"schema":"https","addr":"ir.serestherapeutics.com/sites/g/files/knoqqb52941/files/js/js_IOyodS2WxvrYi8yxS5GIgnuAZQ1BYMBwt-80-zYLMvg.js?scope=footer\u0026delta=2\u0026language=en\u0026theme=nir_pid2065\u0026include=eJyFjtsOAjEIRH_IbI2J_g6hhSiKZUNZL3_v2jXx8mJ4YGY4mVDFASvqPaS0VD_dgGSZQXGq5bCqf8HRjTqWsXEnwkwzeg_LiUnCHAhjnqzc0lt25DxpyHnGMH3bfh1xv7Q-xYBHvAESQVFsDVDZY2kZhTbr3TbZhd2FuIdXzk2Codr8MC___2TDaz8ANtZsDQ","fqdn":"ir.serestherapeutics.com","domain":"serestherapeutics.com","tld":"com"},"ip":{"addr":"23.36.77.170","port":443,"asn":20940,"as":"Akamai International B.V.","country":"Norway","country_code":"NO"},"is_navigation_request":false,"resource_type":"script","requested_by":"https://ir.serestherapeutics.com/news-releases/news-release-details/seres-therapeutics-reports-ser-155-phase-1b-placebo-controlled","date":"2025-08-13T17:39:12.432Z","timestamp":0,"http_version":"","security_state":"secure","security_info":{"cipher_suite":"TLS_AES_256_GCM_SHA384","key_group_name":"x25519","signature_name":"RSA-PSS-SHA256","protocol":"TLSv1.3","cert":{"subject":{"commonName":"leapfrog-ssl-30.gcs-web.com","organization":""},"issuer":{"commonName":"R10","organization":"Let's Encrypt"},"validity":{"start":"Fri, 13 Jun 2025 04:44:47 GMT","end":"Thu, 11 Sep 2025 04:44:46 GMT"},"fingerprint":{"sha1":"76:56:CB:1C:2A:EB:BC:6C:AD:AC:F9:46:52:00:98:68:6F:36:7E:4D","sha256":"2E:92:CD:78:D5:3F:E1:8C:2B:75:38:93:FD:B6:D7:66:20:2F:C1:D0:0B:A0:AE:7D:AE:10:26:7A:9B:48:60:40"}}},"request":{"raw":"GET /sites/g/files/knoqqb52941/files/js/js_IOyodS2WxvrYi8yxS5GIgnuAZQ1BYMBwt-80-zYLMvg.js?scope=footer\u0026delta=2\u0026language=en\u0026theme=nir_pid2065\u0026include=eJyFjtsOAjEIRH_IbI2J_g6hhSiKZUNZL3_v2jXx8mJ4YGY4mVDFASvqPaS0VD_dgGSZQXGq5bCqf8HRjTqWsXEnwkwzeg_LiUnCHAhjnqzc0lt25DxpyHnGMH3bfh1xv7Q-xYBHvAESQVFsDVDZY2kZhTbr3TbZhd2FuIdXzk2Codr8MC___2TDaz8ANtZsDQ HTTP/1.1\r\nHost: ir.serestherapeutics.com\r\nUser-Agent: Mozilla/5.0 (Windows NT 10.0; Win64; x64; rv:134.0) Gecko/20100101 Firefox/134.0\r\nAccept: */*\r\nAccept-Language: en-US,en;q=0.5\r\nAccept-Encoding: gzip, deflate, br\r\nReferer: https://ir.serestherapeutics.com/news-releases/news-release-details/seres-therapeutics-reports-ser-155-phase-1b-placebo-controlled\r\nDNT: 1\r\nConnection: keep-alive\r\nCookie: bm_ss=ab8e18ef4e; ak_bmsc=8B3E3F53D6F1D551950B130550D015A2~000000000000000000000000000000~YAAQ9U0kF2FfO52YAQAAsLaDpBzYHEeJiZORhrKmMvVJl6htT4U5E/6alOnsN1WLbK0JNN0FxV6QIk3CXK6SZzJXWuElqmWB1WWYdY8quqhpWza5ivcl5im9nJoX7vrrq3G0vDVDRbOFK+CpHpJKlNA7AFE8qUMYv2oy8l08ONFK9GC3Aonufb2qXf/9ZjIkKIaaJrJwo1KUNgFeJmFTmRFsbb4oS3Jv2xmpV6uIXbaBeN9UhBTyS0HA2CF3KtgNehkaNLOEZnMBc1mLg/Q+bEEutjMUDLWyhdWbq0cnrrkhtimNWHnJcupfFzlIfpxdU3sj4xzZZ/Md5pzLYIOYZrVV2/12xnbT2CkSBSpx2FJsR/0yDsO84EToiNJUl0y3pFgjA1wezQP5EqYWYF8qXo/BI+qA; bm_s=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; bm_so=076452BA7F785C26C0D039192D414EE322EFEBEE47C9D32A826B033A65229333~YAAQ9U0kF2RfO52YAQAAsLaDpARpo2xHJdjU4Jxa73zUq51KuxsW+QSmb5iP/ENmk7iqOGRhZyjdzqR50bYOPoK0krDYMKoypGPYm3hLRIvJAjzEPSWU9v0AmtzNP00zTXG2hPxPx54udTSSuGTM2KzBDJRiwCiOkJhUWlTdDefECbi1wnKokP5hnBjxGDCQMAE2aCXe4HqNbDgvHE7G5jmtqONfD1YgD6Cw25QL5pfAPYy0BKE94QkgYz+X0zy3rLB0HCSNr0ZOGQwVNzi2iZcJKo5SMvwmYjG5K9U0kZTVIUSy4tJGLP5ot1++FSPm+vy3pNdvnFN2MubC56GIGbx4fuz6N7DiabN7PeQYi+r8MvS04Dnfb7d5OjiIIOID16B38U5M8NVX3SXmdkNgusrIqEHOgLTigWBDKbEIIu1+fexPgsghoQRNJTdw9HEjOj0FOJyf/HSuHOBqCbNWdmrBXQvBXBkw\r\nSec-Fetch-Dest: script\r\nSec-Fetch-Mode: no-cors\r\nSec-Fetch-Site: same-origin\r\nPragma: no-cache\r\nCache-Control: no-cache\r\n\r\n","headers":null,"cookies":null,"method":"GET"},"response":{"raw":"HTTP/2 200 OK\r\naccept-ranges: bytes\r\ncontent-encoding: gzip\r\ncontent-type: text/javascript\r\nlast-modified: Tue, 15 Jul 2025 04:13:19 GMT\r\nx-age: 20565\r\nx-cache-hits: 9\r\nx-content-type-options: nosniff\r\nx-request-id: v-de5df7e0-6147-11f0-9614-ff8340a2c38f\r\ncontent-length: 13839\r\nx-edgeconnect-midmile-rtt: 0, 18, 17\r\nx-edgeconnect-origin-mex-latency: 88, 81, 84\r\ncache-control: max-age=600\r\nexpires: Wed, 13 Aug 2025 17:49:12 GMT\r\ndate: Wed, 13 Aug 2025 17:39:12 GMT\r\nvary: Accept-Encoding\r\nX-Firefox-Spdy: h2\r\n\r\n","headers":null,"cookies":null,"status_code":"200","status_text":"OK","fingerprints":[{"name":"Akamai","description":"Akamai is global content delivery network (CDN) services provider for media and software delivery, and cloud security solutions.","website":"https://akamai.com","common_platform_enumeration":"","icon":"Akamai.svg","categories":["CDN"]}],"data":{"size":51673,"size_decoded":0,"mime_type":"text/javascript","magic":"JavaScript source, ASCII text, with very long lines (20065)","md5":"f7dded42909262556deed32a11ebaba7","sha1":"a804d9e4f3aac2953739b2fc5b3a72d2c44dbf5e","sha256":"bddd4366cbae54a3b45f250dee2846c48876387772d452a4415b0664442f8e35","sha512":"db700b4e78fd66037482bafd7795f7f5478c12b0eaa341f3206ee5ed9de3cf0fa062ccfb4c2a6c831fbde002171ebfbfd54b6beb6a63b280a133ae1602481164","ssdeep":"1536:6N4qqTd14jHMGxJfiSqiYkkugSDhM2rpKN+pT+emPV:dqqhlugSDhJQ+pTBmPV","tlshash":"f733e85274702d3645df14efb4820350363a0c696401e0d8f86c68e9affeec5a7b6b6e","first_seen":"2025-06-24T06:10:32.606296Z","last_seen":"2026-02-24T21:53:20.201227Z","times_seen":20,"resource_available":true,"data":null}},"time_used":252,"timings":{"blocked":-1,"dns":0,"connect":0,"send":0,"wait":251,"receive":1,"ssl":0},"alerts":{"ids":null,"analyzer":null,"urlquery":null}},{"url":{"schema":"https","addr":"ir.serestherapeutics.com/sites/g/files/knoqqb52941/files/js/js_PtDMcSRiFptmwcSpb0SAL1rDxUyMsgq3E5pFfNxiZUQ.js?scope=footer\u0026delta=5\u0026language=en\u0026theme=nir_pid2065\u0026include=eJyFjtsOAjEIRH_IbI2J_g6hhSiKZUNZL3_v2jXx8mJ4YGY4mVDFASvqPaS0VD_dgGSZQXGq5bCqf8HRjTqWsXEnwkwzeg_LiUnCHAhjnqzc0lt25DxpyHnGMH3bfh1xv7Q-xYBHvAESQVFsDVDZY2kZhTbr3TbZhd2FuIdXzk2Codr8MC___2TDaz8ANtZsDQ","fqdn":"ir.serestherapeutics.com","domain":"serestherapeutics.com","tld":"com"},"ip":{"addr":"23.36.77.170","port":443,"asn":20940,"as":"Akamai International B.V.","country":"Norway","country_code":"NO"},"is_navigation_request":false,"resource_type":"script","requested_by":"https://ir.serestherapeutics.com/news-releases/news-release-details/seres-therapeutics-reports-ser-155-phase-1b-placebo-controlled","date":"2025-08-13T17:39:12.436Z","timestamp":0,"http_version":"","security_state":"secure","security_info":{"cipher_suite":"TLS_AES_256_GCM_SHA384","key_group_name":"x25519","signature_name":"RSA-PSS-SHA256","protocol":"TLSv1.3","cert":{"subject":{"commonName":"leapfrog-ssl-30.gcs-web.com","organization":""},"issuer":{"commonName":"R10","organization":"Let's Encrypt"},"validity":{"start":"Fri, 13 Jun 2025 04:44:47 GMT","end":"Thu, 11 Sep 2025 04:44:46 GMT"},"fingerprint":{"sha1":"76:56:CB:1C:2A:EB:BC:6C:AD:AC:F9:46:52:00:98:68:6F:36:7E:4D","sha256":"2E:92:CD:78:D5:3F:E1:8C:2B:75:38:93:FD:B6:D7:66:20:2F:C1:D0:0B:A0:AE:7D:AE:10:26:7A:9B:48:60:40"}}},"request":{"raw":"GET /sites/g/files/knoqqb52941/files/js/js_PtDMcSRiFptmwcSpb0SAL1rDxUyMsgq3E5pFfNxiZUQ.js?scope=footer\u0026delta=5\u0026language=en\u0026theme=nir_pid2065\u0026include=eJyFjtsOAjEIRH_IbI2J_g6hhSiKZUNZL3_v2jXx8mJ4YGY4mVDFASvqPaS0VD_dgGSZQXGq5bCqf8HRjTqWsXEnwkwzeg_LiUnCHAhjnqzc0lt25DxpyHnGMH3bfh1xv7Q-xYBHvAESQVFsDVDZY2kZhTbr3TbZhd2FuIdXzk2Codr8MC___2TDaz8ANtZsDQ HTTP/1.1\r\nHost: ir.serestherapeutics.com\r\nUser-Agent: Mozilla/5.0 (Windows NT 10.0; Win64; x64; rv:134.0) Gecko/20100101 Firefox/134.0\r\nAccept: */*\r\nAccept-Language: en-US,en;q=0.5\r\nAccept-Encoding: gzip, deflate, br\r\nReferer: https://ir.serestherapeutics.com/news-releases/news-release-details/seres-therapeutics-reports-ser-155-phase-1b-placebo-controlled\r\nDNT: 1\r\nConnection: keep-alive\r\nCookie: bm_ss=ab8e18ef4e; ak_bmsc=8B3E3F53D6F1D551950B130550D015A2~000000000000000000000000000000~YAAQ9U0kF2FfO52YAQAAsLaDpBzYHEeJiZORhrKmMvVJl6htT4U5E/6alOnsN1WLbK0JNN0FxV6QIk3CXK6SZzJXWuElqmWB1WWYdY8quqhpWza5ivcl5im9nJoX7vrrq3G0vDVDRbOFK+CpHpJKlNA7AFE8qUMYv2oy8l08ONFK9GC3Aonufb2qXf/9ZjIkKIaaJrJwo1KUNgFeJmFTmRFsbb4oS3Jv2xmpV6uIXbaBeN9UhBTyS0HA2CF3KtgNehkaNLOEZnMBc1mLg/Q+bEEutjMUDLWyhdWbq0cnrrkhtimNWHnJcupfFzlIfpxdU3sj4xzZZ/Md5pzLYIOYZrVV2/12xnbT2CkSBSpx2FJsR/0yDsO84EToiNJUl0y3pFgjA1wezQP5EqYWYF8qXo/BI+qA; bm_s=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; bm_so=076452BA7F785C26C0D039192D414EE322EFEBEE47C9D32A826B033A65229333~YAAQ9U0kF2RfO52YAQAAsLaDpARpo2xHJdjU4Jxa73zUq51KuxsW+QSmb5iP/ENmk7iqOGRhZyjdzqR50bYOPoK0krDYMKoypGPYm3hLRIvJAjzEPSWU9v0AmtzNP00zTXG2hPxPx54udTSSuGTM2KzBDJRiwCiOkJhUWlTdDefECbi1wnKokP5hnBjxGDCQMAE2aCXe4HqNbDgvHE7G5jmtqONfD1YgD6Cw25QL5pfAPYy0BKE94QkgYz+X0zy3rLB0HCSNr0ZOGQwVNzi2iZcJKo5SMvwmYjG5K9U0kZTVIUSy4tJGLP5ot1++FSPm+vy3pNdvnFN2MubC56GIGbx4fuz6N7DiabN7PeQYi+r8MvS04Dnfb7d5OjiIIOID16B38U5M8NVX3SXmdkNgusrIqEHOgLTigWBDKbEIIu1+fexPgsghoQRNJTdw9HEjOj0FOJyf/HSuHOBqCbNWdmrBXQvBXBkw\r\nSec-Fetch-Dest: script\r\nSec-Fetch-Mode: no-cors\r\nSec-Fetch-Site: same-origin\r\nPragma: no-cache\r\nCache-Control: no-cache\r\n\r\n","headers":null,"cookies":null,"method":"GET"},"response":{"raw":"HTTP/2 200 OK\r\naccept-ranges: bytes\r\ncontent-encoding: gzip\r\ncontent-type: text/javascript\r\nlast-modified: Tue, 15 Jul 2025 04:44:13 GMT\r\nx-age: 27710\r\nx-cache-hits: 17\r\nx-content-type-options: nosniff\r\nx-request-id: v-3c1a64e2-6137-11f0-9822-5fc904e2d24b\r\ncontent-length: 83343\r\nx-edgeconnect-midmile-rtt: 19, 16\r\nx-edgeconnect-origin-mex-latency: 89, 81\r\ncache-control: max-age=600\r\nexpires: Wed, 13 Aug 2025 17:49:12 GMT\r\ndate: Wed, 13 Aug 2025 17:39:12 GMT\r\nvary: Accept-Encoding\r\nX-Firefox-Spdy: h2\r\n\r\n","headers":null,"cookies":null,"status_code":"200","status_text":"OK","fingerprints":[{"name":"Akamai","description":"Akamai is global content delivery network (CDN) services provider for media and software delivery, and cloud security solutions.","website":"https://akamai.com","common_platform_enumeration":"","icon":"Akamai.svg","categories":["CDN"]}],"data":{"size":331879,"size_decoded":0,"mime_type":"text/javascript","magic":"JavaScript source, Unicode text, UTF-8 text, with very long lines (65461)","md5":"ba7b5058dd4458874d391ccb4b9255b4","sha1":"88207a2ba1fe8e595da1e1804ff1cf6fe65060fd","sha256":"70172f18455d34079d19b9e22ccf94b90144ae38f78c8f6f86240df2235fc1b7","sha512":"93feba18748b82c85a8fe55d7fa2015b8b2e900722fc712f6a3c8c5aa07b950f6e7ae37e410c1bc2bd460868746eba71301e8877ea85acf0ba11152cf8498c89","ssdeep":"6144:ay9ic07hVOESsw1MyW3knUUBYMmsH5JgTZC:ay9ic0qESsiMyW3kpJgTZC","tlshash":"9e641848bb50313943efb0fba49f4709723a990a8449e468f538c9d81eb5c45b5abf7c","first_seen":"2025-08-13T17:39:41.404533Z","last_seen":"2025-08-13T17:39:41.404533Z","times_seen":1,"resource_available":true,"data":null}},"time_used":228,"timings":{"blocked":-1,"dns":0,"connect":0,"send":0,"wait":224,"receive":4,"ssl":0},"alerts":{"ids":null,"analyzer":null,"urlquery":null}},{"url":{"schema":"https","addr":"use.typekit.net/af/4b28f4/00000000000000003b9acb08/27/l?primer=7cdcb44be4a7db8877ffa5c0007b8dd865b3bbc383831fe2ea177f62257a9191\u0026fvd=n4\u0026v=3","fqdn":"use.typekit.net","domain":"typekit.net","tld":"net"},"ip":{"addr":"23.36.77.81","port":443,"asn":20940,"as":"Akamai International B.V.","country":"Norway","country_code":"NO"},"is_navigation_request":false,"resource_type":"font","requested_by":"https://ir.serestherapeutics.com/news-releases/news-release-details/seres-therapeutics-reports-ser-155-phase-1b-placebo-controlled","date":"2025-08-13T17:39:13.086Z","timestamp":0,"http_version":"","security_state":"secure","security_info":{"cipher_suite":"TLS_AES_256_GCM_SHA384","key_group_name":"x25519","signature_name":"ECDSA-P256-SHA256","protocol":"TLSv1.3","cert":{"subject":{"commonName":"use.typekit.net","organization":"Adobe Inc."},"issuer":{"commonName":"DigiCert Global G2 TLS RSA SHA256 2020 CA1","organization":"DigiCert Inc"},"validity":{"start":"Tue, 10 Dec 2024 00:00:00 GMT","end":"Sat, 10 Jan 2026 23:59:59 GMT"},"fingerprint":{"sha1":"F3:36:2A:08:11:E8:8C:54:E5:3C:6A:03:53:BF:AA:D7:7A:84:8B:89","sha256":"6A:79:75:73:C0:A8:12:54:14:ED:26:F6:54:AA:3F:01:34:4E:41:17:1C:AB:70:3C:72:0B:AF:BE:E1:75:6F:6E"}}},"request":{"raw":"GET /af/4b28f4/00000000000000003b9acb08/27/l?primer=7cdcb44be4a7db8877ffa5c0007b8dd865b3bbc383831fe2ea177f62257a9191\u0026fvd=n4\u0026v=3 HTTP/1.1\r\nHost: use.typekit.net\r\nUser-Agent: Mozilla/5.0 (Windows NT 10.0; Win64; x64; rv:134.0) Gecko/20100101 Firefox/134.0\r\nAccept: application/font-woff2;q=1.0,application/font-woff;q=0.9,*/*;q=0.8\r\nAccept-Language: en-US,en;q=0.5\r\nAccept-Encoding: identity\r\nOrigin: https://ir.serestherapeutics.com\r\nDNT: 1\r\nConnection: keep-alive\r\nReferer: https://use.typekit.net/\r\nSec-Fetch-Dest: font\r\nSec-Fetch-Mode: cors\r\nSec-Fetch-Site: cross-site\r\nPragma: no-cache\r\nCache-Control: no-cache\r\n\r\n","headers":null,"cookies":null,"method":"GET"},"response":{"raw":"HTTP/2 200 OK\r\nserver: nginx\r\ncontent-type: application/font-woff2\r\ncontent-length: 25976\r\netag: \"9b2f7f4f97b2a727703206062462973fb459907c\"\r\ntiming-allow-origin: *\r\naccess-control-allow-origin: *\r\ncross-origin-resource-policy: cross-origin\r\ncache-control: public, max-age=31536000\r\ndate: Wed, 13 Aug 2025 17:39:13 GMT\r\nakamai-grn: 0.474d2417.1755106753.608252b\r\nX-Firefox-Spdy: h2\r\n\r\n","headers":null,"cookies":null,"status_code":"200","status_text":"OK","fingerprints":[{"name":"Nginx","description":"Nginx is a web server that can also be used as a reverse proxy, load balancer, mail proxy and HTTP cache.","website":"https://nginx.org/en","common_platform_enumeration":"cpe:2.3:a:f5:nginx:*:*:*:*:*:*:*:*","icon":"Nginx.svg","categories":["Web servers","Reverse proxies"]}],"data":{"size":25976,"size_decoded":0,"mime_type":"application/font-woff2","magic":"Web Open Font Format (Version 2), TrueType, length 25976, version 1.0","md5":"aaac96c1ad8458412aeec906e2075df4","sha1":"2ec8dc426c5dab7dcd5c5e766ecb0967b0c5ca2c","sha256":"74e66c6fffa12e9f5637a8c5e46aae8afe022b8ae19370d7bd0a9fb4dc5ed7fa","sha512":"5a79fa2cd81fb01d1a31916a7cfc8181170073e5700a24246e06cbbf65dd7474f0aff4035d30036fbdfc73a1e6594dfe78e1afcb6a551431590ae02696afaded","ssdeep":"384:BwQyX1TO9M59C/bCISPTEkZrzES9QR+Nxwj/G2a9Cv6Hgmb3u5gzpoMpL55J:BMZO9M5gzCSilPcOh9Cv873FNoMpL55J","tlshash":"5fc2f1ce4112c49c8f0db8341475532a292b843f54bad26dc7b3bf7fe0a602b79d8999","first_seen":"2023-04-09T12:31:25Z","last_seen":"2026-03-31T02:00:56.064202Z","times_seen":209,"resource_available":false,"data":null}},"time_used":51,"timings":{"blocked":21,"dns":1,"connect":1,"send":0,"wait":2,"receive":1,"ssl":21},"alerts":{"ids":null,"analyzer":null,"urlquery":null}},{"url":{"schema":"https","addr":"ir.serestherapeutics.com/sites/g/files/knoqqb52941/themes/site/nir_pid2065/dist/img/sprite.svg","fqdn":"ir.serestherapeutics.com","domain":"serestherapeutics.com","tld":"com"},"ip":{"addr":"23.36.77.170","port":443,"asn":20940,"as":"Akamai International B.V.","country":"Norway","country_code":"NO"},"is_navigation_request":false,"resource_type":"other","requested_by":"https://ir.serestherapeutics.com/news-releases/news-release-details/seres-therapeutics-reports-ser-155-phase-1b-placebo-controlled","date":"2025-08-13T17:39:13.058Z","timestamp":0,"http_version":"","security_state":"secure","security_info":{"cipher_suite":"TLS_AES_256_GCM_SHA384","key_group_name":"x25519","signature_name":"RSA-PSS-SHA256","protocol":"TLSv1.3","cert":{"subject":{"commonName":"leapfrog-ssl-30.gcs-web.com","organization":""},"issuer":{"commonName":"R10","organization":"Let's Encrypt"},"validity":{"start":"Fri, 13 Jun 2025 04:44:47 GMT","end":"Thu, 11 Sep 2025 04:44:46 GMT"},"fingerprint":{"sha1":"76:56:CB:1C:2A:EB:BC:6C:AD:AC:F9:46:52:00:98:68:6F:36:7E:4D","sha256":"2E:92:CD:78:D5:3F:E1:8C:2B:75:38:93:FD:B6:D7:66:20:2F:C1:D0:0B:A0:AE:7D:AE:10:26:7A:9B:48:60:40"}}},"request":{"raw":"GET /sites/g/files/knoqqb52941/themes/site/nir_pid2065/dist/img/sprite.svg HTTP/1.1\r\nHost: ir.serestherapeutics.com\r\nUser-Agent: Mozilla/5.0 (Windows NT 10.0; Win64; x64; rv:134.0) Gecko/20100101 Firefox/134.0\r\nAccept: */*\r\nAccept-Language: en-US,en;q=0.5\r\nAccept-Encoding: gzip, deflate, br\r\nReferer: https://ir.serestherapeutics.com/news-releases/news-release-details/seres-therapeutics-reports-ser-155-phase-1b-placebo-controlled\r\nDNT: 1\r\nConnection: keep-alive\r\nCookie: bm_ss=ab8e18ef4e; ak_bmsc=4E19C384354D9168EC037A0AE57F6E73~000000000000000000000000000000~YAAQ9U0kF3FfO52YAQAAoLiDpBzRDcrnH6JVmuZe+X7eJCmtLVP5oR5k3kXGARYJJVBAsw+q81DIcLQmOV8N1ujMBrXUamJHnJS7hNYlYdEDIAeNK/IANgppOIGPWSD30vdHue4X8W3dI7qdSkeDiXL8vWDfixSOhBbxDuqdFA/9Cv2o/FiNUUfmV6SuQVibYQXOJ+wagXSrei1Zkl9X2gVN/Gwom++A8v7BTG4rDWjjmLmzRJy6d4g31vDW+5uTeETmQZZUc4HHnbyxlOBP+//XhF7R8CFq5vH1FQ8GKtDX34wS1DW4XlTLGeAmusrcuOEBmNIflJmGwJOrY5EqLZDfcLRBdsHSY8BlxpWAWSyb+95E1IMm49gqrCGvKrPaRuI94Gf0m5uZE3N19M9ZYvwmQHv+8eP0+Cgn1KAO8sB4ofSwMJovneYg1yUOVzgENB4=; bm_s=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; bm_so=076452BA7F785C26C0D039192D414EE322EFEBEE47C9D32A826B033A65229333~YAAQ9U0kF2RfO52YAQAAsLaDpARpo2xHJdjU4Jxa73zUq51KuxsW+QSmb5iP/ENmk7iqOGRhZyjdzqR50bYOPoK0krDYMKoypGPYm3hLRIvJAjzEPSWU9v0AmtzNP00zTXG2hPxPx54udTSSuGTM2KzBDJRiwCiOkJhUWlTdDefECbi1wnKokP5hnBjxGDCQMAE2aCXe4HqNbDgvHE7G5jmtqONfD1YgD6Cw25QL5pfAPYy0BKE94QkgYz+X0zy3rLB0HCSNr0ZOGQwVNzi2iZcJKo5SMvwmYjG5K9U0kZTVIUSy4tJGLP5ot1++FSPm+vy3pNdvnFN2MubC56GIGbx4fuz6N7DiabN7PeQYi+r8MvS04Dnfb7d5OjiIIOID16B38U5M8NVX3SXmdkNgusrIqEHOgLTigWBDKbEIIu1+fexPgsghoQRNJTdw9HEjOj0FOJyf/HSuHOBqCbNWdmrBXQvBXBkw\r\nSec-Fetch-Dest: empty\r\nSec-Fetch-Mode: same-origin\r\nSec-Fetch-Site: same-origin\r\nPragma: no-cache\r\nCache-Control: no-cache\r\n\r\n","headers":null,"cookies":null,"method":"GET"},"response":{"raw":"HTTP/2 200 OK\r\naccept-ranges: bytes\r\ncontent-type: image/svg+xml\r\nlast-modified: Mon, 14 Jul 2025 09:57:48 GMT\r\nx-age: 1123350\r\nx-cache-hits: 683\r\nx-content-type-options: nosniff\r\nx-request-id: v-00fe3bf2-6c42-11f0-b070-17a67f970d91\r\ncontent-encoding: gzip\r\ncontent-length: 774\r\nx-edgeconnect-midmile-rtt: 17, 17\r\nx-edgeconnect-origin-mex-latency: 81, 83\r\ncache-control: max-age=600\r\nexpires: Wed, 13 Aug 2025 17:49:13 GMT\r\ndate: Wed, 13 Aug 2025 17:39:13 GMT\r\nvary: Accept-Encoding\r\nset-cookie: ak_bmsc=4E19C384354D9168EC037A0AE57F6E73~000000000000000000000000000000~YAAQ9U0kF3ZfO52YAQAApLqDpBzNkmnFw1vH4xazUfHl1P17UydIYj1MERl1pCSDUIpGOnwWfo3o/spVd+0CKqAWwxzlYeioMdPOVHy5vsDVpJIOU4IM74BKZP4K6g4rV0CfVElr9YDN2DfAXrHgXmr/RGMnEpNoV0NwSaBX/mVKmbAgPJWRODlC3itEJGy2RyDpwg8QNKrANEOfqbgFPNjJ1H8MXWQrPSulivLaYz+548GNHfQVj41KatnB6J9tP83MeFhLU9wSnX2n8TaElvgTRslg5N6E/OZxGKcdXVMlz0LFKfQHaafjXSSpwg+dAUmJoVxsqJmYOwVuS5juLFowuRUP4LkpSCUrW18AFR97MwDjozmVW8aBGBZW++faCiy+C3sV69LIM4bozCWKyShL0p+1sm/jitm/y9Fx2iG4G4Z4UOIwibQuOPXfxt58B1KTEOl/yNhj/YBl; Domain=.serestherapeutics.com; Path=/; Expires=Wed, 13 Aug 2025 19:39:11 GMT; Max-Age=7198\r\nX-Firefox-Spdy: h2\r\n\r\n","headers":null,"cookies":null,"status_code":"200","status_text":"OK","fingerprints":[{"name":"Akamai","description":"Akamai is global content delivery network (CDN) services provider for media and software delivery, and cloud security solutions.","website":"https://akamai.com","common_platform_enumeration":"","icon":"Akamai.svg","categories":["CDN"]},{"name":"Akamai Bot Manager","description":"Akamai Bot Manager detect bots using device fingerprinting bot signatures.","website":"https://www.akamai.com/us/en/products/security/bot-manager.jsp","common_platform_enumeration":"","icon":"Akamai.svg","categories":["Security"]}],"data":{"size":1551,"size_decoded":0,"mime_type":"image/svg+xml","magic":"SVG Scalable Vector Graphics image","md5":"9d374d621b3a43f47d03fc56a56ac977","sha1":"a82b176d91941ad8e5827e06bfced3cb354a9d6b","sha256":"971c5d9b5e5814c77a291a030b4c413abb6a0ea71efe0bc7d1e634514d677a6e","sha512":"bbad6a4a67bc4249a6dddeab72c0005cec4842611847063e6291a18495bd0142718cf6f2294ba6a4a01edc0d5e5daa514fa3b5e7f5aeaff93d355ae9445b524d","ssdeep":"","tlshash":"c531ddfa0330e598654d2f6bdfba88ce291233f636d1448c967de980ee63dc0e6056c5","first_seen":"2025-08-13T17:39:41.407776Z","last_seen":"2025-08-13T17:39:41.407776Z","times_seen":1,"resource_available":false,"data":null}},"time_used":131,"timings":{"blocked":0,"dns":0,"connect":0,"send":0,"wait":131,"receive":0,"ssl":0},"alerts":{"ids":null,"analyzer":null,"urlquery":null}},{"url":{"schema":"https","addr":"ir.serestherapeutics.com/sites/g/files/knoqqb52941/themes/site/nir_pid2065/dist/img/chevron-down.svg","fqdn":"ir.serestherapeutics.com","domain":"serestherapeutics.com","tld":"com"},"ip":{"addr":"23.36.77.170","port":443,"asn":20940,"as":"Akamai International B.V.","country":"Norway","country_code":"NO"},"is_navigation_request":false,"resource_type":"img","requested_by":"https://ir.serestherapeutics.com/news-releases/news-release-details/seres-therapeutics-reports-ser-155-phase-1b-placebo-controlled","date":"2025-08-13T17:39:13.066Z","timestamp":0,"http_version":"","security_state":"secure","security_info":{"cipher_suite":"TLS_AES_256_GCM_SHA384","key_group_name":"x25519","signature_name":"RSA-PSS-SHA256","protocol":"TLSv1.3","cert":{"subject":{"commonName":"leapfrog-ssl-30.gcs-web.com","organization":""},"issuer":{"commonName":"R10","organization":"Let's Encrypt"},"validity":{"start":"Fri, 13 Jun 2025 04:44:47 GMT","end":"Thu, 11 Sep 2025 04:44:46 GMT"},"fingerprint":{"sha1":"76:56:CB:1C:2A:EB:BC:6C:AD:AC:F9:46:52:00:98:68:6F:36:7E:4D","sha256":"2E:92:CD:78:D5:3F:E1:8C:2B:75:38:93:FD:B6:D7:66:20:2F:C1:D0:0B:A0:AE:7D:AE:10:26:7A:9B:48:60:40"}}},"request":{"raw":"GET /sites/g/files/knoqqb52941/themes/site/nir_pid2065/dist/img/chevron-down.svg HTTP/1.1\r\nHost: ir.serestherapeutics.com\r\nUser-Agent: Mozilla/5.0 (Windows NT 10.0; Win64; x64; rv:134.0) Gecko/20100101 Firefox/134.0\r\nAccept: image/avif,image/webp,*/*\r\nAccept-Language: en-US,en;q=0.5\r\nAccept-Encoding: gzip, deflate, br\r\nDNT: 1\r\nConnection: keep-alive\r\nReferer: https://ir.serestherapeutics.com/sites/g/files/knoqqb52941/files/css/css_kzaM5d7Hf_D4urQRrPnMNG7ZSmDxlul3AoaRuCcLFBg.css?delta=1\u0026language=en\u0026theme=nir_pid2065\u0026include=eJyNj9EKwjAMRX9orCLo74TbNsxim4w0Cvt7O_eiD4Jvl8NNcpLUOGR7rKhzLqi6TFKMIjqHPZSk0r-Rq9YIe8MGu7NThoNi1XQPENStOxm8yDKmjNIN5n_VOzli5R_dxhAyTtoay-BF5WP3iuXw28M8tJ3FqW-ShoQIH8JryefT9RL0yWYl89THdW5h_-4Fhv1pRA\r\nCookie: bm_ss=ab8e18ef4e; ak_bmsc=4E19C384354D9168EC037A0AE57F6E73~000000000000000000000000000000~YAAQ9U0kF3FfO52YAQAAoLiDpBzRDcrnH6JVmuZe+X7eJCmtLVP5oR5k3kXGARYJJVBAsw+q81DIcLQmOV8N1ujMBrXUamJHnJS7hNYlYdEDIAeNK/IANgppOIGPWSD30vdHue4X8W3dI7qdSkeDiXL8vWDfixSOhBbxDuqdFA/9Cv2o/FiNUUfmV6SuQVibYQXOJ+wagXSrei1Zkl9X2gVN/Gwom++A8v7BTG4rDWjjmLmzRJy6d4g31vDW+5uTeETmQZZUc4HHnbyxlOBP+//XhF7R8CFq5vH1FQ8GKtDX34wS1DW4XlTLGeAmusrcuOEBmNIflJmGwJOrY5EqLZDfcLRBdsHSY8BlxpWAWSyb+95E1IMm49gqrCGvKrPaRuI94Gf0m5uZE3N19M9ZYvwmQHv+8eP0+Cgn1KAO8sB4ofSwMJovneYg1yUOVzgENB4=; bm_s=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; bm_so=076452BA7F785C26C0D039192D414EE322EFEBEE47C9D32A826B033A65229333~YAAQ9U0kF2RfO52YAQAAsLaDpARpo2xHJdjU4Jxa73zUq51KuxsW+QSmb5iP/ENmk7iqOGRhZyjdzqR50bYOPoK0krDYMKoypGPYm3hLRIvJAjzEPSWU9v0AmtzNP00zTXG2hPxPx54udTSSuGTM2KzBDJRiwCiOkJhUWlTdDefECbi1wnKokP5hnBjxGDCQMAE2aCXe4HqNbDgvHE7G5jmtqONfD1YgD6Cw25QL5pfAPYy0BKE94QkgYz+X0zy3rLB0HCSNr0ZOGQwVNzi2iZcJKo5SMvwmYjG5K9U0kZTVIUSy4tJGLP5ot1++FSPm+vy3pNdvnFN2MubC56GIGbx4fuz6N7DiabN7PeQYi+r8MvS04Dnfb7d5OjiIIOID16B38U5M8NVX3SXmdkNgusrIqEHOgLTigWBDKbEIIu1+fexPgsghoQRNJTdw9HEjOj0FOJyf/HSuHOBqCbNWdmrBXQvBXBkw\r\nSec-Fetch-Dest: image\r\nSec-Fetch-Mode: no-cors\r\nSec-Fetch-Site: same-origin\r\nPragma: no-cache\r\nCache-Control: no-cache\r\n\r\n","headers":null,"cookies":null,"method":"GET"},"response":{"raw":"HTTP/2 200 OK\r\naccept-ranges: bytes\r\ncontent-type: image/svg+xml\r\nlast-modified: Mon, 14 Jul 2025 09:43:39 GMT\r\nx-age: 1138347\r\nx-cache-hits: 413\r\nx-content-type-options: nosniff\r\nx-request-id: v-17aa2762-6c42-11f0-977d-27eeb0610604\r\ncontent-encoding: gzip\r\ncontent-length: 259\r\nx-edgeconnect-midmile-rtt: 17, 21\r\nx-edgeconnect-origin-mex-latency: 89, 84\r\ncache-control: max-age=600\r\nexpires: Wed, 13 Aug 2025 17:49:13 GMT\r\ndate: Wed, 13 Aug 2025 17:39:13 GMT\r\nvary: Accept-Encoding\r\nset-cookie: ak_bmsc=4E19C384354D9168EC037A0AE57F6E73~000000000000000000000000000000~YAAQ9U0kF3dfO52YAQAAqrqDpBxysQHwPFhFlEyYo5edAoL8pPvgEBtLRd7hzr+rot1Q9Wj1Ro+fEuMygI2lV1xWy3OP2YBTX4WzBnw4NmuP8iI4/auIS1FKHCv0I1Ka8uZQFtGEmlTHJV9GizVJmAKPdg44flkMNomVy5Q8ON2110zRA89dfAGFBbtS7AFku3/i6kLiqcBBIDHcd7hiqjWOUp0j68c6oC5EWpKu3AiHYoI2zkI20j2B8+bUXmsA0ZtMbnHFYa1hy+SAGddBMaXCRB27q3u6Fx1eSW1AQbRBcjnlDCkstQ8sd3SCIC50wxwLnOvzxJHi88xIzM3TrE31mSyrHGAQiZ7ggcRzpbDdn+DCBfXh7dW8HK+fc5P34SGeKFJbBicw4C30b3YUG+HIO59wpBqUU8EH+dnITPp+MQfooOC6T0bboUWImzqWF3arJIm8sgweoO0q; Domain=.serestherapeutics.com; Path=/; Expires=Wed, 13 Aug 2025 19:39:11 GMT; Max-Age=7198\r\nX-Firefox-Spdy: h2\r\n\r\n","headers":null,"cookies":null,"status_code":"200","status_text":"OK","fingerprints":[{"name":"Akamai","description":"Akamai is global content delivery network (CDN) services provider for media and software delivery, and cloud security solutions.","website":"https://akamai.com","common_platform_enumeration":"","icon":"Akamai.svg","categories":["CDN"]},{"name":"Akamai Bot Manager","description":"Akamai Bot Manager detect bots using device fingerprinting bot signatures.","website":"https://www.akamai.com/us/en/products/security/bot-manager.jsp","common_platform_enumeration":"","icon":"Akamai.svg","categories":["Security"]}],"data":{"size":410,"size_decoded":0,"mime_type":"image/svg+xml","magic":"HTML document, ASCII text","md5":"a65242c90172c78bee452125dde9d830","sha1":"80b069785af7c1449c056954780177a3ff15994a","sha256":"e0f0cb5400838107a3b5d880657830e0e0f758bc378d573d4da50467443f2310","sha512":"edc3c70d88e7e84c373c3171decafefac83f5b9844d5c5241c6054e658b6d55c27030e21fe74792afc7d769c4f8799d04246a0e36ef7bfdeb910747cee0c91d1","ssdeep":"","tlshash":"9de0edfe03b480e87a4f0ef08662d240287320ac8bd0009c4118bb0ae081ea2593eaed","first_seen":"2025-08-13T17:39:41.409576Z","last_seen":"2025-08-13T17:39:41.409576Z","times_seen":1,"resource_available":false,"data":null}},"time_used":130,"timings":{"blocked":-1,"dns":0,"connect":0,"send":0,"wait":130,"receive":0,"ssl":0},"alerts":{"ids":null,"analyzer":null,"urlquery":null}},{"url":{"schema":"https","addr":"use.typekit.net/af/69b3c5/00000000000000003b9acb0e/27/l?primer=7cdcb44be4a7db8877ffa5c0007b8dd865b3bbc383831fe2ea177f62257a9191\u0026fvd=n7\u0026v=3","fqdn":"use.typekit.net","domain":"typekit.net","tld":"net"},"ip":{"addr":"23.36.77.81","port":443,"asn":20940,"as":"Akamai International B.V.","country":"Norway","country_code":"NO"},"is_navigation_request":false,"resource_type":"font","requested_by":"https://ir.serestherapeutics.com/news-releases/news-release-details/seres-therapeutics-reports-ser-155-phase-1b-placebo-controlled","date":"2025-08-13T17:39:13.103Z","timestamp":0,"http_version":"","security_state":"secure","security_info":{"cipher_suite":"TLS_AES_256_GCM_SHA384","key_group_name":"x25519","signature_name":"ECDSA-P256-SHA256","protocol":"TLSv1.3","cert":{"subject":{"commonName":"use.typekit.net","organization":"Adobe Inc."},"issuer":{"commonName":"DigiCert Global G2 TLS RSA SHA256 2020 CA1","organization":"DigiCert Inc"},"validity":{"start":"Tue, 10 Dec 2024 00:00:00 GMT","end":"Sat, 10 Jan 2026 23:59:59 GMT"},"fingerprint":{"sha1":"F3:36:2A:08:11:E8:8C:54:E5:3C:6A:03:53:BF:AA:D7:7A:84:8B:89","sha256":"6A:79:75:73:C0:A8:12:54:14:ED:26:F6:54:AA:3F:01:34:4E:41:17:1C:AB:70:3C:72:0B:AF:BE:E1:75:6F:6E"}}},"request":{"raw":"GET /af/69b3c5/00000000000000003b9acb0e/27/l?primer=7cdcb44be4a7db8877ffa5c0007b8dd865b3bbc383831fe2ea177f62257a9191\u0026fvd=n7\u0026v=3 HTTP/1.1\r\nHost: use.typekit.net\r\nUser-Agent: Mozilla/5.0 (Windows NT 10.0; Win64; x64; rv:134.0) Gecko/20100101 Firefox/134.0\r\nAccept: application/font-woff2;q=1.0,application/font-woff;q=0.9,*/*;q=0.8\r\nAccept-Language: en-US,en;q=0.5\r\nAccept-Encoding: identity\r\nOrigin: https://ir.serestherapeutics.com\r\nDNT: 1\r\nConnection: keep-alive\r\nReferer: https://use.typekit.net/\r\nSec-Fetch-Dest: font\r\nSec-Fetch-Mode: cors\r\nSec-Fetch-Site: cross-site\r\nPragma: no-cache\r\nCache-Control: no-cache\r\n\r\n","headers":null,"cookies":null,"method":"GET"},"response":{"raw":"HTTP/2 200 OK\r\nserver: nginx\r\ncontent-type: application/font-woff2\r\ncontent-length: 25632\r\netag: \"dcd1ab979ab586a950ef155f1a511b1ec739aeed\"\r\ntiming-allow-origin: *\r\naccess-control-allow-origin: *\r\ncross-origin-resource-policy: cross-origin\r\ncache-control: public, max-age=31536000\r\ndate: Wed, 13 Aug 2025 17:39:13 GMT\r\nakamai-grn: 0.474d2417.1755106753.608252d\r\nX-Firefox-Spdy: h2\r\n\r\n","headers":null,"cookies":null,"status_code":"200","status_text":"OK","fingerprints":[{"name":"Nginx","description":"Nginx is a web server that can also be used as a reverse proxy, load balancer, mail proxy and HTTP cache.","website":"https://nginx.org/en","common_platform_enumeration":"cpe:2.3:a:f5:nginx:*:*:*:*:*:*:*:*","icon":"Nginx.svg","categories":["Web servers","Reverse proxies"]}],"data":{"size":25632,"size_decoded":0,"mime_type":"application/font-woff2","magic":"Web Open Font Format (Version 2), TrueType, length 25632, version 1.0","md5":"932d075a4fd364422e7307f0f20c7cec","sha1":"999db76670dcba146d803a3fae281a351b07a269","sha256":"36b1e1e2216f868764bddd51fd6b566062777491dfefc1027f0b4540b95038ce","sha512":"d1f66695c2be1bff5935bd24f11e6351d5226507f331de9502dda8e8002c68d768916ccbfa52b8bb73c53d4dda1184b81cf0fd061d0a773c43de4e8261252634","ssdeep":"384:9Nmq7IUgWU5eDC1GjIIFb/TvvNdpog3d969eMZPnE8StJxEZxomwC:PF77FU0FjRFb/LlY/ZPnEHJxw","tlshash":"36b2d0935b479215fc5c20f4762e0224ce441036ba6b26fb0fe5c862da462d99d67d8b","first_seen":"2023-04-09T12:31:25Z","last_seen":"2026-04-02T16:50:59.727124Z","times_seen":228,"resource_available":false,"data":null}},"time_used":13,"timings":{"blocked":5,"dns":0,"connect":0,"send":0,"wait":7,"receive":1,"ssl":0},"alerts":{"ids":null,"analyzer":null,"urlquery":null}},{"url":{"schema":"https","addr":"ir.serestherapeutics.com/akam/13/6167875b","fqdn":"ir.serestherapeutics.com","domain":"serestherapeutics.com","tld":"com"},"ip":{"addr":"23.36.77.170","port":443,"asn":20940,"as":"Akamai International B.V.","country":"Norway","country_code":"NO"},"is_navigation_request":false,"resource_type":"script","requested_by":"https://ir.serestherapeutics.com/news-releases/news-release-details/seres-therapeutics-reports-ser-155-phase-1b-placebo-controlled","date":"2025-08-13T17:39:12.423Z","timestamp":0,"http_version":"","security_state":"secure","security_info":{"cipher_suite":"TLS_AES_256_GCM_SHA384","key_group_name":"x25519","signature_name":"RSA-PSS-SHA256","protocol":"TLSv1.3","cert":{"subject":{"commonName":"leapfrog-ssl-30.gcs-web.com","organization":""},"issuer":{"commonName":"R10","organization":"Let's Encrypt"},"validity":{"start":"Fri, 13 Jun 2025 04:44:47 GMT","end":"Thu, 11 Sep 2025 04:44:46 GMT"},"fingerprint":{"sha1":"76:56:CB:1C:2A:EB:BC:6C:AD:AC:F9:46:52:00:98:68:6F:36:7E:4D","sha256":"2E:92:CD:78:D5:3F:E1:8C:2B:75:38:93:FD:B6:D7:66:20:2F:C1:D0:0B:A0:AE:7D:AE:10:26:7A:9B:48:60:40"}}},"request":{"raw":"GET /akam/13/6167875b HTTP/1.1\r\nHost: ir.serestherapeutics.com\r\nUser-Agent: Mozilla/5.0 (Windows NT 10.0; Win64; x64; rv:134.0) Gecko/20100101 Firefox/134.0\r\nAccept: */*\r\nAccept-Language: en-US,en;q=0.5\r\nAccept-Encoding: gzip, deflate, br\r\nReferer: https://ir.serestherapeutics.com/news-releases/news-release-details/seres-therapeutics-reports-ser-155-phase-1b-placebo-controlled\r\nDNT: 1\r\nConnection: keep-alive\r\nCookie: bm_ss=ab8e18ef4e; ak_bmsc=8B3E3F53D6F1D551950B130550D015A2~000000000000000000000000000000~YAAQ9U0kF2FfO52YAQAAsLaDpBzYHEeJiZORhrKmMvVJl6htT4U5E/6alOnsN1WLbK0JNN0FxV6QIk3CXK6SZzJXWuElqmWB1WWYdY8quqhpWza5ivcl5im9nJoX7vrrq3G0vDVDRbOFK+CpHpJKlNA7AFE8qUMYv2oy8l08ONFK9GC3Aonufb2qXf/9ZjIkKIaaJrJwo1KUNgFeJmFTmRFsbb4oS3Jv2xmpV6uIXbaBeN9UhBTyS0HA2CF3KtgNehkaNLOEZnMBc1mLg/Q+bEEutjMUDLWyhdWbq0cnrrkhtimNWHnJcupfFzlIfpxdU3sj4xzZZ/Md5pzLYIOYZrVV2/12xnbT2CkSBSpx2FJsR/0yDsO84EToiNJUl0y3pFgjA1wezQP5EqYWYF8qXo/BI+qA; bm_s=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; bm_so=076452BA7F785C26C0D039192D414EE322EFEBEE47C9D32A826B033A65229333~YAAQ9U0kF2RfO52YAQAAsLaDpARpo2xHJdjU4Jxa73zUq51KuxsW+QSmb5iP/ENmk7iqOGRhZyjdzqR50bYOPoK0krDYMKoypGPYm3hLRIvJAjzEPSWU9v0AmtzNP00zTXG2hPxPx54udTSSuGTM2KzBDJRiwCiOkJhUWlTdDefECbi1wnKokP5hnBjxGDCQMAE2aCXe4HqNbDgvHE7G5jmtqONfD1YgD6Cw25QL5pfAPYy0BKE94QkgYz+X0zy3rLB0HCSNr0ZOGQwVNzi2iZcJKo5SMvwmYjG5K9U0kZTVIUSy4tJGLP5ot1++FSPm+vy3pNdvnFN2MubC56GIGbx4fuz6N7DiabN7PeQYi+r8MvS04Dnfb7d5OjiIIOID16B38U5M8NVX3SXmdkNgusrIqEHOgLTigWBDKbEIIu1+fexPgsghoQRNJTdw9HEjOj0FOJyf/HSuHOBqCbNWdmrBXQvBXBkw\r\nSec-Fetch-Dest: script\r\nSec-Fetch-Mode: no-cors\r\nSec-Fetch-Site: same-origin\r\nPragma: no-cache\r\nCache-Control: no-cache\r\n\r\n","headers":null,"cookies":null,"method":"GET"},"response":{"raw":"HTTP/2 200 OK\r\nstored-attribute-sha-checksum: 676296369c77b3a4ec69d376e1b8bc4f0a515b24cd9e634835a6dd715666110b\r\nlast-modified: Thu, 22 Feb 2024 19:47:50 GMT\r\netag: \"709ab6391eca09c8aec63451c0bd7f7f2d02935da3d2d9ef683a3f0c0c6704b0\"\r\ncontent-type: application/javascript\r\ncontent-encoding: gzip\r\ncontent-length: 8820\r\nexpires: Wed, 13 Aug 2025 17:39:12 GMT\r\npragma: no-cache\r\ndate: Wed, 13 Aug 2025 17:39:12 GMT\r\nvary: Accept-Encoding\r\ncache-control: max-age=21600\r\nset-cookie: ak_bmsc=4E19C384354D9168EC037A0AE57F6E73~000000000000000000000000000000~YAAQ9U0kF3FfO52YAQAAoLiDpBzRDcrnH6JVmuZe+X7eJCmtLVP5oR5k3kXGARYJJVBAsw+q81DIcLQmOV8N1ujMBrXUamJHnJS7hNYlYdEDIAeNK/IANgppOIGPWSD30vdHue4X8W3dI7qdSkeDiXL8vWDfixSOhBbxDuqdFA/9Cv2o/FiNUUfmV6SuQVibYQXOJ+wagXSrei1Zkl9X2gVN/Gwom++A8v7BTG4rDWjjmLmzRJy6d4g31vDW+5uTeETmQZZUc4HHnbyxlOBP+//XhF7R8CFq5vH1FQ8GKtDX34wS1DW4XlTLGeAmusrcuOEBmNIflJmGwJOrY5EqLZDfcLRBdsHSY8BlxpWAWSyb+95E1IMm49gqrCGvKrPaRuI94Gf0m5uZE3N19M9ZYvwmQHv+8eP0+Cgn1KAO8sB4ofSwMJovneYg1yUOVzgENB4=; Domain=.serestherapeutics.com; Path=/; Expires=Wed, 13 Aug 2025 19:39:11 GMT; Max-Age=7199\r\nX-Firefox-Spdy: h2\r\n\r\n","headers":null,"cookies":null,"status_code":"200","status_text":"OK","fingerprints":[{"name":"Akamai Bot Manager","description":"Akamai Bot Manager detect bots using device fingerprinting bot signatures.","website":"https://www.akamai.com/us/en/products/security/bot-manager.jsp","common_platform_enumeration":"","icon":"Akamai.svg","categories":["Security"]},{"name":"Akamai","description":"Akamai is global content delivery network (CDN) services provider for media and software delivery, and cloud security solutions.","website":"https://akamai.com","common_platform_enumeration":"","icon":"Akamai.svg","categories":["CDN"]}],"data":{"size":26708,"size_decoded":0,"mime_type":"application/javascript","magic":"JavaScript source, ASCII text, with very long lines (14360)","md5":"f31d2ec966807d3b27af05b9a2abdf7d","sha1":"70f73b2b646a38fbfd3e95e9c8df92c65495965f","sha256":"676296369c77b3a4ec69d376e1b8bc4f0a515b24cd9e634835a6dd715666110b","sha512":"77f96a89520a79d08d889c5ce112375fdf2168dbc83ef833264909cd5a10ab52e4afaa5c22a5ff4e578ecbb021261095101e629f922081a34640fce54957bb7d","ssdeep":"768:7m+7iP/4DUfVutdN0of4fDnbwkVq4SoNfLqlsO:7NiP/WUfVlof4bbwKPO","tlshash":"bdc297d872d7ed0b678f4a83fd945efe2172857790c53247c3aeb98d16e828bd208944","first_seen":"2024-10-29T08:43:30.204658Z","last_seen":"2026-04-02T09:24:50.916416Z","times_seen":58,"resource_available":true,"data":null}},"time_used":266,"timings":{"blocked":-1,"dns":0,"connect":0,"send":0,"wait":265,"receive":1,"ssl":0},"alerts":{"ids":null,"analyzer":null,"urlquery":null}},{"url":{"schema":"https","addr":"www.globenewswire.com/newsroom/ti?nf=OTIyOTY2MiM2NDc1NTQ4IzIwMTczNjE=","fqdn":"www.globenewswire.com","domain":"globenewswire.com","tld":"com"},"ip":{"addr":"23.36.77.218","port":443,"asn":20940,"as":"Akamai International B.V.","country":"Norway","country_code":"NO"},"is_navigation_request":false,"resource_type":"img","requested_by":"https://ir.serestherapeutics.com/news-releases/news-release-details/seres-therapeutics-reports-ser-155-phase-1b-placebo-controlled","date":"2025-08-13T17:39:12.426Z","timestamp":0,"http_version":"","security_state":"secure","security_info":{"cipher_suite":"TLS_AES_256_GCM_SHA384","key_group_name":"x25519","signature_name":"ECDSA-P256-SHA256","protocol":"TLSv1.3","cert":{"subject":{"commonName":"www.globenewswire.com","organization":""},"issuer":{"commonName":"E6","organization":"Let's Encrypt"},"validity":{"start":"Mon, 11 Aug 2025 11:09:30 GMT","end":"Sun, 09 Nov 2025 11:09:29 GMT"},"fingerprint":{"sha1":"DD:81:42:72:61:3D:C7:47:FE:6D:27:29:BB:B5:5B:3C:97:33:A3:C2","sha256":"CD:54:4C:99:04:9E:4B:36:DC:9A:66:D3:F3:F6:D0:D0:83:39:97:2F:F7:2C:E8:2C:32:13:67:4D:EA:3A:25:2F"}}},"request":{"raw":"GET /newsroom/ti?nf=OTIyOTY2MiM2NDc1NTQ4IzIwMTczNjE= HTTP/1.1\r\nHost: www.globenewswire.com\r\nUser-Agent: Mozilla/5.0 (Windows NT 10.0; Win64; x64; rv:134.0) Gecko/20100101 Firefox/134.0\r\nAccept: image/avif,image/webp,*/*\r\nAccept-Language: en-US,en;q=0.5\r\nAccept-Encoding: gzip, deflate, br\r\nDNT: 1\r\nConnection: keep-alive\r\nReferer: https://ir.serestherapeutics.com/\r\nSec-Fetch-Dest: image\r\nSec-Fetch-Mode: no-cors\r\nSec-Fetch-Site: cross-site\r\nPragma: no-cache\r\nCache-Control: no-cache\r\n\r\n","headers":null,"cookies":null,"method":"GET"},"response":{"raw":"HTTP/2 200 OK\r\ncontent-type: image/gif\r\nlast-modified: Wed, 13 Aug 2025 17:39:12 GMT\r\nx-content-type-options: nosniff\r\nx-frame-options: SAMEORIGIN\r\nx-robots-tag: noindex\r\nstrict-transport-security: max-age=31536000; includeSubDomains; preload\r\ncontent-length: 43\r\ncache-control: public, max-age=600\r\ndate: Wed, 13 Aug 2025 17:39:12 GMT\r\nset-cookie: ASP.NET_SessionId=bqojqkys11t4tf0fetmgcvyp; path=/; secure; HttpOnly; SameSite=Lax\nGNWTracker=4d0b5909-3b77-4f65-908d-e12927009e24; expires=Tue, 12-Aug-2025 17:39:12 GMT; path=/; secure\r\nX-Firefox-Spdy: h2\r\n\r\n","headers":null,"cookies":null,"status_code":"200","status_text":"OK","fingerprints":[{"name":"HSTS","description":"HTTP Strict Transport Security (HSTS) informs browsers that the site should only be accessed using HTTPS.","website":"https://www.rfc-editor.org/rfc/rfc6797#section-6.1","common_platform_enumeration":"","icon":"","categories":["Security"]},{"name":"Microsoft ASP.NET","description":"ASP.NET is an open-source, server-side web-application framework designed for web development to produce dynamic web pages.","website":"https://www.asp.net","common_platform_enumeration":"cpe:2.3:a:microsoft:asp.net:*:*:*:*:*:*:*:*","icon":"Microsoft ASP.NET.svg","categories":["Web frameworks"]}],"data":{"size":43,"size_decoded":0,"mime_type":"image/gif","magic":"GIF image data, version 89a, 1 x 1","md5":"db04c7b378cb2db912c3ba8a5a774ee3","sha1":"dee34bd86c3484d31002182aa2b7caa4699126b8","sha256":"98b3d9d20e032f90aca49e9b116225d539ff6fbdb7e42c3c363f63896ac03d2a","sha512":"826225fc21717d8861a05b9d2f959539aad2d2b131b2afed75d88fbca535e1b0d5a0da8ac69713a0876a0d467848a37a0a7f926aeafad8cf28201382d16466ab","ssdeep":"","tlshash":"6490000bca888002caa2c0302b8883022b88b0320228832e80bc30a8ee3b3a20c02000","first_seen":"2023-04-05T02:54:03Z","last_seen":"2026-04-03T18:31:44.690978Z","times_seen":354925,"resource_available":true,"data":null}},"time_used":351,"timings":{"blocked":90,"dns":86,"connect":4,"send":0,"wait":151,"receive":0,"ssl":0},"alerts":{"ids":null,"analyzer":null,"urlquery":null}},{"url":{"schema":"https","addr":"ir.serestherapeutics.com/profiles/nasdaqir/modules/custom/nir_ckeditor_datatables/js/build/datatables.js?v=1.10.9","fqdn":"ir.serestherapeutics.com","domain":"serestherapeutics.com","tld":"com"},"ip":{"addr":"23.36.77.170","port":443,"asn":20940,"as":"Akamai International B.V.","country":"Norway","country_code":"NO"},"is_navigation_request":false,"resource_type":"script","requested_by":"https://ir.serestherapeutics.com/news-releases/news-release-details/seres-therapeutics-reports-ser-155-phase-1b-placebo-controlled","date":"2025-08-13T17:39:12.435Z","timestamp":0,"http_version":"","security_state":"secure","security_info":{"cipher_suite":"TLS_AES_256_GCM_SHA384","key_group_name":"x25519","signature_name":"RSA-PSS-SHA256","protocol":"TLSv1.3","cert":{"subject":{"commonName":"leapfrog-ssl-30.gcs-web.com","organization":""},"issuer":{"commonName":"R10","organization":"Let's Encrypt"},"validity":{"start":"Fri, 13 Jun 2025 04:44:47 GMT","end":"Thu, 11 Sep 2025 04:44:46 GMT"},"fingerprint":{"sha1":"76:56:CB:1C:2A:EB:BC:6C:AD:AC:F9:46:52:00:98:68:6F:36:7E:4D","sha256":"2E:92:CD:78:D5:3F:E1:8C:2B:75:38:93:FD:B6:D7:66:20:2F:C1:D0:0B:A0:AE:7D:AE:10:26:7A:9B:48:60:40"}}},"request":{"raw":"GET /profiles/nasdaqir/modules/custom/nir_ckeditor_datatables/js/build/datatables.js?v=1.10.9 HTTP/1.1\r\nHost: ir.serestherapeutics.com\r\nUser-Agent: Mozilla/5.0 (Windows NT 10.0; Win64; x64; rv:134.0) Gecko/20100101 Firefox/134.0\r\nAccept: */*\r\nAccept-Language: en-US,en;q=0.5\r\nAccept-Encoding: gzip, deflate, br\r\nReferer: https://ir.serestherapeutics.com/news-releases/news-release-details/seres-therapeutics-reports-ser-155-phase-1b-placebo-controlled\r\nDNT: 1\r\nConnection: keep-alive\r\nCookie: bm_ss=ab8e18ef4e; ak_bmsc=8B3E3F53D6F1D551950B130550D015A2~000000000000000000000000000000~YAAQ9U0kF2FfO52YAQAAsLaDpBzYHEeJiZORhrKmMvVJl6htT4U5E/6alOnsN1WLbK0JNN0FxV6QIk3CXK6SZzJXWuElqmWB1WWYdY8quqhpWza5ivcl5im9nJoX7vrrq3G0vDVDRbOFK+CpHpJKlNA7AFE8qUMYv2oy8l08ONFK9GC3Aonufb2qXf/9ZjIkKIaaJrJwo1KUNgFeJmFTmRFsbb4oS3Jv2xmpV6uIXbaBeN9UhBTyS0HA2CF3KtgNehkaNLOEZnMBc1mLg/Q+bEEutjMUDLWyhdWbq0cnrrkhtimNWHnJcupfFzlIfpxdU3sj4xzZZ/Md5pzLYIOYZrVV2/12xnbT2CkSBSpx2FJsR/0yDsO84EToiNJUl0y3pFgjA1wezQP5EqYWYF8qXo/BI+qA; bm_s=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; bm_so=076452BA7F785C26C0D039192D414EE322EFEBEE47C9D32A826B033A65229333~YAAQ9U0kF2RfO52YAQAAsLaDpARpo2xHJdjU4Jxa73zUq51KuxsW+QSmb5iP/ENmk7iqOGRhZyjdzqR50bYOPoK0krDYMKoypGPYm3hLRIvJAjzEPSWU9v0AmtzNP00zTXG2hPxPx54udTSSuGTM2KzBDJRiwCiOkJhUWlTdDefECbi1wnKokP5hnBjxGDCQMAE2aCXe4HqNbDgvHE7G5jmtqONfD1YgD6Cw25QL5pfAPYy0BKE94QkgYz+X0zy3rLB0HCSNr0ZOGQwVNzi2iZcJKo5SMvwmYjG5K9U0kZTVIUSy4tJGLP5ot1++FSPm+vy3pNdvnFN2MubC56GIGbx4fuz6N7DiabN7PeQYi+r8MvS04Dnfb7d5OjiIIOID16B38U5M8NVX3SXmdkNgusrIqEHOgLTigWBDKbEIIu1+fexPgsghoQRNJTdw9HEjOj0FOJyf/HSuHOBqCbNWdmrBXQvBXBkw\r\nSec-Fetch-Dest: script\r\nSec-Fetch-Mode: no-cors\r\nSec-Fetch-Site: same-origin\r\nPragma: no-cache\r\nCache-Control: no-cache\r\n\r\n","headers":null,"cookies":null,"method":"GET"},"response":{"raw":"HTTP/2 200 OK\r\naccept-ranges: bytes\r\ncontent-encoding: gzip\r\ncontent-type: application/javascript\r\nlast-modified: Mon, 14 Jul 2025 09:56:40 GMT\r\nx-age: 753825\r\nx-cache-hits: 491\r\nx-content-type-options: nosniff\r\nx-request-id: v-19ca723a-6c34-11f0-b2aa-e7ca56fea9b3\r\ncontent-length: 107766\r\nx-edgeconnect-midmile-rtt: 17, 16\r\nx-edgeconnect-origin-mex-latency: 87, 83\r\ncache-control: max-age=600\r\nexpires: Wed, 13 Aug 2025 17:49:12 GMT\r\ndate: Wed, 13 Aug 2025 17:39:12 GMT\r\nvary: Accept-Encoding\r\nX-Firefox-Spdy: h2\r\n\r\n","headers":null,"cookies":null,"status_code":"200","status_text":"OK","fingerprints":[{"name":"Akamai","description":"Akamai is global content delivery network (CDN) services provider for media and software delivery, and cloud security solutions.","website":"https://akamai.com","common_platform_enumeration":"","icon":"Akamai.svg","categories":["CDN"]}],"data":{"size":361843,"size_decoded":0,"mime_type":"application/javascript","magic":"JavaScript source, ASCII text, with very long lines (65536), with no line terminators","md5":"e8f5ef34f9aec47f102221346f808ea5","sha1":"076fd225f030af6b40bf0f92737691236a89bd83","sha256":"8299e462bd401d41bb12d29c3daf388e40a7681f4bf609d733a0df91f043a5d8","sha512":"5e43f1267e83380017233a4fcfc6394af2fa290e555ad88d4e52b746309e014cabcfbe19d52959d4853894cc44dbc821f7a7b6ed0d991c1fe018737040cdc5f7","ssdeep":"3072:/GoUvqY0bAS0GetPWJzBCO+IOS2pqL/+GkUcrvTO:Eqpr","tlshash":"ba74a4ac9f2456fcd98e43d08cbe586c2b1fa2fd3a078535d26c57e05d2bd0dc986a42","first_seen":"2025-02-13T16:09:49.443604Z","last_seen":"2026-04-02T06:14:20.657521Z","times_seen":70,"resource_available":true,"data":null}},"time_used":232,"timings":{"blocked":-1,"dns":0,"connect":0,"send":0,"wait":227,"receive":5,"ssl":0},"alerts":{"ids":null,"analyzer":null,"urlquery":null}},{"url":{"schema":"https","addr":"p.typekit.net/p.css?s=1\u0026k=hom2xog\u0026ht=tk\u0026f=26053.26054.26056.26062.25998.25999.26000.26001.26016.26017.26018.26019.26036.26037.26046.26047.26072.26073.26086.26087\u0026a=83870961\u0026app=typekit\u0026e=css","fqdn":"p.typekit.net","domain":"typekit.net","tld":"net"},"ip":{"addr":"23.36.77.57","port":443,"asn":20940,"as":"Akamai International B.V.","country":"Norway","country_code":"NO"},"is_navigation_request":false,"resource_type":"stylesheet","requested_by":"https://ir.serestherapeutics.com/news-releases/news-release-details/seres-therapeutics-reports-ser-155-phase-1b-placebo-controlled","date":"2025-08-13T17:39:12.633Z","timestamp":0,"http_version":"","security_state":"secure","security_info":{"cipher_suite":"TLS_AES_256_GCM_SHA384","key_group_name":"x25519","signature_name":"ECDSA-P256-SHA256","protocol":"TLSv1.3","cert":{"subject":{"commonName":"use.typekit.net","organization":"Adobe Inc."},"issuer":{"commonName":"DigiCert Global G2 TLS RSA SHA256 2020 CA1","organization":"DigiCert Inc"},"validity":{"start":"Tue, 10 Dec 2024 00:00:00 GMT","end":"Sat, 10 Jan 2026 23:59:59 GMT"},"fingerprint":{"sha1":"F3:36:2A:08:11:E8:8C:54:E5:3C:6A:03:53:BF:AA:D7:7A:84:8B:89","sha256":"6A:79:75:73:C0:A8:12:54:14:ED:26:F6:54:AA:3F:01:34:4E:41:17:1C:AB:70:3C:72:0B:AF:BE:E1:75:6F:6E"}}},"request":{"raw":"GET /p.css?s=1\u0026k=hom2xog\u0026ht=tk\u0026f=26053.26054.26056.26062.25998.25999.26000.26001.26016.26017.26018.26019.26036.26037.26046.26047.26072.26073.26086.26087\u0026a=83870961\u0026app=typekit\u0026e=css HTTP/1.1\r\nHost: p.typekit.net\r\nUser-Agent: Mozilla/5.0 (Windows NT 10.0; Win64; x64; rv:134.0) Gecko/20100101 Firefox/134.0\r\nAccept: text/css,*/*;q=0.1\r\nAccept-Language: en-US,en;q=0.5\r\nAccept-Encoding: gzip, deflate, br\r\nDNT: 1\r\nConnection: keep-alive\r\nReferer: https://use.typekit.net/\r\nSec-Fetch-Dest: style\r\nSec-Fetch-Mode: no-cors\r\nSec-Fetch-Site: same-site\r\nPragma: no-cache\r\nCache-Control: no-cache\r\n\r\n","headers":null,"cookies":null,"method":"GET"},"response":{"raw":"HTTP/2 200 OK\r\nserver: nginx\r\ncontent-type: text/css\r\ncontent-length: 5\r\nlast-modified: Sun, 01 Dec 2024 12:58:09 GMT\r\netag: \"674c5d61-5\"\r\ncache-control: public, max-age=604800\r\naccess-control-allow-origin: *\r\ncross-origin-resource-policy: cross-origin\r\naccept-ranges: bytes\r\ndate: Wed, 13 Aug 2025 17:39:12 GMT\r\nX-Firefox-Spdy: h2\r\n\r\n","headers":null,"cookies":null,"status_code":"200","status_text":"OK","fingerprints":[{"name":"Nginx","description":"Nginx is a web server that can also be used as a reverse proxy, load balancer, mail proxy and HTTP cache.","website":"https://nginx.org/en","common_platform_enumeration":"cpe:2.3:a:f5:nginx:*:*:*:*:*:*:*:*","icon":"Nginx.svg","categories":["Web servers","Reverse proxies"]}],"data":{"size":5,"size_decoded":0,"mime_type":"text/css","magic":"ASCII text","md5":"83d24d4b43cc7eef2b61e66c95f3d158","sha1":"f0cafc285ee23bb6c28c5166f305493c4331c84d","sha256":"1c0ff118a4290c99f39c90abb38703a866e47251b23cca20266c69c812ccafeb","sha512":"e6e84563d3a55767f8e5f36c4e217a0768120d6e15ce4d01aa63d36af7ec8d20b600ce96dcc56de91ec7e55e83a8267baddd68b61447069b82abdb2e92c6acb6","ssdeep":"","tlshash":"e630000000000000000000000000000000000c00000000000000000000000000000000","first_seen":"2023-03-12T07:28:04Z","last_seen":"2026-04-03T18:32:07.892124Z","times_seen":119502,"resource_available":true,"data":null}},"time_used":95,"timings":{"blocked":38,"dns":1,"connect":1,"send":0,"wait":19,"receive":0,"ssl":34},"alerts":{"ids":null,"analyzer":null,"urlquery":null}},{"url":{"schema":"https","addr":"ir.serestherapeutics.com/sites/g/files/knoqqb52941/themes/site/nir_pid2065/dist/fonts/lato-v16-latin-300.woff2","fqdn":"ir.serestherapeutics.com","domain":"serestherapeutics.com","tld":"com"},"ip":{"addr":"23.36.77.170","port":443,"asn":20940,"as":"Akamai International B.V.","country":"Norway","country_code":"NO"},"is_navigation_request":false,"resource_type":"font","requested_by":"https://ir.serestherapeutics.com/news-releases/news-release-details/seres-therapeutics-reports-ser-155-phase-1b-placebo-controlled","date":"2025-08-13T17:39:13.607Z","timestamp":0,"http_version":"","security_state":"secure","security_info":{"cipher_suite":"TLS_AES_256_GCM_SHA384","key_group_name":"x25519","signature_name":"RSA-PSS-SHA256","protocol":"TLSv1.3","cert":{"subject":{"commonName":"leapfrog-ssl-30.gcs-web.com","organization":""},"issuer":{"commonName":"R10","organization":"Let's Encrypt"},"validity":{"start":"Fri, 13 Jun 2025 04:44:47 GMT","end":"Thu, 11 Sep 2025 04:44:46 GMT"},"fingerprint":{"sha1":"76:56:CB:1C:2A:EB:BC:6C:AD:AC:F9:46:52:00:98:68:6F:36:7E:4D","sha256":"2E:92:CD:78:D5:3F:E1:8C:2B:75:38:93:FD:B6:D7:66:20:2F:C1:D0:0B:A0:AE:7D:AE:10:26:7A:9B:48:60:40"}}},"request":{"raw":"GET /sites/g/files/knoqqb52941/themes/site/nir_pid2065/dist/fonts/lato-v16-latin-300.woff2 HTTP/1.1\r\nHost: ir.serestherapeutics.com\r\nUser-Agent: Mozilla/5.0 (Windows NT 10.0; Win64; x64; rv:134.0) Gecko/20100101 Firefox/134.0\r\nAccept: application/font-woff2;q=1.0,application/font-woff;q=0.9,*/*;q=0.8\r\nAccept-Language: en-US,en;q=0.5\r\nAccept-Encoding: identity\r\nDNT: 1\r\nConnection: keep-alive\r\nReferer: https://ir.serestherapeutics.com/sites/g/files/knoqqb52941/files/css/css_kzaM5d7Hf_D4urQRrPnMNG7ZSmDxlul3AoaRuCcLFBg.css?delta=1\u0026language=en\u0026theme=nir_pid2065\u0026include=eJyNj9EKwjAMRX9orCLo74TbNsxim4w0Cvt7O_eiD4Jvl8NNcpLUOGR7rKhzLqi6TFKMIjqHPZSk0r-Rq9YIe8MGu7NThoNi1XQPENStOxm8yDKmjNIN5n_VOzli5R_dxhAyTtoay-BF5WP3iuXw28M8tJ3FqW-ShoQIH8JryefT9RL0yWYl89THdW5h_-4Fhv1pRA\r\nCookie: bm_ss=ab8e18ef4e; ak_bmsc=4E19C384354D9168EC037A0AE57F6E73~000000000000000000000000000000~YAAQ9U0kF3pfO52YAQAAyrqDpBxZNiQhgQ/mLbHzuEyKUI1B5Q02Uo0y/Q8t/RN651uf3zXQrlH74xzEGFZJh8Z3EipvPaPk8w7Is198IT9ERHRfRPKa2M7lbnLucg3cEIMP0T5Us1UtqKrkD4IyfMWS5Il+7GYb/LonOBcDcZfDHDidfuuSIQ6TrFLomDSIbFN39zhVmt4CPEAYeJCFpnrqAGm+u+JZOxVfbd6hq2X8CRbwAnpU/qIeEkfJZTcbdrKuCAfQd9nnNvAIY60IM359bhv/qJQdbTtF9ptE/8TrJUyq6y1eZieW7441XaaLDTJjdbbmD+kIh76nTK2tFfqRYBRM+LJxo4h7ROy+Jg0nL8xfVSOAHRJQZeKb/jZ7i3pBOoDbq2YYcEhFDfwAdJJtM3L3MIx/VHn8srwrv/OxDJmiCmO13LX5jQfOZxx+mwR2mwpsu1ypGLyV; bm_s=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; bm_so=076452BA7F785C26C0D039192D414EE322EFEBEE47C9D32A826B033A65229333~YAAQ9U0kF2RfO52YAQAAsLaDpARpo2xHJdjU4Jxa73zUq51KuxsW+QSmb5iP/ENmk7iqOGRhZyjdzqR50bYOPoK0krDYMKoypGPYm3hLRIvJAjzEPSWU9v0AmtzNP00zTXG2hPxPx54udTSSuGTM2KzBDJRiwCiOkJhUWlTdDefECbi1wnKokP5hnBjxGDCQMAE2aCXe4HqNbDgvHE7G5jmtqONfD1YgD6Cw25QL5pfAPYy0BKE94QkgYz+X0zy3rLB0HCSNr0ZOGQwVNzi2iZcJKo5SMvwmYjG5K9U0kZTVIUSy4tJGLP5ot1++FSPm+vy3pNdvnFN2MubC56GIGbx4fuz6N7DiabN7PeQYi+r8MvS04Dnfb7d5OjiIIOID16B38U5M8NVX3SXmdkNgusrIqEHOgLTigWBDKbEIIu1+fexPgsghoQRNJTdw9HEjOj0FOJyf/HSuHOBqCbNWdmrBXQvBXBkw\r\nSec-Fetch-Dest: font\r\nSec-Fetch-Mode: cors\r\nSec-Fetch-Site: same-origin\r\nPragma: no-cache\r\nCache-Control: no-cache\r\n\r\n","headers":null,"cookies":null,"method":"GET"},"response":{"raw":"HTTP/2 200 OK\r\naccept-ranges: bytes\r\nlast-modified: Mon, 14 Jul 2025 09:43:39 GMT\r\nx-age: 865651\r\nx-cache-hits: 379\r\nx-content-type-options: nosniff\r\nx-request-id: v-4548b57a-6c3e-11f0-8661-cf8d713a140f\r\ncontent-length: 23248\r\nx-edgeconnect-midmile-rtt: 18, 22\r\nx-edgeconnect-origin-mex-latency: 81, 90\r\ncache-control: max-age=600\r\nexpires: Wed, 13 Aug 2025 17:49:13 GMT\r\ndate: Wed, 13 Aug 2025 17:39:13 GMT\r\nX-Firefox-Spdy: h2\r\n\r\n","headers":null,"cookies":null,"status_code":"200","status_text":"OK","fingerprints":[{"name":"Akamai","description":"Akamai is global content delivery network (CDN) services provider for media and software delivery, and cloud security solutions.","website":"https://akamai.com","common_platform_enumeration":"","icon":"Akamai.svg","categories":["CDN"]}],"data":{"size":23248,"size_decoded":0,"mime_type":"font/woff2","magic":"Web Open Font Format (Version 2), TrueType, length 23248, version 1.0","md5":"98d8cf792834c0bef59c2be99dc3533d","sha1":"f48e6d698147781b82f573a71f904355274015cd","sha256":"9194059997d722ec01e41980dffbff03ebe00808b1cdd164a7fd18a561bc312a","sha512":"d6877b880861a94a9c5798c764d14f2762fa4e1e4c61e24000c0fe74052e519d8efa9b4a12ee6f438d6acd814efb03714568c405ac37000983dcbab978db1570","ssdeep":"384:/lH2SiZYjzY0O/TlG0biKGhvw5XMOvgHpTR8VNUNj0kjorfTDQ0pFRVOjxrqbDq0:/lHjjCGUiKGCupN87U9jorfT80XRVOj8","tlshash":"3aa2d08038dbd09be0bd52756e3bd80fcb625f6892607c905b371c6e2c58254424defb","first_seen":"2023-04-10T09:56:19Z","last_seen":"2026-04-02T04:41:21.335741Z","times_seen":383,"resource_available":false,"data":null}},"time_used":28,"timings":{"blocked":-1,"dns":0,"connect":0,"send":0,"wait":27,"receive":1,"ssl":0},"alerts":{"ids":null,"analyzer":null,"urlquery":null}},{"url":{"schema":"https","addr":"ir.serestherapeutics.com/sites/g/files/knoqqb52941/files/css/css_zv9vDmDcIvrHl__ber4i2QUMwi4S6HDYNAI1_X6j6yo.css?delta=0\u0026language=en\u0026theme=nir_pid2065\u0026include=eJyNj9EKwjAMRX9orCLo74TbNsxim4w0Cvt7O_eiD4Jvl8NNcpLUOGR7rKhzLqi6TFKMIjqHPZSk0r-Rq9YIe8MGu7NThoNi1XQPENStOxm8yDKmjNIN5n_VOzli5R_dxhAyTtoay-BF5WP3iuXw28M8tJ3FqW-ShoQIH8JryefT9RL0yWYl89THdW5h_-4Fhv1pRA","fqdn":"ir.serestherapeutics.com","domain":"serestherapeutics.com","tld":"com"},"ip":{"addr":"23.36.77.170","port":443,"asn":20940,"as":"Akamai International B.V.","country":"Norway","country_code":"NO"},"is_navigation_request":false,"resource_type":"stylesheet","requested_by":"https://ir.serestherapeutics.com/news-releases/news-release-details/seres-therapeutics-reports-ser-155-phase-1b-placebo-controlled","date":"2025-08-13T17:39:12.413Z","timestamp":0,"http_version":"","security_state":"secure","security_info":{"cipher_suite":"TLS_AES_256_GCM_SHA384","key_group_name":"x25519","signature_name":"RSA-PSS-SHA256","protocol":"TLSv1.3","cert":{"subject":{"commonName":"leapfrog-ssl-30.gcs-web.com","organization":""},"issuer":{"commonName":"R10","organization":"Let's Encrypt"},"validity":{"start":"Fri, 13 Jun 2025 04:44:47 GMT","end":"Thu, 11 Sep 2025 04:44:46 GMT"},"fingerprint":{"sha1":"76:56:CB:1C:2A:EB:BC:6C:AD:AC:F9:46:52:00:98:68:6F:36:7E:4D","sha256":"2E:92:CD:78:D5:3F:E1:8C:2B:75:38:93:FD:B6:D7:66:20:2F:C1:D0:0B:A0:AE:7D:AE:10:26:7A:9B:48:60:40"}}},"request":{"raw":"GET /sites/g/files/knoqqb52941/files/css/css_zv9vDmDcIvrHl__ber4i2QUMwi4S6HDYNAI1_X6j6yo.css?delta=0\u0026language=en\u0026theme=nir_pid2065\u0026include=eJyNj9EKwjAMRX9orCLo74TbNsxim4w0Cvt7O_eiD4Jvl8NNcpLUOGR7rKhzLqi6TFKMIjqHPZSk0r-Rq9YIe8MGu7NThoNi1XQPENStOxm8yDKmjNIN5n_VOzli5R_dxhAyTtoay-BF5WP3iuXw28M8tJ3FqW-ShoQIH8JryefT9RL0yWYl89THdW5h_-4Fhv1pRA HTTP/1.1\r\nHost: ir.serestherapeutics.com\r\nUser-Agent: Mozilla/5.0 (Windows NT 10.0; Win64; x64; rv:134.0) Gecko/20100101 Firefox/134.0\r\nAccept: text/css,*/*;q=0.1\r\nAccept-Language: en-US,en;q=0.5\r\nAccept-Encoding: gzip, deflate, br\r\nReferer: https://ir.serestherapeutics.com/news-releases/news-release-details/seres-therapeutics-reports-ser-155-phase-1b-placebo-controlled\r\nDNT: 1\r\nConnection: keep-alive\r\nCookie: bm_ss=ab8e18ef4e; ak_bmsc=8B3E3F53D6F1D551950B130550D015A2~000000000000000000000000000000~YAAQ9U0kF2FfO52YAQAAsLaDpBzYHEeJiZORhrKmMvVJl6htT4U5E/6alOnsN1WLbK0JNN0FxV6QIk3CXK6SZzJXWuElqmWB1WWYdY8quqhpWza5ivcl5im9nJoX7vrrq3G0vDVDRbOFK+CpHpJKlNA7AFE8qUMYv2oy8l08ONFK9GC3Aonufb2qXf/9ZjIkKIaaJrJwo1KUNgFeJmFTmRFsbb4oS3Jv2xmpV6uIXbaBeN9UhBTyS0HA2CF3KtgNehkaNLOEZnMBc1mLg/Q+bEEutjMUDLWyhdWbq0cnrrkhtimNWHnJcupfFzlIfpxdU3sj4xzZZ/Md5pzLYIOYZrVV2/12xnbT2CkSBSpx2FJsR/0yDsO84EToiNJUl0y3pFgjA1wezQP5EqYWYF8qXo/BI+qA; bm_s=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; bm_so=076452BA7F785C26C0D039192D414EE322EFEBEE47C9D32A826B033A65229333~YAAQ9U0kF2RfO52YAQAAsLaDpARpo2xHJdjU4Jxa73zUq51KuxsW+QSmb5iP/ENmk7iqOGRhZyjdzqR50bYOPoK0krDYMKoypGPYm3hLRIvJAjzEPSWU9v0AmtzNP00zTXG2hPxPx54udTSSuGTM2KzBDJRiwCiOkJhUWlTdDefECbi1wnKokP5hnBjxGDCQMAE2aCXe4HqNbDgvHE7G5jmtqONfD1YgD6Cw25QL5pfAPYy0BKE94QkgYz+X0zy3rLB0HCSNr0ZOGQwVNzi2iZcJKo5SMvwmYjG5K9U0kZTVIUSy4tJGLP5ot1++FSPm+vy3pNdvnFN2MubC56GIGbx4fuz6N7DiabN7PeQYi+r8MvS04Dnfb7d5OjiIIOID16B38U5M8NVX3SXmdkNgusrIqEHOgLTigWBDKbEIIu1+fexPgsghoQRNJTdw9HEjOj0FOJyf/HSuHOBqCbNWdmrBXQvBXBkw\r\nSec-Fetch-Dest: style\r\nSec-Fetch-Mode: no-cors\r\nSec-Fetch-Site: same-origin\r\nPragma: no-cache\r\nCache-Control: no-cache\r\n\r\n","headers":null,"cookies":null,"method":"GET"},"response":{"raw":"HTTP/2 200 OK\r\naccept-ranges: bytes\r\ncontent-encoding: gzip\r\ncontent-type: text/css\r\nlast-modified: Tue, 15 Jul 2025 04:37:05 GMT\r\nx-age: 27956\r\nx-cache-hits: 15\r\nx-content-type-options: nosniff\r\nx-request-id: v-a4318570-6136-11f0-a5c2-9f42cc195325\r\ncontent-length: 7392\r\nx-edgeconnect-midmile-rtt: 0, 20, 17\r\nx-edgeconnect-origin-mex-latency: 89, 91, 84\r\ncache-control: max-age=600\r\nexpires: Wed, 13 Aug 2025 17:49:12 GMT\r\ndate: Wed, 13 Aug 2025 17:39:12 GMT\r\nvary: Accept-Encoding\r\nX-Firefox-Spdy: h2\r\n\r\n","headers":null,"cookies":null,"status_code":"200","status_text":"OK","fingerprints":[{"name":"Akamai","description":"Akamai is global content delivery network (CDN) services provider for media and software delivery, and cloud security solutions.","website":"https://akamai.com","common_platform_enumeration":"","icon":"Akamai.svg","categories":["CDN"]}],"data":{"size":42754,"size_decoded":0,"mime_type":"text/css","magic":"assembler source, ASCII text, with very long lines (14110)","md5":"ecf932380f362580dac91ad82b543d5e","sha1":"21be82cd51fa210e2207f74a9911437cf91ad39c","sha256":"2f9805bed8b26970f14a52fb81e9384ae482e1d7a310a8e1809ec8c353ad640b","sha512":"9fa64f9282f88c16ec09dfbfc72477560b2471e4d8142d0c712d21792cd4a4cfa78757b4d2003b298af0a3983969924693ee8f5a8c1591b70645392416ca1d92","ssdeep":"768:liuAla1/zlzcVRW6GJWlE9211feQB5m3n8:suAeGeQBr","tlshash":"4713ee14f4f2383abe17c92e61e08af0122e4142e9474ffcac6635d9a9c94dc876bd75","first_seen":"2025-07-12T08:36:43.413257Z","last_seen":"2026-03-29T14:02:39.93235Z","times_seen":20,"resource_available":false,"data":null}},"time_used":268,"timings":{"blocked":-1,"dns":0,"connect":0,"send":0,"wait":268,"receive":0,"ssl":0},"alerts":{"ids":null,"analyzer":null,"urlquery":null}},{"url":{"schema":"https","addr":"ir.serestherapeutics.com/sites/g/files/knoqqb52941/themes/site/nir_pid2065/dist/fonts/lato-v16-latin-700.woff2","fqdn":"ir.serestherapeutics.com","domain":"serestherapeutics.com","tld":"com"},"ip":{"addr":"23.36.77.170","port":443,"asn":20940,"as":"Akamai International B.V.","country":"Norway","country_code":"NO"},"is_navigation_request":false,"resource_type":"font","requested_by":"https://ir.serestherapeutics.com/news-releases/news-release-details/seres-therapeutics-reports-ser-155-phase-1b-placebo-controlled","date":"2025-08-13T17:39:13.604Z","timestamp":0,"http_version":"","security_state":"secure","security_info":{"cipher_suite":"TLS_AES_256_GCM_SHA384","key_group_name":"x25519","signature_name":"RSA-PSS-SHA256","protocol":"TLSv1.3","cert":{"subject":{"commonName":"leapfrog-ssl-30.gcs-web.com","organization":""},"issuer":{"commonName":"R10","organization":"Let's Encrypt"},"validity":{"start":"Fri, 13 Jun 2025 04:44:47 GMT","end":"Thu, 11 Sep 2025 04:44:46 GMT"},"fingerprint":{"sha1":"76:56:CB:1C:2A:EB:BC:6C:AD:AC:F9:46:52:00:98:68:6F:36:7E:4D","sha256":"2E:92:CD:78:D5:3F:E1:8C:2B:75:38:93:FD:B6:D7:66:20:2F:C1:D0:0B:A0:AE:7D:AE:10:26:7A:9B:48:60:40"}}},"request":{"raw":"GET /sites/g/files/knoqqb52941/themes/site/nir_pid2065/dist/fonts/lato-v16-latin-700.woff2 HTTP/1.1\r\nHost: ir.serestherapeutics.com\r\nUser-Agent: Mozilla/5.0 (Windows NT 10.0; Win64; x64; rv:134.0) Gecko/20100101 Firefox/134.0\r\nAccept: application/font-woff2;q=1.0,application/font-woff;q=0.9,*/*;q=0.8\r\nAccept-Language: en-US,en;q=0.5\r\nAccept-Encoding: identity\r\nDNT: 1\r\nConnection: keep-alive\r\nReferer: https://ir.serestherapeutics.com/sites/g/files/knoqqb52941/files/css/css_kzaM5d7Hf_D4urQRrPnMNG7ZSmDxlul3AoaRuCcLFBg.css?delta=1\u0026language=en\u0026theme=nir_pid2065\u0026include=eJyNj9EKwjAMRX9orCLo74TbNsxim4w0Cvt7O_eiD4Jvl8NNcpLUOGR7rKhzLqi6TFKMIjqHPZSk0r-Rq9YIe8MGu7NThoNi1XQPENStOxm8yDKmjNIN5n_VOzli5R_dxhAyTtoay-BF5WP3iuXw28M8tJ3FqW-ShoQIH8JryefT9RL0yWYl89THdW5h_-4Fhv1pRA\r\nCookie: bm_ss=ab8e18ef4e; ak_bmsc=4E19C384354D9168EC037A0AE57F6E73~000000000000000000000000000000~YAAQ9U0kF3pfO52YAQAAyrqDpBxZNiQhgQ/mLbHzuEyKUI1B5Q02Uo0y/Q8t/RN651uf3zXQrlH74xzEGFZJh8Z3EipvPaPk8w7Is198IT9ERHRfRPKa2M7lbnLucg3cEIMP0T5Us1UtqKrkD4IyfMWS5Il+7GYb/LonOBcDcZfDHDidfuuSIQ6TrFLomDSIbFN39zhVmt4CPEAYeJCFpnrqAGm+u+JZOxVfbd6hq2X8CRbwAnpU/qIeEkfJZTcbdrKuCAfQd9nnNvAIY60IM359bhv/qJQdbTtF9ptE/8TrJUyq6y1eZieW7441XaaLDTJjdbbmD+kIh76nTK2tFfqRYBRM+LJxo4h7ROy+Jg0nL8xfVSOAHRJQZeKb/jZ7i3pBOoDbq2YYcEhFDfwAdJJtM3L3MIx/VHn8srwrv/OxDJmiCmO13LX5jQfOZxx+mwR2mwpsu1ypGLyV; bm_s=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; bm_so=076452BA7F785C26C0D039192D414EE322EFEBEE47C9D32A826B033A65229333~YAAQ9U0kF2RfO52YAQAAsLaDpARpo2xHJdjU4Jxa73zUq51KuxsW+QSmb5iP/ENmk7iqOGRhZyjdzqR50bYOPoK0krDYMKoypGPYm3hLRIvJAjzEPSWU9v0AmtzNP00zTXG2hPxPx54udTSSuGTM2KzBDJRiwCiOkJhUWlTdDefECbi1wnKokP5hnBjxGDCQMAE2aCXe4HqNbDgvHE7G5jmtqONfD1YgD6Cw25QL5pfAPYy0BKE94QkgYz+X0zy3rLB0HCSNr0ZOGQwVNzi2iZcJKo5SMvwmYjG5K9U0kZTVIUSy4tJGLP5ot1++FSPm+vy3pNdvnFN2MubC56GIGbx4fuz6N7DiabN7PeQYi+r8MvS04Dnfb7d5OjiIIOID16B38U5M8NVX3SXmdkNgusrIqEHOgLTigWBDKbEIIu1+fexPgsghoQRNJTdw9HEjOj0FOJyf/HSuHOBqCbNWdmrBXQvBXBkw\r\nSec-Fetch-Dest: font\r\nSec-Fetch-Mode: cors\r\nSec-Fetch-Site: same-origin\r\nPragma: no-cache\r\nCache-Control: no-cache\r\n\r\n","headers":null,"cookies":null,"method":"GET"},"response":{"raw":"HTTP/2 200 OK\r\naccept-ranges: bytes\r\nlast-modified: Mon, 14 Jul 2025 09:57:48 GMT\r\nx-age: 785838\r\nx-cache-hits: 347\r\nx-content-type-options: nosniff\r\nx-request-id: v-5809fb96-6c3f-11f0-8b00-6b0112848aeb\r\ncontent-length: 22992\r\nx-edgeconnect-midmile-rtt: 17, 21\r\nx-edgeconnect-origin-mex-latency: 84, 81\r\ncache-control: max-age=600\r\nexpires: Wed, 13 Aug 2025 17:49:13 GMT\r\ndate: Wed, 13 Aug 2025 17:39:13 GMT\r\nX-Firefox-Spdy: h2\r\n\r\n","headers":null,"cookies":null,"status_code":"200","status_text":"OK","fingerprints":[{"name":"Akamai","description":"Akamai is global content delivery network (CDN) services provider for media and software delivery, and cloud security solutions.","website":"https://akamai.com","common_platform_enumeration":"","icon":"Akamai.svg","categories":["CDN"]}],"data":{"size":22992,"size_decoded":0,"mime_type":"font/woff2","magic":"Web Open Font Format (Version 2), TrueType, length 22992, version 1.0","md5":"1efbd38aa76ddae2580fedf378276333","sha1":"8a49976f2470ba2a1db6144245355d3b889312e4","sha256":"8d3ca80fa271e94b0c36cf3053b0f806b7a42bb3395b424c99dc0bd218f0ac20","sha512":"dd16efd323a38dad99a105e7443546e112ff42158018c885091df498c8c5b88c4d83737b4887332ea54ef3a83483e660c783073c4ce61fca4098d24aac05ed6c","ssdeep":"384:i8dkfSOTyQBgarmZBcC60rEJq/VcteWhh/nqgYA7L3ittJ2MY+0K7YXr5eC:xfHQBgGmZBtnytL/tYSLStDJY+0K0bD","tlshash":"5ba2d0ae5a223af4d77235a4d1bc351db3ddf0c22193e90e73e77138cc7a6451182069","first_seen":"2023-04-07T01:34:48Z","last_seen":"2026-04-03T16:56:39.525993Z","times_seen":1936,"resource_available":false,"data":null}},"time_used":28,"timings":{"blocked":0,"dns":0,"connect":0,"send":0,"wait":27,"receive":1,"ssl":0},"alerts":{"ids":null,"analyzer":null,"urlquery":null}},{"url":{"schema":"https","addr":"ir.serestherapeutics.com/sites/g/files/knoqqb52941/themes/site/nir_pid2065/fonts/ndqfonticons.ttf","fqdn":"ir.serestherapeutics.com","domain":"serestherapeutics.com","tld":"com"},"ip":{"addr":"23.36.77.170","port":443,"asn":20940,"as":"Akamai International B.V.","country":"Norway","country_code":"NO"},"is_navigation_request":false,"resource_type":"font","requested_by":"https://ir.serestherapeutics.com/news-releases/news-release-details/seres-therapeutics-reports-ser-155-phase-1b-placebo-controlled","date":"2025-08-13T17:39:14.444Z","timestamp":0,"http_version":"","security_state":"secure","security_info":{"cipher_suite":"TLS_AES_256_GCM_SHA384","key_group_name":"x25519","signature_name":"RSA-PSS-SHA256","protocol":"TLSv1.3","cert":{"subject":{"commonName":"leapfrog-ssl-30.gcs-web.com","organization":""},"issuer":{"commonName":"R10","organization":"Let's Encrypt"},"validity":{"start":"Fri, 13 Jun 2025 04:44:47 GMT","end":"Thu, 11 Sep 2025 04:44:46 GMT"},"fingerprint":{"sha1":"76:56:CB:1C:2A:EB:BC:6C:AD:AC:F9:46:52:00:98:68:6F:36:7E:4D","sha256":"2E:92:CD:78:D5:3F:E1:8C:2B:75:38:93:FD:B6:D7:66:20:2F:C1:D0:0B:A0:AE:7D:AE:10:26:7A:9B:48:60:40"}}},"request":{"raw":"GET /sites/g/files/knoqqb52941/themes/site/nir_pid2065/fonts/ndqfonticons.ttf HTTP/1.1\r\nHost: ir.serestherapeutics.com\r\nUser-Agent: Mozilla/5.0 (Windows NT 10.0; Win64; x64; rv:134.0) Gecko/20100101 Firefox/134.0\r\nAccept: application/font-woff2;q=1.0,application/font-woff;q=0.9,*/*;q=0.8\r\nAccept-Language: en-US,en;q=0.5\r\nAccept-Encoding: gzip, deflate, br\r\nDNT: 1\r\nConnection: keep-alive\r\nReferer: https://ir.serestherapeutics.com/sites/g/files/knoqqb52941/files/css/css_aO3gfVpreLC_ok0rmlGqfTNnOYGIjQgI1drc006UnII.css?delta=5\u0026language=en\u0026theme=nir_pid2065\u0026include=eJyNj9EKwjAMRX9orCLo74TbNsxim4w0Cvt7O_eiD4Jvl8NNcpLUOGR7rKhzLqi6TFKMIjqHPZSk0r-Rq9YIe8MGu7NThoNi1XQPENStOxm8yDKmjNIN5n_VOzli5R_dxhAyTtoay-BF5WP3iuXw28M8tJ3FqW-ShoQIH8JryefT9RL0yWYl89THdW5h_-4Fhv1pRA\r\nCookie: bm_ss=ab8e18ef4e; ak_bmsc=4E19C384354D9168EC037A0AE57F6E73~000000000000000000000000000000~YAAQ9U0kF3RfO52YAQAAd7qDpBw5F+q3Uc5v0N7+PDFzsbd7US5lA8rWlWvLno9HKg/X2sIOTfJntg/q7EBuiT+pIEeaFH/wg4KzFCU93Nv0olc9dX8xpQR06oZ3gERte/SdeorndYWd9RFZdhQM80Cu2pDypc8UhsWbGf8lr+/knh7ONEmk3ShcQA9PRLImzOypnFuQBCHv4jsuACpevJmiCZzQp847Myc0lvKkgtrRbHt/L5zRZT+X5L19GrQ1s+sD2U4aOOCiVvPRMkyzlLvUSizr+fmrE44xCqQeIlumDAkPO5fqUBDjdLB0o5nu7EWc8K9g2uUTkBxB1H/UALUHDyTQgbbIc0iGmdA4jDi7n8u9NyBxGZz0K8wryScePwIL3i++X2T+1NWhj13wA4+10C0x6g/ihykRb9J+Xxln9gUF/CNPH7RZsRuMvkYuCrpQI4xb0TLRAX4A; bm_s=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; bm_so=076452BA7F785C26C0D039192D414EE322EFEBEE47C9D32A826B033A65229333~YAAQ9U0kF2RfO52YAQAAsLaDpARpo2xHJdjU4Jxa73zUq51KuxsW+QSmb5iP/ENmk7iqOGRhZyjdzqR50bYOPoK0krDYMKoypGPYm3hLRIvJAjzEPSWU9v0AmtzNP00zTXG2hPxPx54udTSSuGTM2KzBDJRiwCiOkJhUWlTdDefECbi1wnKokP5hnBjxGDCQMAE2aCXe4HqNbDgvHE7G5jmtqONfD1YgD6Cw25QL5pfAPYy0BKE94QkgYz+X0zy3rLB0HCSNr0ZOGQwVNzi2iZcJKo5SMvwmYjG5K9U0kZTVIUSy4tJGLP5ot1++FSPm+vy3pNdvnFN2MubC56GIGbx4fuz6N7DiabN7PeQYi+r8MvS04Dnfb7d5OjiIIOID16B38U5M8NVX3SXmdkNgusrIqEHOgLTigWBDKbEIIu1+fexPgsghoQRNJTdw9HEjOj0FOJyf/HSuHOBqCbNWdmrBXQvBXBkw; bm_lso=076452BA7F785C26C0D039192D414EE322EFEBEE47C9D32A826B033A65229333~YAAQ9U0kF2RfO52YAQAAsLaDpARpo2xHJdjU4Jxa73zUq51KuxsW+QSmb5iP/ENmk7iqOGRhZyjdzqR50bYOPoK0krDYMKoypGPYm3hLRIvJAjzEPSWU9v0AmtzNP00zTXG2hPxPx54udTSSuGTM2KzBDJRiwCiOkJhUWlTdDefECbi1wnKokP5hnBjxGDCQMAE2aCXe4HqNbDgvHE7G5jmtqONfD1YgD6Cw25QL5pfAPYy0BKE94QkgYz+X0zy3rLB0HCSNr0ZOGQwVNzi2iZcJKo5SMvwmYjG5K9U0kZTVIUSy4tJGLP5ot1++FSPm+vy3pNdvnFN2MubC56GIGbx4fuz6N7DiabN7PeQYi+r8MvS04Dnfb7d5OjiIIOID16B38U5M8NVX3SXmdkNgusrIqEHOgLTigWBDKbEIIu1+fexPgsghoQRNJTdw9HEjOj0FOJyf/HSuHOBqCbNWdmrBXQvBXBkw^1755106754250; _pk_id.310.7332=2c4a18add8648920.1755106754.; _pk_ses.310.7332=1\r\nSec-Fetch-Dest: font\r\nSec-Fetch-Mode: cors\r\nSec-Fetch-Site: same-origin\r\nPragma: no-cache\r\nCache-Control: no-cache\r\n\r\n","headers":null,"cookies":null,"method":"GET"},"response":{"raw":"HTTP/2 200 OK\r\naccept-ranges: bytes\r\nlast-modified: Mon, 14 Jul 2025 09:27:14 GMT\r\nx-age: 896395\r\nx-cache-hits: 387\r\nx-content-type-options: nosniff\r\nx-request-id: v-560906a4-6c47-11f0-9b58-fb380fe46e9c\r\ncontent-encoding: gzip\r\ncontent-length: 31720\r\nx-edgeconnect-midmile-rtt: 20, 21\r\nx-edgeconnect-origin-mex-latency: 84, 161\r\ncache-control: max-age=600\r\nexpires: Wed, 13 Aug 2025 17:49:14 GMT\r\ndate: Wed, 13 Aug 2025 17:39:14 GMT\r\nvary: Accept-Encoding\r\nX-Firefox-Spdy: h2\r\n\r\n","headers":null,"cookies":null,"status_code":"200","status_text":"OK","fingerprints":[{"name":"Akamai","description":"Akamai is global content delivery network (CDN) services provider for media and software delivery, and cloud security solutions.","website":"https://akamai.com","common_platform_enumeration":"","icon":"Akamai.svg","categories":["CDN"]}],"data":{"size":64080,"size_decoded":0,"mime_type":"font/ttf","magic":"TrueType Font data, 13 tables, 1st \"FFTM\", 12 names, Macintosh, type 1 string","md5":"3cab0136d276d536246d5a2305314fb0","sha1":"b36aebd5b3400da3e94d124e9b2eb3d8d2d649d3","sha256":"efa66e544d0b31c17bc40e6268b2ea3cbdf722ff73f2f2da74e834cdb445ecb5","sha512":"a40452c313befb96e07721a7be2644a5034c342fec0ae58d8688c26107dbc44f9907b007785ac9d24a59dd2d1ef392d4548a85fa8cf51f738f563c17262584b9","ssdeep":"1536:XwoSpG7xWGNIJWfYQa2ksTZ9fLgW4Ahoi7WXQaOhbC6CHCG2c9qoGzjPtEjFPQmW:XwTpG7XIJWfYQ9PzfLgW4Ahoi7WXQaOD","tlshash":"39536d4ed3aeadafe17757390549250f93e0c51ceb0333a7dadc7479ca6309018aa627","first_seen":"2024-10-14T13:57:00.078717Z","last_seen":"2025-11-28T03:39:16.549454Z","times_seen":9,"resource_available":false,"data":null}},"time_used":325,"timings":{"blocked":-1,"dns":0,"connect":0,"send":0,"wait":323,"receive":2,"ssl":0},"alerts":{"ids":null,"analyzer":null,"urlquery":null}},{"url":{"schema":"https","addr":"ir.serestherapeutics.com/sites/g/files/knoqqb52941/files/css/css_kzaM5d7Hf_D4urQRrPnMNG7ZSmDxlul3AoaRuCcLFBg.css?delta=1\u0026language=en\u0026theme=nir_pid2065\u0026include=eJyNj9EKwjAMRX9orCLo74TbNsxim4w0Cvt7O_eiD4Jvl8NNcpLUOGR7rKhzLqi6TFKMIjqHPZSk0r-Rq9YIe8MGu7NThoNi1XQPENStOxm8yDKmjNIN5n_VOzli5R_dxhAyTtoay-BF5WP3iuXw28M8tJ3FqW-ShoQIH8JryefT9RL0yWYl89THdW5h_-4Fhv1pRA","fqdn":"ir.serestherapeutics.com","domain":"serestherapeutics.com","tld":"com"},"ip":{"addr":"23.36.77.170","port":443,"asn":20940,"as":"Akamai International B.V.","country":"Norway","country_code":"NO"},"is_navigation_request":false,"resource_type":"stylesheet","requested_by":"https://ir.serestherapeutics.com/news-releases/news-release-details/seres-therapeutics-reports-ser-155-phase-1b-placebo-controlled","date":"2025-08-13T17:39:12.415Z","timestamp":0,"http_version":"","security_state":"secure","security_info":{"cipher_suite":"TLS_AES_256_GCM_SHA384","key_group_name":"x25519","signature_name":"RSA-PSS-SHA256","protocol":"TLSv1.3","cert":{"subject":{"commonName":"leapfrog-ssl-30.gcs-web.com","organization":""},"issuer":{"commonName":"R10","organization":"Let's Encrypt"},"validity":{"start":"Fri, 13 Jun 2025 04:44:47 GMT","end":"Thu, 11 Sep 2025 04:44:46 GMT"},"fingerprint":{"sha1":"76:56:CB:1C:2A:EB:BC:6C:AD:AC:F9:46:52:00:98:68:6F:36:7E:4D","sha256":"2E:92:CD:78:D5:3F:E1:8C:2B:75:38:93:FD:B6:D7:66:20:2F:C1:D0:0B:A0:AE:7D:AE:10:26:7A:9B:48:60:40"}}},"request":{"raw":"GET /sites/g/files/knoqqb52941/files/css/css_kzaM5d7Hf_D4urQRrPnMNG7ZSmDxlul3AoaRuCcLFBg.css?delta=1\u0026language=en\u0026theme=nir_pid2065\u0026include=eJyNj9EKwjAMRX9orCLo74TbNsxim4w0Cvt7O_eiD4Jvl8NNcpLUOGR7rKhzLqi6TFKMIjqHPZSk0r-Rq9YIe8MGu7NThoNi1XQPENStOxm8yDKmjNIN5n_VOzli5R_dxhAyTtoay-BF5WP3iuXw28M8tJ3FqW-ShoQIH8JryefT9RL0yWYl89THdW5h_-4Fhv1pRA HTTP/1.1\r\nHost: ir.serestherapeutics.com\r\nUser-Agent: Mozilla/5.0 (Windows NT 10.0; Win64; x64; rv:134.0) Gecko/20100101 Firefox/134.0\r\nAccept: text/css,*/*;q=0.1\r\nAccept-Language: en-US,en;q=0.5\r\nAccept-Encoding: gzip, deflate, br\r\nReferer: https://ir.serestherapeutics.com/news-releases/news-release-details/seres-therapeutics-reports-ser-155-phase-1b-placebo-controlled\r\nDNT: 1\r\nConnection: keep-alive\r\nCookie: bm_ss=ab8e18ef4e; ak_bmsc=8B3E3F53D6F1D551950B130550D015A2~000000000000000000000000000000~YAAQ9U0kF2FfO52YAQAAsLaDpBzYHEeJiZORhrKmMvVJl6htT4U5E/6alOnsN1WLbK0JNN0FxV6QIk3CXK6SZzJXWuElqmWB1WWYdY8quqhpWza5ivcl5im9nJoX7vrrq3G0vDVDRbOFK+CpHpJKlNA7AFE8qUMYv2oy8l08ONFK9GC3Aonufb2qXf/9ZjIkKIaaJrJwo1KUNgFeJmFTmRFsbb4oS3Jv2xmpV6uIXbaBeN9UhBTyS0HA2CF3KtgNehkaNLOEZnMBc1mLg/Q+bEEutjMUDLWyhdWbq0cnrrkhtimNWHnJcupfFzlIfpxdU3sj4xzZZ/Md5pzLYIOYZrVV2/12xnbT2CkSBSpx2FJsR/0yDsO84EToiNJUl0y3pFgjA1wezQP5EqYWYF8qXo/BI+qA; bm_s=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; bm_so=076452BA7F785C26C0D039192D414EE322EFEBEE47C9D32A826B033A65229333~YAAQ9U0kF2RfO52YAQAAsLaDpARpo2xHJdjU4Jxa73zUq51KuxsW+QSmb5iP/ENmk7iqOGRhZyjdzqR50bYOPoK0krDYMKoypGPYm3hLRIvJAjzEPSWU9v0AmtzNP00zTXG2hPxPx54udTSSuGTM2KzBDJRiwCiOkJhUWlTdDefECbi1wnKokP5hnBjxGDCQMAE2aCXe4HqNbDgvHE7G5jmtqONfD1YgD6Cw25QL5pfAPYy0BKE94QkgYz+X0zy3rLB0HCSNr0ZOGQwVNzi2iZcJKo5SMvwmYjG5K9U0kZTVIUSy4tJGLP5ot1++FSPm+vy3pNdvnFN2MubC56GIGbx4fuz6N7DiabN7PeQYi+r8MvS04Dnfb7d5OjiIIOID16B38U5M8NVX3SXmdkNgusrIqEHOgLTigWBDKbEIIu1+fexPgsghoQRNJTdw9HEjOj0FOJyf/HSuHOBqCbNWdmrBXQvBXBkw\r\nSec-Fetch-Dest: style\r\nSec-Fetch-Mode: no-cors\r\nSec-Fetch-Site: same-origin\r\nPragma: no-cache\r\nCache-Control: no-cache\r\n\r\n","headers":null,"cookies":null,"method":"GET"},"response":{"raw":"HTTP/2 200 OK\r\naccept-ranges: bytes\r\ncontent-encoding: gzip\r\ncontent-type: text/css\r\nlast-modified: Tue, 15 Jul 2025 04:37:05 GMT\r\nx-age: 27956\r\nx-cache-hits: 19\r\nx-content-type-options: nosniff\r\nx-request-id: v-a3ff9f4c-6136-11f0-8909-a75750b448e4\r\ncontent-length: 32145\r\nx-edgeconnect-midmile-rtt: 17, 21\r\nx-edgeconnect-origin-mex-latency: 92, 359\r\ncache-control: max-age=600\r\nexpires: Wed, 13 Aug 2025 17:49:12 GMT\r\ndate: Wed, 13 Aug 2025 17:39:12 GMT\r\nvary: Accept-Encoding\r\nX-Firefox-Spdy: h2\r\n\r\n","headers":null,"cookies":null,"status_code":"200","status_text":"OK","fingerprints":[{"name":"Akamai","description":"Akamai is global content delivery network (CDN) services provider for media and software delivery, and cloud security solutions.","website":"https://akamai.com","common_platform_enumeration":"","icon":"Akamai.svg","categories":["CDN"]}],"data":{"size":228987,"size_decoded":0,"mime_type":"text/css","magic":"Unicode text, UTF-8 text, with very long lines (38242)","md5":"cb5c2100fc47ac1c9a0856fb01e73d69","sha1":"0e628cf0dbe41908c1c613ef9ef126b0614cb436","sha256":"437bb138b03b2ac31d5550b726e5e55118f35baf6c802fb4595514cf87bbaaa0","sha512":"783fb8431e814d760eb88c13c6e53abbe484875f6b2d692f6a441751492de25a24ff8e24fe79647e9e54ad2aa7b0629da353858e360fd204f9279db0f1297bcf","ssdeep":"1536:ViKerP3LXoXW3wryK8GBqbOQTnbl1KRlThzhXbIjgTzzFXDIC+CRf0gyH3SgyH3x:OGRfH3","tlshash":"612461f0e19521ab53b3c42f57807360222e96e5d9032eede4d6f16e86c5b8713e2b74","first_seen":"2025-08-13T17:39:41.421133Z","last_seen":"2025-08-13T17:39:41.421133Z","times_seen":1,"resource_available":false,"data":null}},"time_used":525,"timings":{"blocked":-1,"dns":0,"connect":0,"send":0,"wait":524,"receive":1,"ssl":0},"alerts":{"ids":null,"analyzer":null,"urlquery":null}},{"url":{"schema":"https","addr":"ir.serestherapeutics.com/sites/g/files/knoqqb52941/themes/site/nir_pid2065/dist/img/Seres-Logo.svg","fqdn":"ir.serestherapeutics.com","domain":"serestherapeutics.com","tld":"com"},"ip":{"addr":"23.36.77.170","port":443,"asn":20940,"as":"Akamai International B.V.","country":"Norway","country_code":"NO"},"is_navigation_request":false,"resource_type":"img","requested_by":"https://ir.serestherapeutics.com/news-releases/news-release-details/seres-therapeutics-reports-ser-155-phase-1b-placebo-controlled","date":"2025-08-13T17:39:12.424Z","timestamp":0,"http_version":"","security_state":"secure","security_info":{"cipher_suite":"TLS_AES_256_GCM_SHA384","key_group_name":"x25519","signature_name":"RSA-PSS-SHA256","protocol":"TLSv1.3","cert":{"subject":{"commonName":"leapfrog-ssl-30.gcs-web.com","organization":""},"issuer":{"commonName":"R10","organization":"Let's Encrypt"},"validity":{"start":"Fri, 13 Jun 2025 04:44:47 GMT","end":"Thu, 11 Sep 2025 04:44:46 GMT"},"fingerprint":{"sha1":"76:56:CB:1C:2A:EB:BC:6C:AD:AC:F9:46:52:00:98:68:6F:36:7E:4D","sha256":"2E:92:CD:78:D5:3F:E1:8C:2B:75:38:93:FD:B6:D7:66:20:2F:C1:D0:0B:A0:AE:7D:AE:10:26:7A:9B:48:60:40"}}},"request":{"raw":"GET /sites/g/files/knoqqb52941/themes/site/nir_pid2065/dist/img/Seres-Logo.svg HTTP/1.1\r\nHost: ir.serestherapeutics.com\r\nUser-Agent: Mozilla/5.0 (Windows NT 10.0; Win64; x64; rv:134.0) Gecko/20100101 Firefox/134.0\r\nAccept: image/avif,image/webp,*/*\r\nAccept-Language: en-US,en;q=0.5\r\nAccept-Encoding: gzip, deflate, br\r\nReferer: https://ir.serestherapeutics.com/news-releases/news-release-details/seres-therapeutics-reports-ser-155-phase-1b-placebo-controlled\r\nDNT: 1\r\nConnection: keep-alive\r\nCookie: bm_ss=ab8e18ef4e; ak_bmsc=8B3E3F53D6F1D551950B130550D015A2~000000000000000000000000000000~YAAQ9U0kF2FfO52YAQAAsLaDpBzYHEeJiZORhrKmMvVJl6htT4U5E/6alOnsN1WLbK0JNN0FxV6QIk3CXK6SZzJXWuElqmWB1WWYdY8quqhpWza5ivcl5im9nJoX7vrrq3G0vDVDRbOFK+CpHpJKlNA7AFE8qUMYv2oy8l08ONFK9GC3Aonufb2qXf/9ZjIkKIaaJrJwo1KUNgFeJmFTmRFsbb4oS3Jv2xmpV6uIXbaBeN9UhBTyS0HA2CF3KtgNehkaNLOEZnMBc1mLg/Q+bEEutjMUDLWyhdWbq0cnrrkhtimNWHnJcupfFzlIfpxdU3sj4xzZZ/Md5pzLYIOYZrVV2/12xnbT2CkSBSpx2FJsR/0yDsO84EToiNJUl0y3pFgjA1wezQP5EqYWYF8qXo/BI+qA; bm_s=YAAQ9U0kF2NfO52YAQAAsLaDpANJewrJRPUx4DHVcrnOcZ7sVqltownShqY7SA5J7P2fAELqqdwmzSucJRjPsxId1EF4TmDZURYHb7n01CRK30SA+mUklVxtAE4zmW3TAWq2nHxRgzAyU0YyXX5tbZjOBj+VTSet7JQ69ITcnPY97GTiQX4m93h2DTstxwX8uKbX/4BfJv60UvC7O0A9FsYsnu8OV/gOoVT7AcUpSXx+jnJV9i+XSIgFd6J3bc3mBWXJh2BDK1i1JsxJhID21MywYiYV8TM3cn8NKiaEoAh7Low19cGBcIPP3Cg2IiiOaDcMCAWGV89x2zREZFKavuK/ueQ/Nsubk/Q+Zb7XK0WVyXHRJS6mnCHtKtd35z7FOMm24VcMSR/uukTKCmytCDWWduQ4GQzX+GVj2orukXoiipN+KQ1NXCoa4C51w6Xg7btGDbpYGfhr/0wiL8qBR2f6E9KZOYuviVUEQzzOeMk19ovSoTuj6UCBSIoBrapa1hMf8u8Hzt4wxgMHTa5GeHaXxx/lHPfnd6mC66DF0CWGtP1V3N9b8gP/fx9qP/H8cjo=; bm_so=076452BA7F785C26C0D039192D414EE322EFEBEE47C9D32A826B033A65229333~YAAQ9U0kF2RfO52YAQAAsLaDpARpo2xHJdjU4Jxa73zUq51KuxsW+QSmb5iP/ENmk7iqOGRhZyjdzqR50bYOPoK0krDYMKoypGPYm3hLRIvJAjzEPSWU9v0AmtzNP00zTXG2hPxPx54udTSSuGTM2KzBDJRiwCiOkJhUWlTdDefECbi1wnKokP5hnBjxGDCQMAE2aCXe4HqNbDgvHE7G5jmtqONfD1YgD6Cw25QL5pfAPYy0BKE94QkgYz+X0zy3rLB0HCSNr0ZOGQwVNzi2iZcJKo5SMvwmYjG5K9U0kZTVIUSy4tJGLP5ot1++FSPm+vy3pNdvnFN2MubC56GIGbx4fuz6N7DiabN7PeQYi+r8MvS04Dnfb7d5OjiIIOID16B38U5M8NVX3SXmdkNgusrIqEHOgLTigWBDKbEIIu1+fexPgsghoQRNJTdw9HEjOj0FOJyf/HSuHOBqCbNWdmrBXQvBXBkw\r\nSec-Fetch-Dest: image\r\nSec-Fetch-Mode: no-cors\r\nSec-Fetch-Site: same-origin\r\nPragma: no-cache\r\nCache-Control: no-cache\r\n\r\n","headers":null,"cookies":null,"method":"GET"},"response":{"raw":"HTTP/2 200 OK\r\naccept-ranges: bytes\r\ncontent-type: image/svg+xml\r\nlast-modified: Mon, 14 Jul 2025 09:57:48 GMT\r\nx-age: 1139991\r\nx-cache-hits: 447\r\nx-content-type-options: nosniff\r\nx-request-id: v-43e8a1d6-6c3e-11f0-8bd2-9b998d93a7de\r\ncontent-encoding: gzip\r\ncontent-length: 18474\r\nx-edgeconnect-midmile-rtt: 17, 17\r\nx-edgeconnect-origin-mex-latency: 82, 243\r\ncache-control: max-age=600\r\nexpires: Wed, 13 Aug 2025 17:49:12 GMT\r\ndate: Wed, 13 Aug 2025 17:39:12 GMT\r\nvary: Accept-Encoding\r\nX-Firefox-Spdy: h2\r\n\r\n","headers":null,"cookies":null,"status_code":"200","status_text":"OK","fingerprints":[{"name":"Akamai","description":"Akamai is global content delivery network (CDN) services provider for media and software delivery, and cloud security solutions.","website":"https://akamai.com","common_platform_enumeration":"","icon":"Akamai.svg","categories":["CDN"]}],"data":{"size":60154,"size_decoded":0,"mime_type":"image/svg+xml","magic":"SVG Scalable Vector Graphics image","md5":"d032af2beb3262c213d95cb80ef7a632","sha1":"59553238059077c98a626d523b35033766f87f39","sha256":"d4bfa035e32f64e6e36b354ad96ba8d2d3b139f33f763c4ff4fe5b55c6c2462d","sha512":"c569aaa2d1dfc75de0ab5b7bd7fe0d44792b6c75cdd9caa509c066181f4ba047be0fb31d838ce74e49a1ffae71da5b8fb0f0d56cd46c38737f401c181c41c1dd","ssdeep":"768:JmnqqpbpfPu1K3sDXx7/+8kThehL2qrB7n4UHbUvakLVmCA9KxB3+R+dSQ5:JyfO1K3Q2renV7n4dxA9KPa+dSQ5","tlshash":"e1435347033cd5dc385529b85aa13bd23bfc98be8561a0c4f33bac269546e3ea15ce71","first_seen":"2025-08-13T17:39:41.423711Z","last_seen":"2025-08-13T17:39:41.423711Z","times_seen":1,"resource_available":false,"data":null}},"time_used":394,"timings":{"blocked":-1,"dns":0,"connect":0,"send":0,"wait":392,"receive":2,"ssl":0},"alerts":{"ids":null,"analyzer":null,"urlquery":null}},{"url":{"schema":"https","addr":"ir.serestherapeutics.com/akam/13/pixel_6167875b","fqdn":"ir.serestherapeutics.com","domain":"serestherapeutics.com","tld":"com"},"ip":{"addr":"23.36.77.170","port":443,"asn":20940,"as":"Akamai International B.V.","country":"Norway","country_code":"NO"},"is_navigation_request":false,"resource_type":"xhr","requested_by":"https://ir.serestherapeutics.com/news-releases/news-release-details/seres-therapeutics-reports-ser-155-phase-1b-placebo-controlled","date":"2025-08-13T17:39:14.494Z","timestamp":0,"http_version":"","security_state":"secure","security_info":{"cipher_suite":"TLS_AES_256_GCM_SHA384","key_group_name":"x25519","signature_name":"RSA-PSS-SHA256","protocol":"TLSv1.3","cert":{"subject":{"commonName":"leapfrog-ssl-30.gcs-web.com","organization":""},"issuer":{"commonName":"R10","organization":"Let's Encrypt"},"validity":{"start":"Fri, 13 Jun 2025 04:44:47 GMT","end":"Thu, 11 Sep 2025 04:44:46 GMT"},"fingerprint":{"sha1":"76:56:CB:1C:2A:EB:BC:6C:AD:AC:F9:46:52:00:98:68:6F:36:7E:4D","sha256":"2E:92:CD:78:D5:3F:E1:8C:2B:75:38:93:FD:B6:D7:66:20:2F:C1:D0:0B:A0:AE:7D:AE:10:26:7A:9B:48:60:40"}}},"request":{"raw":"POST /akam/13/pixel_6167875b HTTP/1.1\r\nHost: ir.serestherapeutics.com\r\nUser-Agent: Mozilla/5.0 (Windows NT 10.0; Win64; x64; rv:134.0) Gecko/20100101 Firefox/134.0\r\nAccept: */*\r\nAccept-Language: en-US,en;q=0.5\r\nAccept-Encoding: gzip, deflate, br\r\nReferer: https://ir.serestherapeutics.com/news-releases/news-release-details/seres-therapeutics-reports-ser-155-phase-1b-placebo-controlled\r\nContent-Type: application/x-www-form-urlencoded\r\nContent-Length: 2854\r\nOrigin: https://ir.serestherapeutics.com\r\nDNT: 1\r\nConnection: keep-alive\r\nCookie: bm_ss=ab8e18ef4e; ak_bmsc=4E19C384354D9168EC037A0AE57F6E73~000000000000000000000000000000~YAAQ9U0kF3RfO52YAQAAd7qDpBw5F+q3Uc5v0N7+PDFzsbd7US5lA8rWlWvLno9HKg/X2sIOTfJntg/q7EBuiT+pIEeaFH/wg4KzFCU93Nv0olc9dX8xpQR06oZ3gERte/SdeorndYWd9RFZdhQM80Cu2pDypc8UhsWbGf8lr+/knh7ONEmk3ShcQA9PRLImzOypnFuQBCHv4jsuACpevJmiCZzQp847Myc0lvKkgtrRbHt/L5zRZT+X5L19GrQ1s+sD2U4aOOCiVvPRMkyzlLvUSizr+fmrE44xCqQeIlumDAkPO5fqUBDjdLB0o5nu7EWc8K9g2uUTkBxB1H/UALUHDyTQgbbIc0iGmdA4jDi7n8u9NyBxGZz0K8wryScePwIL3i++X2T+1NWhj13wA4+10C0x6g/ihykRb9J+Xxln9gUF/CNPH7RZsRuMvkYuCrpQI4xb0TLRAX4A; bm_s=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; bm_so=076452BA7F785C26C0D039192D414EE322EFEBEE47C9D32A826B033A65229333~YAAQ9U0kF2RfO52YAQAAsLaDpARpo2xHJdjU4Jxa73zUq51KuxsW+QSmb5iP/ENmk7iqOGRhZyjdzqR50bYOPoK0krDYMKoypGPYm3hLRIvJAjzEPSWU9v0AmtzNP00zTXG2hPxPx54udTSSuGTM2KzBDJRiwCiOkJhUWlTdDefECbi1wnKokP5hnBjxGDCQMAE2aCXe4HqNbDgvHE7G5jmtqONfD1YgD6Cw25QL5pfAPYy0BKE94QkgYz+X0zy3rLB0HCSNr0ZOGQwVNzi2iZcJKo5SMvwmYjG5K9U0kZTVIUSy4tJGLP5ot1++FSPm+vy3pNdvnFN2MubC56GIGbx4fuz6N7DiabN7PeQYi+r8MvS04Dnfb7d5OjiIIOID16B38U5M8NVX3SXmdkNgusrIqEHOgLTigWBDKbEIIu1+fexPgsghoQRNJTdw9HEjOj0FOJyf/HSuHOBqCbNWdmrBXQvBXBkw; bm_lso=076452BA7F785C26C0D039192D414EE322EFEBEE47C9D32A826B033A65229333~YAAQ9U0kF2RfO52YAQAAsLaDpARpo2xHJdjU4Jxa73zUq51KuxsW+QSmb5iP/ENmk7iqOGRhZyjdzqR50bYOPoK0krDYMKoypGPYm3hLRIvJAjzEPSWU9v0AmtzNP00zTXG2hPxPx54udTSSuGTM2KzBDJRiwCiOkJhUWlTdDefECbi1wnKokP5hnBjxGDCQMAE2aCXe4HqNbDgvHE7G5jmtqONfD1YgD6Cw25QL5pfAPYy0BKE94QkgYz+X0zy3rLB0HCSNr0ZOGQwVNzi2iZcJKo5SMvwmYjG5K9U0kZTVIUSy4tJGLP5ot1++FSPm+vy3pNdvnFN2MubC56GIGbx4fuz6N7DiabN7PeQYi+r8MvS04Dnfb7d5OjiIIOID16B38U5M8NVX3SXmdkNgusrIqEHOgLTigWBDKbEIIu1+fexPgsghoQRNJTdw9HEjOj0FOJyf/HSuHOBqCbNWdmrBXQvBXBkw^1755106754250; _pk_id.310.7332=2c4a18add8648920.1755106754.; _pk_ses.310.7332=1\r\nSec-Fetch-Dest: empty\r\nSec-Fetch-Mode: cors\r\nSec-Fetch-Site: same-origin\r\nPragma: no-cache\r\nCache-Control: no-cache\r\n\r\n","headers":null,"cookies":null,"method":"POST"},"response":{"raw":"HTTP/2 200 OK\r\ncontent-type: text/html\r\ncontent-length: 0\r\ndate: Wed, 13 Aug 2025 17:39:14 GMT\r\nset-cookie: ak_bmsc=4E19C384354D9168EC037A0AE57F6E73~000000000000000000000000000000~YAAQ9U0kF35fO52YAQAAx7+DpBySZ/dfHdC4B5oUtNpuV2adhHIky7zORHESo+cA0boAKlpN0M1F0xemTlMj/fjitsk1gqPk8Rnv/JXOTVU1pJjkRHE4cvI1fxp7EOGzBft8N148JDVfar1U580eQu7mdWb4woUsrQ9CiwpG3Sh/GCoUOTSod4yVM6PXFf0x6S+wv0PQcfS8Adrxzqfl1Ma+/rkBJb9LxKTjiedjFZ2dIy3Hkd0qo9v67qkS0kSAzuHAgYjwXUROH/c6DnpyWQWD6GuvM4QWEhRa1q3HQdkE+HEd4nQrs6wKVajPvLFHGf+YkJRmLWLlPd5np30wqIS7bymQ/R6U7rSFiwI55664EdT1uWwylPUhd9tgyXc0G1RPEzRBF+HMs3Vj0hPTvjvNZYGjuGZN7oA2Uls4Z1LLzAPNLg4rFXi4vFoOl9OGIwqJ+w1ROra+oPpmbDznVyX1t53SC/Hh; Domain=.serestherapeutics.com; Path=/; Expires=Wed, 13 Aug 2025 19:39:11 GMT; Max-Age=7197\r\nX-Firefox-Spdy: h2\r\n\r\n","headers":null,"cookies":null,"status_code":"200","status_text":"OK","fingerprints":[{"name":"Akamai","description":"Akamai is global content delivery network (CDN) services provider for media and software delivery, and cloud security solutions.","website":"https://akamai.com","common_platform_enumeration":"","icon":"Akamai.svg","categories":["CDN"]},{"name":"Akamai Bot Manager","description":"Akamai Bot Manager detect bots using device fingerprinting bot signatures.","website":"https://www.akamai.com/us/en/products/security/bot-manager.jsp","common_platform_enumeration":"","icon":"Akamai.svg","categories":["Security"]}],"data":{"size":0,"size_decoded":0,"mime_type":"text/html","magic":"","md5":"d41d8cd98f00b204e9800998ecf8427e","sha1":"da39a3ee5e6b4b0d3255bfef95601890afd80709","sha256":"e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855","sha512":"cf83e1357eefb8bdf1542850d66d8007d620e4050b5715dc83f4a921d36ce9ce47d0d13c5d85f2b0ff8318d2877eec2f63b931bd47417a81a538327af927da3e","ssdeep":"","tlshash":"","first_seen":"0001-01-01T00:00:00Z","last_seen":"2026-04-03T18:31:03.533086Z","times_seen":13299059,"resource_available":true,"data":null}},"time_used":9,"timings":{"blocked":0,"dns":0,"connect":0,"send":0,"wait":9,"receive":0,"ssl":0},"alerts":{"ids":null,"analyzer":null,"urlquery":null}},{"url":{"schema":"https","addr":"ir.serestherapeutics.com/sites/g/files/knoqqb52941/themes/site/nir_pid2065/dist/fonts/lato-v16-latin-700.woff2","fqdn":"ir.serestherapeutics.com","domain":"serestherapeutics.com","tld":"com"},"ip":{"addr":"23.36.77.170","port":443,"asn":20940,"as":"Akamai International B.V.","country":"Norway","country_code":"NO"},"is_navigation_request":false,"resource_type":"font","requested_by":"https://ir.serestherapeutics.com/news-releases/news-release-details/seres-therapeutics-reports-ser-155-phase-1b-placebo-controlled","date":"2025-08-13T17:39:13.090Z","timestamp":0,"http_version":"","security_state":"secure","security_info":{"cipher_suite":"TLS_AES_256_GCM_SHA384","key_group_name":"x25519","signature_name":"RSA-PSS-SHA256","protocol":"TLSv1.3","cert":{"subject":{"commonName":"leapfrog-ssl-30.gcs-web.com","organization":""},"issuer":{"commonName":"R10","organization":"Let's Encrypt"},"validity":{"start":"Fri, 13 Jun 2025 04:44:47 GMT","end":"Thu, 11 Sep 2025 04:44:46 GMT"},"fingerprint":{"sha1":"76:56:CB:1C:2A:EB:BC:6C:AD:AC:F9:46:52:00:98:68:6F:36:7E:4D","sha256":"2E:92:CD:78:D5:3F:E1:8C:2B:75:38:93:FD:B6:D7:66:20:2F:C1:D0:0B:A0:AE:7D:AE:10:26:7A:9B:48:60:40"}}},"request":{"raw":"GET /sites/g/files/knoqqb52941/themes/site/nir_pid2065/dist/fonts/lato-v16-latin-700.woff2 HTTP/1.1\r\nHost: ir.serestherapeutics.com\r\nUser-Agent: Mozilla/5.0 (Windows NT 10.0; Win64; x64; rv:134.0) Gecko/20100101 Firefox/134.0\r\nAccept: application/font-woff2;q=1.0,application/font-woff;q=0.9,*/*;q=0.8\r\nAccept-Language: en-US,en;q=0.5\r\nAccept-Encoding: identity\r\nDNT: 1\r\nConnection: keep-alive\r\nReferer: https://ir.serestherapeutics.com/sites/g/files/knoqqb52941/files/css/css_kzaM5d7Hf_D4urQRrPnMNG7ZSmDxlul3AoaRuCcLFBg.css?delta=1\u0026language=en\u0026theme=nir_pid2065\u0026include=eJyNj9EKwjAMRX9orCLo74TbNsxim4w0Cvt7O_eiD4Jvl8NNcpLUOGR7rKhzLqi6TFKMIjqHPZSk0r-Rq9YIe8MGu7NThoNi1XQPENStOxm8yDKmjNIN5n_VOzli5R_dxhAyTtoay-BF5WP3iuXw28M8tJ3FqW-ShoQIH8JryefT9RL0yWYl89THdW5h_-4Fhv1pRA\r\nCookie: bm_ss=ab8e18ef4e; ak_bmsc=4E19C384354D9168EC037A0AE57F6E73~000000000000000000000000000000~YAAQ9U0kF3FfO52YAQAAoLiDpBzRDcrnH6JVmuZe+X7eJCmtLVP5oR5k3kXGARYJJVBAsw+q81DIcLQmOV8N1ujMBrXUamJHnJS7hNYlYdEDIAeNK/IANgppOIGPWSD30vdHue4X8W3dI7qdSkeDiXL8vWDfixSOhBbxDuqdFA/9Cv2o/FiNUUfmV6SuQVibYQXOJ+wagXSrei1Zkl9X2gVN/Gwom++A8v7BTG4rDWjjmLmzRJy6d4g31vDW+5uTeETmQZZUc4HHnbyxlOBP+//XhF7R8CFq5vH1FQ8GKtDX34wS1DW4XlTLGeAmusrcuOEBmNIflJmGwJOrY5EqLZDfcLRBdsHSY8BlxpWAWSyb+95E1IMm49gqrCGvKrPaRuI94Gf0m5uZE3N19M9ZYvwmQHv+8eP0+Cgn1KAO8sB4ofSwMJovneYg1yUOVzgENB4=; bm_s=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; bm_so=076452BA7F785C26C0D039192D414EE322EFEBEE47C9D32A826B033A65229333~YAAQ9U0kF2RfO52YAQAAsLaDpARpo2xHJdjU4Jxa73zUq51KuxsW+QSmb5iP/ENmk7iqOGRhZyjdzqR50bYOPoK0krDYMKoypGPYm3hLRIvJAjzEPSWU9v0AmtzNP00zTXG2hPxPx54udTSSuGTM2KzBDJRiwCiOkJhUWlTdDefECbi1wnKokP5hnBjxGDCQMAE2aCXe4HqNbDgvHE7G5jmtqONfD1YgD6Cw25QL5pfAPYy0BKE94QkgYz+X0zy3rLB0HCSNr0ZOGQwVNzi2iZcJKo5SMvwmYjG5K9U0kZTVIUSy4tJGLP5ot1++FSPm+vy3pNdvnFN2MubC56GIGbx4fuz6N7DiabN7PeQYi+r8MvS04Dnfb7d5OjiIIOID16B38U5M8NVX3SXmdkNgusrIqEHOgLTigWBDKbEIIu1+fexPgsghoQRNJTdw9HEjOj0FOJyf/HSuHOBqCbNWdmrBXQvBXBkw\r\nSec-Fetch-Dest: font\r\nSec-Fetch-Mode: cors\r\nSec-Fetch-Site: same-origin\r\nPragma: no-cache\r\nCache-Control: no-cache\r\n\r\n","headers":null,"cookies":null,"method":"GET"},"response":{"raw":"HTTP/2 200 OK\r\naccept-ranges: bytes\r\nlast-modified: Mon, 14 Jul 2025 09:57:48 GMT\r\nx-age: 785838\r\nx-cache-hits: 347\r\nx-content-type-options: nosniff\r\nx-request-id: v-5809fb96-6c3f-11f0-8b00-6b0112848aeb\r\ncontent-length: 22992\r\nx-edgeconnect-midmile-rtt: 17, 21\r\nx-edgeconnect-origin-mex-latency: 84, 81\r\ncache-control: max-age=600\r\nexpires: Wed, 13 Aug 2025 17:49:13 GMT\r\ndate: Wed, 13 Aug 2025 17:39:13 GMT\r\nset-cookie: ak_bmsc=4E19C384354D9168EC037A0AE57F6E73~000000000000000000000000000000~YAAQ9U0kF3lfO52YAQAAxbqDpBxseakcXYA3UPJDk73q/iRbnhxteDBDlFpLr9eMrDTKpIortFW1neg+LMLTfP4iJtHGpcSwwOpJwgp8RdAY8K516BpXKpaPfRCvO4bxVTRufOC4C+TbP4+IP++eJPqWjjYhhNkXNUGtIpapq1uG6OtHof8RxRlSowrOvf2C0mwghLV3RB36pYMeHXXfhjyLhM4enZzmWcI/3FMDKF4o8/nuV8FDXaITdU5xZzJnXa1bO6IIsekAZvSG608eAfxj1QXKyoRDNo/kvHc3CKtrHf83zF7LQHQGJcYme4/4dgKx44tdV0GEc8ma9sZQKQPlxz55fbROEAcV2tcWzmNJqdbocjgV1NxzpMhzj5c7BDmfeNNP4EfQ2/AsCmz5IfYiYhXN7SdrCgUztcH+T1G5oyH3X6OMeS5pWTJO9cQOAUmDrzbwdTLMHR7+; Domain=.serestherapeutics.com; Path=/; Expires=Wed, 13 Aug 2025 19:39:11 GMT; Max-Age=7198\r\nX-Firefox-Spdy: h2\r\n\r\n","headers":null,"cookies":null,"status_code":"200","status_text":"OK","fingerprints":[{"name":"Akamai Bot Manager","description":"Akamai Bot Manager detect bots using device fingerprinting bot signatures.","website":"https://www.akamai.com/us/en/products/security/bot-manager.jsp","common_platform_enumeration":"","icon":"Akamai.svg","categories":["Security"]},{"name":"Akamai","description":"Akamai is global content delivery network (CDN) services provider for media and software delivery, and cloud security solutions.","website":"https://akamai.com","common_platform_enumeration":"","icon":"Akamai.svg","categories":["CDN"]}],"data":{"size":22992,"size_decoded":0,"mime_type":"font/woff2","magic":"Web Open Font Format (Version 2), TrueType, length 22992, version 1.0","md5":"1efbd38aa76ddae2580fedf378276333","sha1":"8a49976f2470ba2a1db6144245355d3b889312e4","sha256":"8d3ca80fa271e94b0c36cf3053b0f806b7a42bb3395b424c99dc0bd218f0ac20","sha512":"dd16efd323a38dad99a105e7443546e112ff42158018c885091df498c8c5b88c4d83737b4887332ea54ef3a83483e660c783073c4ce61fca4098d24aac05ed6c","ssdeep":"384:i8dkfSOTyQBgarmZBcC60rEJq/VcteWhh/nqgYA7L3ittJ2MY+0K7YXr5eC:xfHQBgGmZBtnytL/tYSLStDJY+0K0bD","tlshash":"5ba2d0ae5a223af4d77235a4d1bc351db3ddf0c22193e90e73e77138cc7a6451182069","first_seen":"2023-04-07T01:34:48Z","last_seen":"2026-04-03T16:56:39.525993Z","times_seen":1936,"resource_available":false,"data":null}},"time_used":148,"timings":{"blocked":-1,"dns":0,"connect":0,"send":0,"wait":144,"receive":4,"ssl":0},"alerts":{"ids":null,"analyzer":null,"urlquery":null}},{"url":{"schema":"https","addr":"ir.serestherapeutics.com/sites/g/files/knoqqb52941/themes/site/nir_pid2065/dist/fonts/lato-v16-latin-regular.woff2","fqdn":"ir.serestherapeutics.com","domain":"serestherapeutics.com","tld":"com"},"ip":{"addr":"23.36.77.170","port":443,"asn":20940,"as":"Akamai International B.V.","country":"Norway","country_code":"NO"},"is_navigation_request":false,"resource_type":"font","requested_by":"https://ir.serestherapeutics.com/news-releases/news-release-details/seres-therapeutics-reports-ser-155-phase-1b-placebo-controlled","date":"2025-08-13T17:39:13.609Z","timestamp":0,"http_version":"","security_state":"secure","security_info":{"cipher_suite":"TLS_AES_256_GCM_SHA384","key_group_name":"x25519","signature_name":"RSA-PSS-SHA256","protocol":"TLSv1.3","cert":{"subject":{"commonName":"leapfrog-ssl-30.gcs-web.com","organization":""},"issuer":{"commonName":"R10","organization":"Let's Encrypt"},"validity":{"start":"Fri, 13 Jun 2025 04:44:47 GMT","end":"Thu, 11 Sep 2025 04:44:46 GMT"},"fingerprint":{"sha1":"76:56:CB:1C:2A:EB:BC:6C:AD:AC:F9:46:52:00:98:68:6F:36:7E:4D","sha256":"2E:92:CD:78:D5:3F:E1:8C:2B:75:38:93:FD:B6:D7:66:20:2F:C1:D0:0B:A0:AE:7D:AE:10:26:7A:9B:48:60:40"}}},"request":{"raw":"GET /sites/g/files/knoqqb52941/themes/site/nir_pid2065/dist/fonts/lato-v16-latin-regular.woff2 HTTP/1.1\r\nHost: ir.serestherapeutics.com\r\nUser-Agent: Mozilla/5.0 (Windows NT 10.0; Win64; x64; rv:134.0) Gecko/20100101 Firefox/134.0\r\nAccept: application/font-woff2;q=1.0,application/font-woff;q=0.9,*/*;q=0.8\r\nAccept-Language: en-US,en;q=0.5\r\nAccept-Encoding: identity\r\nDNT: 1\r\nConnection: keep-alive\r\nReferer: https://ir.serestherapeutics.com/sites/g/files/knoqqb52941/files/css/css_kzaM5d7Hf_D4urQRrPnMNG7ZSmDxlul3AoaRuCcLFBg.css?delta=1\u0026language=en\u0026theme=nir_pid2065\u0026include=eJyNj9EKwjAMRX9orCLo74TbNsxim4w0Cvt7O_eiD4Jvl8NNcpLUOGR7rKhzLqi6TFKMIjqHPZSk0r-Rq9YIe8MGu7NThoNi1XQPENStOxm8yDKmjNIN5n_VOzli5R_dxhAyTtoay-BF5WP3iuXw28M8tJ3FqW-ShoQIH8JryefT9RL0yWYl89THdW5h_-4Fhv1pRA\r\nCookie: bm_ss=ab8e18ef4e; ak_bmsc=4E19C384354D9168EC037A0AE57F6E73~000000000000000000000000000000~YAAQ9U0kF3pfO52YAQAAyrqDpBxZNiQhgQ/mLbHzuEyKUI1B5Q02Uo0y/Q8t/RN651uf3zXQrlH74xzEGFZJh8Z3EipvPaPk8w7Is198IT9ERHRfRPKa2M7lbnLucg3cEIMP0T5Us1UtqKrkD4IyfMWS5Il+7GYb/LonOBcDcZfDHDidfuuSIQ6TrFLomDSIbFN39zhVmt4CPEAYeJCFpnrqAGm+u+JZOxVfbd6hq2X8CRbwAnpU/qIeEkfJZTcbdrKuCAfQd9nnNvAIY60IM359bhv/qJQdbTtF9ptE/8TrJUyq6y1eZieW7441XaaLDTJjdbbmD+kIh76nTK2tFfqRYBRM+LJxo4h7ROy+Jg0nL8xfVSOAHRJQZeKb/jZ7i3pBOoDbq2YYcEhFDfwAdJJtM3L3MIx/VHn8srwrv/OxDJmiCmO13LX5jQfOZxx+mwR2mwpsu1ypGLyV; bm_s=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; bm_so=076452BA7F785C26C0D039192D414EE322EFEBEE47C9D32A826B033A65229333~YAAQ9U0kF2RfO52YAQAAsLaDpARpo2xHJdjU4Jxa73zUq51KuxsW+QSmb5iP/ENmk7iqOGRhZyjdzqR50bYOPoK0krDYMKoypGPYm3hLRIvJAjzEPSWU9v0AmtzNP00zTXG2hPxPx54udTSSuGTM2KzBDJRiwCiOkJhUWlTdDefECbi1wnKokP5hnBjxGDCQMAE2aCXe4HqNbDgvHE7G5jmtqONfD1YgD6Cw25QL5pfAPYy0BKE94QkgYz+X0zy3rLB0HCSNr0ZOGQwVNzi2iZcJKo5SMvwmYjG5K9U0kZTVIUSy4tJGLP5ot1++FSPm+vy3pNdvnFN2MubC56GIGbx4fuz6N7DiabN7PeQYi+r8MvS04Dnfb7d5OjiIIOID16B38U5M8NVX3SXmdkNgusrIqEHOgLTigWBDKbEIIu1+fexPgsghoQRNJTdw9HEjOj0FOJyf/HSuHOBqCbNWdmrBXQvBXBkw\r\nSec-Fetch-Dest: font\r\nSec-Fetch-Mode: cors\r\nSec-Fetch-Site: same-origin\r\nPragma: no-cache\r\nCache-Control: no-cache\r\n\r\n","headers":null,"cookies":null,"method":"GET"},"response":{"raw":"HTTP/2 200 OK\r\naccept-ranges: bytes\r\nlast-modified: Mon, 14 Jul 2025 09:57:48 GMT\r\nx-age: 1140847\r\nx-cache-hits: 446\r\nx-content-type-options: nosniff\r\nx-request-id: v-4586e2a2-6c3c-11f0-af3c-1fbf4cbabb80\r\ncontent-length: 23484\r\nx-edgeconnect-midmile-rtt: 17, 21\r\nx-edgeconnect-origin-mex-latency: 167, 89\r\ncache-control: max-age=600\r\nexpires: Wed, 13 Aug 2025 17:49:13 GMT\r\ndate: Wed, 13 Aug 2025 17:39:13 GMT\r\nX-Firefox-Spdy: h2\r\n\r\n","headers":null,"cookies":null,"status_code":"200","status_text":"OK","fingerprints":[{"name":"Akamai","description":"Akamai is global content delivery network (CDN) services provider for media and software delivery, and cloud security solutions.","website":"https://akamai.com","common_platform_enumeration":"","icon":"Akamai.svg","categories":["CDN"]}],"data":{"size":23484,"size_decoded":0,"mime_type":"font/woff2","magic":"Web Open Font Format (Version 2), TrueType, length 23484, version 1.0","md5":"b4d2c4c39853ee244272c04999b230ba","sha1":"c82e22dde9716c40ba20e6c7ed03a1b66556de15","sha256":"c3c0d3f472358aac78455515c4800771426770c22698e2486d39fdb5505634e1","sha512":"d315d6a4e28bb125128d3a4d99fe120e383061d367341f06c4b74a589b4ca29c516cbc8d23ddd37267a1e4497c74fd58b1dffd39cb70348b8a3ea3d48237f8ef","ssdeep":"384:iXFbv7T+soFz7IbR/aBa639y2FNedPuzHQ1eGcYe3mkGtapwx/vX5htghzvcjvm:iXFzP+soFP8RQty2FNedmzocYe3DqapT","tlshash":"40b2e1778269aa70d6d01bb5ffc112a73a79589245d5e3a34e409b02442c73f7eadf40","first_seen":"2023-04-07T01:34:48Z","last_seen":"2026-04-03T16:56:39.518452Z","times_seen":3003,"resource_available":false,"data":null}},"time_used":26,"timings":{"blocked":-1,"dns":0,"connect":0,"send":0,"wait":25,"receive":1,"ssl":0},"alerts":{"ids":null,"analyzer":null,"urlquery":null}},{"url":{"schema":"https","addr":"ir.serestherapeutics.com/sites/g/files/knoqqb52941/files/favicon%20%281%29.ico","fqdn":"ir.serestherapeutics.com","domain":"serestherapeutics.com","tld":"com"},"ip":{"addr":"23.36.77.170","port":443,"asn":20940,"as":"Akamai International B.V.","country":"Norway","country_code":"NO"},"is_navigation_request":false,"resource_type":"img","requested_by":"https://ir.serestherapeutics.com/news-releases/news-release-details/seres-therapeutics-reports-ser-155-phase-1b-placebo-controlled","date":"2025-08-13T17:39:14.745Z","timestamp":0,"http_version":"","security_state":"secure","security_info":{"cipher_suite":"TLS_AES_256_GCM_SHA384","key_group_name":"x25519","signature_name":"RSA-PSS-SHA256","protocol":"TLSv1.3","cert":{"subject":{"commonName":"leapfrog-ssl-30.gcs-web.com","organization":""},"issuer":{"commonName":"R10","organization":"Let's Encrypt"},"validity":{"start":"Fri, 13 Jun 2025 04:44:47 GMT","end":"Thu, 11 Sep 2025 04:44:46 GMT"},"fingerprint":{"sha1":"76:56:CB:1C:2A:EB:BC:6C:AD:AC:F9:46:52:00:98:68:6F:36:7E:4D","sha256":"2E:92:CD:78:D5:3F:E1:8C:2B:75:38:93:FD:B6:D7:66:20:2F:C1:D0:0B:A0:AE:7D:AE:10:26:7A:9B:48:60:40"}}},"request":{"raw":"GET /sites/g/files/knoqqb52941/files/favicon%20%281%29.ico HTTP/1.1\r\nHost: ir.serestherapeutics.com\r\nUser-Agent: Mozilla/5.0 (Windows NT 10.0; Win64; x64; rv:134.0) Gecko/20100101 Firefox/134.0\r\nAccept: image/avif,image/webp,*/*\r\nAccept-Language: en-US,en;q=0.5\r\nAccept-Encoding: gzip, deflate, br\r\nReferer: https://ir.serestherapeutics.com/news-releases/news-release-details/seres-therapeutics-reports-ser-155-phase-1b-placebo-controlled\r\nDNT: 1\r\nConnection: keep-alive\r\nCookie: bm_ss=ab8e18ef4e; ak_bmsc=4E19C384354D9168EC037A0AE57F6E73~000000000000000000000000000000~YAAQ9U0kF35fO52YAQAAx7+DpBySZ/dfHdC4B5oUtNpuV2adhHIky7zORHESo+cA0boAKlpN0M1F0xemTlMj/fjitsk1gqPk8Rnv/JXOTVU1pJjkRHE4cvI1fxp7EOGzBft8N148JDVfar1U580eQu7mdWb4woUsrQ9CiwpG3Sh/GCoUOTSod4yVM6PXFf0x6S+wv0PQcfS8Adrxzqfl1Ma+/rkBJb9LxKTjiedjFZ2dIy3Hkd0qo9v67qkS0kSAzuHAgYjwXUROH/c6DnpyWQWD6GuvM4QWEhRa1q3HQdkE+HEd4nQrs6wKVajPvLFHGf+YkJRmLWLlPd5np30wqIS7bymQ/R6U7rSFiwI55664EdT1uWwylPUhd9tgyXc0G1RPEzRBF+HMs3Vj0hPTvjvNZYGjuGZN7oA2Uls4Z1LLzAPNLg4rFXi4vFoOl9OGIwqJ+w1ROra+oPpmbDznVyX1t53SC/Hh; bm_s=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; bm_so=076452BA7F785C26C0D039192D414EE322EFEBEE47C9D32A826B033A65229333~YAAQ9U0kF2RfO52YAQAAsLaDpARpo2xHJdjU4Jxa73zUq51KuxsW+QSmb5iP/ENmk7iqOGRhZyjdzqR50bYOPoK0krDYMKoypGPYm3hLRIvJAjzEPSWU9v0AmtzNP00zTXG2hPxPx54udTSSuGTM2KzBDJRiwCiOkJhUWlTdDefECbi1wnKokP5hnBjxGDCQMAE2aCXe4HqNbDgvHE7G5jmtqONfD1YgD6Cw25QL5pfAPYy0BKE94QkgYz+X0zy3rLB0HCSNr0ZOGQwVNzi2iZcJKo5SMvwmYjG5K9U0kZTVIUSy4tJGLP5ot1++FSPm+vy3pNdvnFN2MubC56GIGbx4fuz6N7DiabN7PeQYi+r8MvS04Dnfb7d5OjiIIOID16B38U5M8NVX3SXmdkNgusrIqEHOgLTigWBDKbEIIu1+fexPgsghoQRNJTdw9HEjOj0FOJyf/HSuHOBqCbNWdmrBXQvBXBkw; bm_lso=076452BA7F785C26C0D039192D414EE322EFEBEE47C9D32A826B033A65229333~YAAQ9U0kF2RfO52YAQAAsLaDpARpo2xHJdjU4Jxa73zUq51KuxsW+QSmb5iP/ENmk7iqOGRhZyjdzqR50bYOPoK0krDYMKoypGPYm3hLRIvJAjzEPSWU9v0AmtzNP00zTXG2hPxPx54udTSSuGTM2KzBDJRiwCiOkJhUWlTdDefECbi1wnKokP5hnBjxGDCQMAE2aCXe4HqNbDgvHE7G5jmtqONfD1YgD6Cw25QL5pfAPYy0BKE94QkgYz+X0zy3rLB0HCSNr0ZOGQwVNzi2iZcJKo5SMvwmYjG5K9U0kZTVIUSy4tJGLP5ot1++FSPm+vy3pNdvnFN2MubC56GIGbx4fuz6N7DiabN7PeQYi+r8MvS04Dnfb7d5OjiIIOID16B38U5M8NVX3SXmdkNgusrIqEHOgLTigWBDKbEIIu1+fexPgsghoQRNJTdw9HEjOj0FOJyf/HSuHOBqCbNWdmrBXQvBXBkw^1755106754250; _pk_id.310.7332=2c4a18add8648920.1755106754.; _pk_ses.310.7332=1; AMCV_98CF678254E93B1B0A4C98A5%40AdobeOrg=179643557%7CMCMID%7C50545728401776829424379634313304809965%7CMCOPTOUT-1755113954s%7CNONE%7CvVersion%7C5.5.0; AMCVS_98CF678254E93B1B0A4C98A5%40AdobeOrg=1; s_cc=true\r\nSec-Fetch-Dest: image\r\nSec-Fetch-Mode: no-cors\r\nSec-Fetch-Site: same-origin\r\nPragma: no-cache\r\nCache-Control: no-cache\r\n\r\n","headers":null,"cookies":null,"method":"GET"},"response":{"raw":"HTTP/2 200 OK\r\naccept-ranges: bytes\r\ncontent-type: image/x-icon\r\nlast-modified: Mon, 29 Jan 2018 11:16:45 GMT\r\nx-age: 261398\r\nx-cache-hits: 415\r\nx-content-type-options: nosniff\r\nx-request-id: v-a22de328-ee8a-11ef-8471-7bd455155677\r\ncontent-encoding: gzip\r\ncontent-length: 778\r\nx-edgeconnect-midmile-rtt: 0, 19, 21\r\nx-edgeconnect-origin-mex-latency: 92, 84, 89\r\ncache-control: max-age=600\r\nexpires: Wed, 13 Aug 2025 17:49:14 GMT\r\ndate: Wed, 13 Aug 2025 17:39:14 GMT\r\nvary: Accept-Encoding\r\nX-Firefox-Spdy: h2\r\n\r\n","headers":null,"cookies":null,"status_code":"200","status_text":"OK","fingerprints":[{"name":"Akamai","description":"Akamai is global content delivery network (CDN) services provider for media and software delivery, and cloud security solutions.","website":"https://akamai.com","common_platform_enumeration":"","icon":"Akamai.svg","categories":["CDN"]}],"data":{"size":1150,"size_decoded":0,"mime_type":"image/x-icon","magic":"MS Windows icon resource - 1 icon, 16x16, 32 bits/pixel","md5":"fa39ac8838329e125d31a6de3984af73","sha1":"5791fb94b6a9a8fd85556fb9e0858dacfc6f848d","sha256":"768fab401890815c32a31442106a29fe94482c2a522c3939715153d9c5a52a52","sha512":"1097cdffa1abec0483aa899282a47500f565c856b1138e70d9da6950a4b22a0ee793175fd6c23d4816b436cfede0d3303a835aafa81933fa0dcbbbd92599df93","ssdeep":"","tlshash":"8b21007053c2bd65d000d3717496f2f303e9edf3346a8ba67d216106301953dd4a390c","first_seen":"2025-08-13T17:39:41.427893Z","last_seen":"2025-10-24T19:10:31.059152Z","times_seen":2,"resource_available":false,"data":null}},"time_used":182,"timings":{"blocked":0,"dns":0,"connect":0,"send":0,"wait":182,"receive":0,"ssl":0},"alerts":{"ids":null,"analyzer":null,"urlquery":null}},{"url":{"schema":"https","addr":"use.typekit.net/hom2xog.css","fqdn":"use.typekit.net","domain":"typekit.net","tld":"net"},"ip":{"addr":"23.36.77.81","port":443,"asn":20940,"as":"Akamai International B.V.","country":"Norway","country_code":"NO"},"is_navigation_request":false,"resource_type":"stylesheet","requested_by":"https://ir.serestherapeutics.com/news-releases/news-release-details/seres-therapeutics-reports-ser-155-phase-1b-placebo-controlled","date":"2025-08-13T17:39:12.417Z","timestamp":0,"http_version":"","security_state":"secure","security_info":{"cipher_suite":"TLS_AES_256_GCM_SHA384","key_group_name":"x25519","signature_name":"ECDSA-P256-SHA256","protocol":"TLSv1.3","cert":{"subject":{"commonName":"use.typekit.net","organization":"Adobe Inc."},"issuer":{"commonName":"DigiCert Global G2 TLS RSA SHA256 2020 CA1","organization":"DigiCert Inc"},"validity":{"start":"Tue, 10 Dec 2024 00:00:00 GMT","end":"Sat, 10 Jan 2026 23:59:59 GMT"},"fingerprint":{"sha1":"F3:36:2A:08:11:E8:8C:54:E5:3C:6A:03:53:BF:AA:D7:7A:84:8B:89","sha256":"6A:79:75:73:C0:A8:12:54:14:ED:26:F6:54:AA:3F:01:34:4E:41:17:1C:AB:70:3C:72:0B:AF:BE:E1:75:6F:6E"}}},"request":{"raw":"GET /hom2xog.css HTTP/1.1\r\nHost: use.typekit.net\r\nUser-Agent: Mozilla/5.0 (Windows NT 10.0; Win64; x64; rv:134.0) Gecko/20100101 Firefox/134.0\r\nAccept: text/css,*/*;q=0.1\r\nAccept-Language: en-US,en;q=0.5\r\nAccept-Encoding: gzip, deflate, br\r\nDNT: 1\r\nConnection: keep-alive\r\nReferer: https://ir.serestherapeutics.com/\r\nSec-Fetch-Dest: style\r\nSec-Fetch-Mode: no-cors\r\nSec-Fetch-Site: cross-site\r\nPragma: no-cache\r\nCache-Control: no-cache\r\n\r\n","headers":null,"cookies":null,"method":"GET"},"response":{"raw":"HTTP/2 200 OK\r\nserver: nginx\r\ncontent-type: text/css;charset=utf-8\r\nvary: Accept-Encoding\r\nstrict-transport-security: max-age=31536000; includeSubDomains;\r\ncache-control: private, max-age=600, stale-while-revalidate=604800\r\ntiming-allow-origin: *\r\naccess-control-allow-origin: *\r\ncross-origin-resource-policy: cross-origin\r\ncontent-encoding: gzip\r\ncontent-length: 1409\r\ndate: Wed, 13 Aug 2025 17:39:12 GMT\r\nakamai-grn: 0.474d2417.1755106752.6081f9a\r\nX-Firefox-Spdy: h2\r\n\r\n","headers":null,"cookies":null,"status_code":"200","status_text":"OK","fingerprints":[{"name":"Nginx","description":"Nginx is a web server that can also be used as a reverse proxy, load balancer, mail proxy and HTTP cache.","website":"https://nginx.org/en","common_platform_enumeration":"cpe:2.3:a:f5:nginx:*:*:*:*:*:*:*:*","icon":"Nginx.svg","categories":["Web servers","Reverse proxies"]},{"name":"HSTS","description":"HTTP Strict Transport Security (HSTS) informs browsers that the site should only be accessed using HTTPS.","website":"https://www.rfc-editor.org/rfc/rfc6797#section-6.1","common_platform_enumeration":"","icon":"","categories":["Security"]}],"data":{"size":15050,"size_decoded":0,"mime_type":"text/css; charset=utf-8","magic":"Unicode text, UTF-8 text, with very long lines (516)","md5":"17e0934ee72643141d4a939c6c373c4f","sha1":"0de7ba27cee2dce180ce20f29e1415992b60ac1b","sha256":"22cd1436c605f07399d70e7eada3f60f6b8ae0e27498177560f5ff2ae1f7bf26","sha512":"81c7007f24a29ae999723c57a20f00d98628acfc5b69ea13e0ab053eec8e7c1db4b148c31a3d180bf06b7b56a240665677f0a64f84ee953855cf963d902d77b2","ssdeep":"192:pAvHwM2M8MUMuMwM+MmMGMfMGM9MBMlM3MSPluMDMTlMDMaMNpPxo:QDVdL57TzUzOCm8moKonNpPxo","tlshash":"f7627be040058cd7c4d12a61348e73f8e86a3e0a25e4cde656258cb79c79ff77251bae","first_seen":"2025-08-13T17:39:41.432891Z","last_seen":"2025-08-13T17:39:41.432891Z","times_seen":1,"resource_available":false,"data":null}},"time_used":217,"timings":{"blocked":19,"dns":1,"connect":1,"send":0,"wait":143,"receive":21,"ssl":29},"alerts":{"ids":null,"analyzer":null,"urlquery":null}},{"url":{"schema":"https","addr":"assets.adobedtm.com/898335afd880/c52ee8aa1e90/launch-5ef258dce664.min.js","fqdn":"assets.adobedtm.com","domain":"adobedtm.com","tld":"com"},"ip":{"addr":"96.6.17.25","port":443,"asn":16625,"as":"AKAMAI-AS","country":"Norway","country_code":"NO"},"is_navigation_request":false,"resource_type":"script","requested_by":"https://ir.serestherapeutics.com/news-releases/news-release-details/seres-therapeutics-reports-ser-155-phase-1b-placebo-controlled","date":"2025-08-13T17:39:12.431Z","timestamp":0,"http_version":"","security_state":"secure","security_info":{"cipher_suite":"TLS_AES_256_GCM_SHA384","key_group_name":"x25519","signature_name":"ECDSA-P256-SHA256","protocol":"TLSv1.3","cert":{"subject":{"commonName":"assets.adobedtm.com","organization":"Adobe Inc."},"issuer":{"commonName":"DigiCert Global G2 TLS RSA SHA256 2020 CA1","organization":"DigiCert Inc"},"validity":{"start":"Tue, 24 Jun 2025 00:00:00 GMT","end":"Sat, 25 Jul 2026 23:59:59 GMT"},"fingerprint":{"sha1":"2F:BD:F6:81:46:EE:C6:68:47:14:7F:F0:63:9A:CA:DE:F6:5D:C7:80","sha256":"F0:43:20:D8:ED:30:30:7B:92:0C:29:1B:07:12:29:EE:72:B4:10:4C:38:64:3C:9A:AD:BF:70:A4:DC:CE:5B:8E"}}},"request":{"raw":"GET /898335afd880/c52ee8aa1e90/launch-5ef258dce664.min.js HTTP/1.1\r\nHost: assets.adobedtm.com\r\nUser-Agent: Mozilla/5.0 (Windows NT 10.0; Win64; x64; rv:134.0) Gecko/20100101 Firefox/134.0\r\nAccept: */*\r\nAccept-Language: en-US,en;q=0.5\r\nAccept-Encoding: gzip, deflate, br\r\nOrigin: https://ir.serestherapeutics.com\r\nDNT: 1\r\nConnection: keep-alive\r\nReferer: https://ir.serestherapeutics.com/\r\nSec-Fetch-Dest: script\r\nSec-Fetch-Mode: cors\r\nSec-Fetch-Site: cross-site\r\nPragma: no-cache\r\nCache-Control: no-cache\r\n\r\n","headers":null,"cookies":null,"method":"GET"},"response":{"raw":"HTTP/2 200 OK\r\naccept-ranges: bytes\r\ncontent-type: application/x-javascript\r\netag: \"48246fd3c5f42a4da830ac25312a135f:1675447237.500488\"\r\nlast-modified: Fri, 03 Feb 2023 18:00:37 GMT\r\nserver: AkamaiNetStorage\r\nvary: Accept-Encoding\r\ncontent-encoding: gzip\r\ncontent-length: 50604\r\ncache-control: max-age=3600\r\nexpires: Wed, 13 Aug 2025 18:39:12 GMT\r\ndate: Wed, 13 Aug 2025 17:39:12 GMT\r\naccess-control-allow-origin: https://ir.serestherapeutics.com\r\nx-content-type-options: nosniff\r\ntiming-allow-origin: *\r\nX-Firefox-Spdy: h2\r\n\r\n","headers":null,"cookies":null,"status_code":"200","status_text":"OK","fingerprints":null,"data":{"size":166662,"size_decoded":0,"mime_type":"application/x-javascript","magic":"JavaScript source, ASCII text, with very long lines (32764)","md5":"48246fd3c5f42a4da830ac25312a135f","sha1":"54384065724227a5b5671752bf5f2da785a856d4","sha256":"3777c25911c0259e059287354a170a0046dabc074b075d6e5ff47045f7a51492","sha512":"42781f96080608dea9650077430417c377b762e049999c8819f224e0918155fa578651805cb4a5a0d11f491d0cc1dee72c2286b83e0e11afcf236f432d894281","ssdeep":"1536:dNOsnc0ZM5ZwzNXIuqJ04zscoS10xSvWF4cLOPeqqcNFHemJB83szK8FekuOOCfz:8T1C4cLOPScDHlkct3Upntj2ImkRBRI","tlshash":"8cf3398a72a4b4a61bd331b5903f210af37b6959285cc034f691d8e17c7968e5273f3d","first_seen":"2023-03-13T20:39:53Z","last_seen":"2026-04-02T06:14:20.709218Z","times_seen":75,"resource_available":true,"data":null}},"time_used":201,"timings":{"blocked":85,"dns":83,"connect":1,"send":0,"wait":6,"receive":3,"ssl":18},"alerts":{"ids":null,"analyzer":null,"urlquery":null}},{"url":{"schema":"https","addr":"ir.serestherapeutics.com/RNdDsxyv1HCi8/5bsN/eeYDOHqv5c/8X9XwQGY/cggyWQ/S2ZjfUY/dTWdCAQ?v=a9e8c51b-ea55-72b0-f92e-4d2e035b1724","fqdn":"ir.serestherapeutics.com","domain":"serestherapeutics.com","tld":"com"},"ip":{"addr":"23.36.77.170","port":443,"asn":20940,"as":"Akamai International B.V.","country":"Norway","country_code":"NO"},"is_navigation_request":false,"resource_type":"script","requested_by":"https://ir.serestherapeutics.com/news-releases/news-release-details/seres-therapeutics-reports-ser-155-phase-1b-placebo-controlled","date":"2025-08-13T17:39:12.438Z","timestamp":0,"http_version":"","security_state":"secure","security_info":{"cipher_suite":"TLS_AES_256_GCM_SHA384","key_group_name":"x25519","signature_name":"RSA-PSS-SHA256","protocol":"TLSv1.3","cert":{"subject":{"commonName":"leapfrog-ssl-30.gcs-web.com","organization":""},"issuer":{"commonName":"R10","organization":"Let's Encrypt"},"validity":{"start":"Fri, 13 Jun 2025 04:44:47 GMT","end":"Thu, 11 Sep 2025 04:44:46 GMT"},"fingerprint":{"sha1":"76:56:CB:1C:2A:EB:BC:6C:AD:AC:F9:46:52:00:98:68:6F:36:7E:4D","sha256":"2E:92:CD:78:D5:3F:E1:8C:2B:75:38:93:FD:B6:D7:66:20:2F:C1:D0:0B:A0:AE:7D:AE:10:26:7A:9B:48:60:40"}}},"request":{"raw":"GET /RNdDsxyv1HCi8/5bsN/eeYDOHqv5c/8X9XwQGY/cggyWQ/S2ZjfUY/dTWdCAQ?v=a9e8c51b-ea55-72b0-f92e-4d2e035b1724 HTTP/1.1\r\nHost: ir.serestherapeutics.com\r\nUser-Agent: Mozilla/5.0 (Windows NT 10.0; Win64; x64; rv:134.0) Gecko/20100101 Firefox/134.0\r\nAccept: */*\r\nAccept-Language: en-US,en;q=0.5\r\nAccept-Encoding: gzip, deflate, br\r\nReferer: https://ir.serestherapeutics.com/news-releases/news-release-details/seres-therapeutics-reports-ser-155-phase-1b-placebo-controlled\r\nDNT: 1\r\nConnection: keep-alive\r\nCookie: bm_ss=ab8e18ef4e; ak_bmsc=8B3E3F53D6F1D551950B130550D015A2~000000000000000000000000000000~YAAQ9U0kF2FfO52YAQAAsLaDpBzYHEeJiZORhrKmMvVJl6htT4U5E/6alOnsN1WLbK0JNN0FxV6QIk3CXK6SZzJXWuElqmWB1WWYdY8quqhpWza5ivcl5im9nJoX7vrrq3G0vDVDRbOFK+CpHpJKlNA7AFE8qUMYv2oy8l08ONFK9GC3Aonufb2qXf/9ZjIkKIaaJrJwo1KUNgFeJmFTmRFsbb4oS3Jv2xmpV6uIXbaBeN9UhBTyS0HA2CF3KtgNehkaNLOEZnMBc1mLg/Q+bEEutjMUDLWyhdWbq0cnrrkhtimNWHnJcupfFzlIfpxdU3sj4xzZZ/Md5pzLYIOYZrVV2/12xnbT2CkSBSpx2FJsR/0yDsO84EToiNJUl0y3pFgjA1wezQP5EqYWYF8qXo/BI+qA; bm_s=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; bm_so=076452BA7F785C26C0D039192D414EE322EFEBEE47C9D32A826B033A65229333~YAAQ9U0kF2RfO52YAQAAsLaDpARpo2xHJdjU4Jxa73zUq51KuxsW+QSmb5iP/ENmk7iqOGRhZyjdzqR50bYOPoK0krDYMKoypGPYm3hLRIvJAjzEPSWU9v0AmtzNP00zTXG2hPxPx54udTSSuGTM2KzBDJRiwCiOkJhUWlTdDefECbi1wnKokP5hnBjxGDCQMAE2aCXe4HqNbDgvHE7G5jmtqONfD1YgD6Cw25QL5pfAPYy0BKE94QkgYz+X0zy3rLB0HCSNr0ZOGQwVNzi2iZcJKo5SMvwmYjG5K9U0kZTVIUSy4tJGLP5ot1++FSPm+vy3pNdvnFN2MubC56GIGbx4fuz6N7DiabN7PeQYi+r8MvS04Dnfb7d5OjiIIOID16B38U5M8NVX3SXmdkNgusrIqEHOgLTigWBDKbEIIu1+fexPgsghoQRNJTdw9HEjOj0FOJyf/HSuHOBqCbNWdmrBXQvBXBkw\r\nSec-Fetch-Dest: script\r\nSec-Fetch-Mode: no-cors\r\nSec-Fetch-Site: same-origin\r\nPragma: no-cache\r\nCache-Control: no-cache\r\n\r\n","headers":null,"cookies":null,"method":"GET"},"response":{"raw":"HTTP/2 200 OK\r\nstored-attribute-sha-checksum: 2038e6c3871f16104567cd3184cb2ac3fe7fff304d4cfd5fb428edabd4dae05a\r\nlast-modified: Mon, 23 Jun 2025 14:24:47 GMT\r\netag: \"3c7fbd0e842d0a461030339c2f693e4776e748d58b209cd64187f1c0a2f1bc3a\"\r\ncontent-type: application/javascript\r\ncontent-encoding: br\r\ncontent-length: 135790\r\nexpires: Fri, 12 Sep 2025 17:00:17 GMT\r\ndate: Wed, 13 Aug 2025 17:39:12 GMT\r\ncache-control: max-age=21600\r\nX-Firefox-Spdy: h2\r\n\r\n","headers":null,"cookies":null,"status_code":"200","status_text":"OK","fingerprints":null,"data":{"size":408805,"size_decoded":0,"mime_type":"application/javascript","magic":"data","md5":"cda6065bdbfecc0ed6b518996f20f21b","sha1":"c130c276c2e24f12cd74a462b715790163849cc2","sha256":"2038e6c3871f16104567cd3184cb2ac3fe7fff304d4cfd5fb428edabd4dae05a","sha512":"c5abdf71e8cc3b893df3749daaa29a9d7c0ecb9946124cb46ed65d8036f13de1550219d1080cf3195f4ed967ff1db402d46fb945c6f3cb6bde368a121c99b515","ssdeep":"6144:9WjwUpQn/TtrobH0KHTUKzUe4ILRys3ApJyTm:9U8ob5osNm","tlshash":"3894f7f29193287a825795c5088e35172d0f5ce3b5fcd27ee901ce970c68b6866fda2c","first_seen":"2025-08-13T17:39:41.439959Z","last_seen":"2025-08-13T17:39:41.439959Z","times_seen":1,"resource_available":true,"data":null}},"time_used":20,"timings":{"blocked":-1,"dns":0,"connect":0,"send":0,"wait":15,"receive":5,"ssl":0},"alerts":{"ids":null,"analyzer":null,"urlquery":null}}]}